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Thesis abstract 
Background 
Highly active anti-retroviral therapy (HAART) has completely transformed the 
clinical course of HIV. HIV is now considered a chronic disease, with patients living 
for decades on treatment. It is anticipated that health services will be placed under 
increasing pressure as the prevalence and age profile of the HIV population 
increases. A deeper understanding of the specific factors driving the use and cost of 
HIV care in Ireland is needed to allow quantification of future resource needs as 
well as the identification of potentially cost-effective service delivery modifications. 
This thesis investigates the current use and direct cost of hospital care by HIV 
patients, and explores some of the patients and clinic level factors influencing the 
cost of HIV care in Ireland. 
Methods 
The total number of patients in care annually as well as the changing age profile of 
patients over time was estimated using routine data on the number of notified 
cases and general mortality in combination with published estimates of HIV related 
deaths. Current resource use and costs of care in 2012 were estimated from two 
studies carried out in the HIV centre located in Cork University Hospital. The first 
study estimated the total cost of outpatient HIV care using micro-costing, including 
data on HAART use and cost. The second study used data extracted from the 
finance department of Cork University Hospital to identify and describe the pattern 
of use and non-drug cost of all hospital services (including inpatient episodes, non-
ID outpatient appointments and emergency department attendances) by HIV 
patients in 2012. A national estimate of the cost of ambulatory HIV care in 2012 
was then generated adjusting the estimated unit costs of outpatient visits, for 
variation in service delivery across the six centres providing adult HIV care in Ireland 
in 2012 and using national anti-retroviral sales data. 
Results 
The number of HIV patients accessing HIV care was estimated to be 3,820 in 2012, 
with 18% of patients aged ≥50 years. Assuming the rate of new diagnosis remains 
stable we estimated that the number of patients in care will have increased by 40% 
to 4,607 by 2020 and that the proportion of patients aged ≥50 years will have 
increased to 30%. 
HAART is the overwhelming driver of the cost of outpatient HIV care. Treatment 
costs accounted for 90% of the total cost of outpatient HIV care estimated in the 
micro-costing study. Patient factors associated with increased total outpatient HIV 
xiii 
costs on multivariate analysis were younger age (< 50 years), female gender and 
being on HAART but not suppressed. When categories of costs were examined 
separately older patients were found to have both significantly lower HAART costs 
as well as HIV outpatient visit costs while female patients only had significantly 
higher HAART costs. On analysis of non-drug hospital costs (i.e. including inpatient 
admissions, non-ID outpatient appointments and emergency department 
attendances) low CD4 count and treatment status were significant, but no 
demographic factors were identified. A small number of patients (2%) with very low 
CD4 counts incurred a disproportionate amount of inpatient (61%) and total 
hospital non drug costs (31%). 
Extrapolating from the micro-costing estimates and taking into account variation in 
service delivery across centres, we estimate that the annual non-drug cost of 
providing ambulatory HIV care in Ireland in 2012 was €1,127 per patient or €4.31 
million, and that including HAART, the cost to the health service provider in 2012 
was approximately €50 million. 
Discussion 
The age profile of HIV patients in care is increasing in Ireland at a similar rate as in 
other developing countries. However, in contrast to what has previously reported in 
the literature, older patients in our study did not appear to incur increased total 
costs compared to their younger counterparts. The main reason for this was that 
the older patients were on less expensive treatment regimens, and HAART cost is 
the main driver of total cost of outpatient HIV care. Exactly why this was is unclear, 
but regimen choice is influenced by many health-system (e.g. drugs available, 
clinician preference etc) as well as patient factors (treatment history, resistance, 
patient preference etc). There was also no difference identified in the non-drug cost 
of care for older patients. This may have been due to the patients themselves being 
possibly younger and/or healthier than in other published studies, but may also be 
due to a lack of co-ordinated routine screening for age-related comorbidities in HIV 
patients in Ireland, as well as the cost estimates being based on data collected in a 
single centre which did not include costs incurred in other hospital, community and 
primary care settings. As the increasing age and total number of patient increases 
demands on HIV services it is imperative that measures to improve service 
efficiency are evaluated in terms of both clinical outcomes and costs. Interventions 
such as increased screening to reduce the number of patients diagnosed with 
advanced disease and increased use of generics have the potential to generate 
cost-savings, however a nationally co-ordinated approach is needed to drive such 
changes while ensuring the current standard of care is maintained. 
 1 Introduction & Background 
  
2 
1.1 Introduction 
This thesis is comprised of a number of papers presenting research on the patterns, 
determinants and cost of hospital resource use by HIV patients in Ireland (Figure 
1-1). 
Firstly a background chapter provides a brief description of the epidemiology, care 
and treatment of HIV, both in Ireland and internationally. This is followed in the 
second chapter by modelled estimates of the total number and age breakdown of 
HIV patients in care in Ireland. The results of a systematic review of the literature to 
identify the determinants of utilisation of outpatient HIV services are presented in 
Chapter 3. Chapter 4 reports the results of a micro-costing study carried out in the 
Infectious Diseases outpatient clinic of CUH, while the patterns of utilisation of all 
hospital services by HIV patients attending Cork University Hospital (CUH) in 2012. 
are presented in Chapter 5. In Chapter 6 the variation in clinical practice between 
HIV centres is described and national estimates of the cost of HIV care to the Health 
Service Executive are estimated, taking into account this variation. In the final 
chapter there is an overall discussion of the main findings including the strengths 
and weaknesses of this thesis. The policy implications of this research are also 
discussed, and possible areas of future research are identified. 
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Figure 1-1. Thesis outline schematic
Objective 1: To 
estimate the number 
and age breakdown of 
HIV patients in care in 
Ireland in 2012, and to 
generate short-term 
predictions of the 
number and age of HIV 
patients in care 
Objective 2: To 
systematically identify 
and describe the 
determinants of use 
outpatient HIV services 
in the HAART era 
 
Objective 3: To identify 
HIV and non-HIV 
related hospital 
utilisation patterns and 
cost by HIV patients 
Objective 4: To 
estimate the total cost 
of providing an 
outpatient HIV service 
from the health service 
provider perspective, 
and to identify 
associated patient 
factors 
Objective 5:To 
generate a national 
estimate of the annual 
cost of outpatient HIV 
care taking into 
account local variation 
in service delivery 
Aim: to describe and explore the determinants of the resource use and cost of ambulatory HIV care in Ireland. 
Paper 1: Estimation of 
the size and age of the 
HIV population in care 
in Ireland 
Paper 2: Determinants 
of HIV outpatient 
utilisation: a systematic 
review 
Paper 3: Utilisation 
patterns and cost of 
hospital care for people 
living with HIV in 
Ireland in 2012: a single 
centre study 
Paper 4: Resource 
utilisation and cost of 
ambulatory HIV care in 
a regional HIV centre in 
Ireland: a micro-costing 
study 
Paper 5: Cost and 
variation of ambulatory 
HIV care in Ireland 
 
 4 
1.2 Background 
The first cases of what was to become known as Acquired Immunodeficiency 
Syndrome (AIDS) were reported in the United States in 1981 [1]. Since then, the 
World Health Organisation (WHO) estimates that almost 78 million people have 
been infected with the Human Immunodeficiency Virus (HIV) which causes AIDS 
and about 39 million people have died as a result of HIV/AIDS [2]. 
1.2.1 Natural history 
The clinical course of untreated HIV infection varies considerably. On initial 
infection 40%-90% of patients display symptoms of an acute illness, called acute 
retroviral syndrome or primary HIV infection [3]. However, the clinical symptoms 
during this phase are usually non-specific and a relatively small proportion of HIV 
infections are diagnosed at this stage, even in those known to be at high risk of 
infection [4]. This is followed by a long period of asymptomatic infection during 
which the number of CD4 T-lymphocytes in the blood (CD4 count) declines 
gradually by about 50-100 cells/µl per year (Figure 1-2). In the absence of treatment 
the median time from infection to developing AIDS is around 10-11 years, although 
the rate of progression varies considerably [5]. Once the CD4 count drops below 
200 cells/µl or an AIDS-defining illness (ADI) has been diagnosed the patient is 
considered to have AIDS [6]. The median survival time of untreated AIDS is 12-20 
months [7]. In the absence of treatment viral load (number of copies of viral RNA 
per ml plasma) strongly predicts the rate of CD4 decrease and progression to AIDS 
and death [8]. 
 5 
Effective treatment (highly active anti-retroviral therapy or HAART), which 
supresses viral replication, has been available since 1996. HAART has dramatically 
improved the prognosis for people infected with HIV and if treatment is started 
early enough patients now have a near normal life-expectancy [9]. Despite this, 
HAART is not curative and treatment is lifelong. Patients on treatment require close 
monitoring due to the possibility of adverse events such as toxicity and/or 
development of resistance. 
 
Figure 1-2. Typical course of untreated HIV infection (reproduced with permission from 
[10], copyright Massachusetts Medical Society) 
 
1.2.2 Global epidemiology 
The first cases of AIDS were reported in men who have sex with men (MSM) in the 
United States in 1981 [1]. It rapidly became apparent that this new disease was 
already widespread both within the US and throughout the world [11-16]. Within 
two years the causative agent, later named HIV, had been identified [17,18], and by 
1985 a diagnostic test for HIV antibodies was commercially available [19].  
 6 
Although first described in the US [1], it has since been established that the virus 
originated from cross-species transmission(s) of simian-immunodeficiency virus(es) 
from non-human primates to humans in central Africa as early as the 1920s [20,21]. 
Around 1960 the growth rate of new infections seems to have increased 
substantially and cases started spreading more widely throughout the rest of the 
world [21,22]. Since then sub-Saharan Africa has continued to suffer 
disproportionally from HIV (Figure 1-3). 
 
Figure 1-3. Global prevalence of HIV infection[2] 
 
In recent years, as a result of global prevention and treatment efforts, the incidence 
of new cases of HIV and AIDS-related deaths worldwide have started to decrease. 
However the prevalence of HIV continues to increase as a result of the decline in 
mortality (Figure 1-4), with an estimated 35 million people living with HIV in 2012 
[23]. The age profile of the epidemic is also changing as people are living longer 
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with HIV infection. The proportion of people living with HIV who are over 50 years 
of age is increasing across all regions of the world, but most dramatically in 
developed countries, where it is estimated that one third of adults living with HIV in 
2012 were aged 50 years or older [24,25]. 
 
Figure 1-4. Number of new HIV infections, AIDS related deaths and people living with HIV 
globally [26] 
 
1.2.3 HIV treatment and care 
1.2.3.1 Treatment 
Initially the only treatments available for patients with HIV/AIDS were prophylactic 
treatments to prevent opportunistic infections (OIs). A number of nucleoside 
reverse transcriptase inhibitors (NRTIs) were trialled, alone and in combination in 
the late 1980s and early 1990s, however their effectiveness was found to be limited 
[27-32]. It was not until drugs from two new classes, protease inhibitors (PIs) and 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) became available in the 
mid-1990s that a real breakthrough was made in HIV treatment. Trials of triple 
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therapy (HAART) consisting of either a PI or an NNRTI combined with two NRTIs 
were found to give substantially better results than previously available therapies 
[33-35]. Subsequent observational studies showed a sharp decline (60%-80%), in 
AIDS, hospitalisations and deaths following the introduction of HAART into clinical 
practice [36,37]. Since then additional classes of drugs have been developed which 
target other stages of the HIV virus lifecycle: fusion inhibitors, entry inhibitors and 
integrase inhibitors (Figure 1-5). Although effective, the early HAART regimens were 
arduous for patients, with multiple tablets with varying requirements and 
significant side-effects. Since then more tolerable formulations and simplified 
regimens have been developed and have resulted in improved adherence [38], for 
instance several single-tablet regimens, which combine 3 or 4 drugs into a single 
daily tablet, are now available [39]. 
Eligibility criteria for treatment have traditionally been based on a patient’s CD4 
count as well as other factors including readiness for treatment and the likelihood 
of onward transmission of infection. However, due to evidence regarding the 
clinical benefits of early HAART treatment and the reduction in transmission of HIV 
in patients on treatment, international guidelines have moved towards 
recommending treatment of all patients regardless of CD4 count [3,40-42]. 
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Figure 1-5. Life cycle of HIV virus and anti-retroviral treatment targets [43] 
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The success of treatment with HAART is measured in terms of the reduction of viral 
load [44,45], preferably to undetectable levels (or <50 copies/ml) within six months 
of initiating treatment [3,40-42]. Virological failure is considered to occur if viral 
suppression is not achieved within 6 months of starting therapy in persons that 
remain on treatment, or if the viral load of a patient on HAART that was previously 
suppressed increases beyond a defined level (the precise definition of which varies 
by guideline) [3,40-42]. Virological failure may occur for a variety of reasons 
including suboptimal adherence, medication intolerance, pharmacokinetic issues 
and resistance [3]. 
1.2.3.2 Setting and organisation of care 
In the HAART era, routine HIV care has tended to be provided by HIV specialist 
services, due to the complex nature of the treatment (e.g. possibility of resistance, 
toxicity and drug-interactions). However the setting and organisation of care can 
vary depending on the local health care system and HIV epidemiology. 
There is clear evidence that the best patient outcomes are achieved when care is 
provided by experienced and expert providers [46]. In developed countries the 
primary care provider tends to be a specialist doctor, however in some countries 
care is shared (in varying degrees) between specialists and primary care [47-51]. 
Research has also shown that with appropriate support the cadre of staff providing 
HIV care may be less important than their level of experience [52]. 
While HIV clinics are often located in hospital settings, there is no evidence that 
clinics need to be located in a hospital setting to provide high quality care. Studies 
looking at patient outcomes in hospital and non-hospital based clinics have found 
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no difference in patient outcomes [53,54] and decentralisation of HIV care from 
hospitals to more peripheral health facilities (often implemented in conjunction 
with task-shifting) has shown no evidence of poorer patient outcomes in the 
developing world [55]. It is important however, that HIV care providers have 
sufficient volumes of patients to maintain the expertise of staff as smaller centres 
have been found to have poorer patient outcomes, although the threshold is not 
entirely clear [56,57]. 
Integration of HIV services into antenatal/maternal/child health settings, TB 
services and opioid substitution-centres, has also been associated with improved 
HAART uptake and retention in care [40], although the evidence regarding the 
economic benefits of integrating HIV care and treatment into general health 
services and services for vulnerable populations (sex workers, mental health and or 
substance abuse service users) is weak and the benefits unclear [58]. 
1.2.3.3 Care cascade 
As the availability of effective treatments has transformed the outcome of HIV 
infection, attention has turned towards the challenge of maximising the proportion 
of patients being successfully treated. There are multiple hurdles along the path to 
successful treatment. Due to the number of steps at which patients can drop out of 
this process HIV care has been likened to a “leaky pipe” [59]. The end result is that a 
surprisingly small proportion of people living with HIV are virally suppressed, with 
figures from the United States and Australia as low as 20%-35% [60-62], although 
rates in Northern European countries appear to be higher at around 50%-60% [62]. 
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The first point in the cascade of care is diagnosis. Late diagnosis (defined as a CD4 
count < 350 µl/ml or an ADI at diagnosis [63]) is associated with poorer outcomes 
[64,65]. Timely diagnosis is not only beneficial for the individual, but also has an 
important role in the reduction of onward HIV transmission [66,67] as knowledge of 
a HIV positive status is associated with a reduction in high-risk sexual behaviour 
[68]. However, timely diagnosis continues to be a challenge worldwide [69-71] and 
it is estimated that as many as 35% of people with HIV in Western Europe are not 
aware of their infection [72]. Some of the reported reasons why diagnosis can be 
delayed include the asymptomatic nature of HIV infection, the perception (of 
individuals and/or clinicians) that the person is not at risk of HIV, fear of diagnosis 
and the associated stigma, and lack of knowledge of healthcare rights and/or 
language difficulties especially in the case of migrants [69]. 
Once diagnosed, patients’ engagement in care can vary along a continuum (Figure 
1-6). Patients need to be linked into care promptly following their initial diagnosis. 
In the US approximately 75% of patients are linked into care within 6-12 months of 
diagnosis [73], while in Europe a smaller proportion of patients, around 8%, appear 
to have delayed entry to care (> 3 months after diagnosis) [65]. Once in care, 
patients require regular monitoring, regardless of whether or not they are on 
treatment [40,74,75]. Monitoring of patients’ general health, immune status, and 
viral load (if on HAART) ensures that treatment can be started promptly and that 
any health problems are identified at an early stage. Early linkage and adherence to 
HIV care are associated with improved outcomes [76], however there is still some 
debate on the optimal frequency of monitoring needed [77,78]. Data from the UK 
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have shown that around 5% of patients drop out of care each year, and a further 
4.2% attended intermittently (i.e. not every year) [79]. 
 
Figure 1-6. HIV continuum of care (reprinted from [80] with permission) 
 
1.2.4 HIV in Ireland 
1.2.4.1 Epidemiology 
Incidence 
The first cases of AIDS were reported in Ireland in 1982 [81]. Since HIV testing 
became available (in 1985) 6,629 people have been diagnosed with HIV in Ireland 
[82]. 
In the early years of the epidemic, HIV infections were concentrated in the injecting 
drug user population (IDUs). However, over time the risk profile of newly diagnosed 
cases has changed (Figure 1-7), and in recent years there has been a steady 
increase in the numbers of new diagnoses who are men who have sex with men 
(MSM). 
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Figure 1-7. Number of reported cases of newly diagnosed HIV in Ireland by risk group 
Sources: pre 2000 data [83], from 2000 onwards, HPSC annual reports. *until 2000 “unknown” were 
included with “heterosexual”, in 2012 and 2013 “other” were included with “unknown”. 
 
Prevalence 
While quite detailed information is available on new diagnoses of HIV particularly 
since 2003 (when a voluntary national HIV surveillance system was introduced), less 
information is available on the prevalence of HIV in the general population in 
Ireland. UNAIDS estimates the figure at between 6,300-10,000 people living with 
HIV in 2012 (0.1%-0.2% of the population) [23]. The UNAIDS estimates for countries 
with concentrated epidemics rely on accurate information on the size of high risk 
groups and the prevalence of HIV within those groups, if these data are lacking the 
estimates may not be accurate [84]. A prevalence study of people in care in Ireland 
found 3,254 were attending for HIV care in 2009/2010 [85]. The discrepancy 
between these figures may be explained by possible inaccuracy of the estimates, as 
well as the proportion of people who are undiagnosed or who are not accessing 
care. 
Information on the prevalence of HIV in the general population is available from the 
routine screening of two groups: antenatal women and blood donors. The 
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proportion of antenatal women who are HIV positive has been decreasing steadily 
since surveillance started from 0.32% in 2002 to 0.14% in 2013 [86]. The reported 
prevalence in blood donors is lower, at 0.005% [87]. HIV prevalence in antenatal 
populations is generally higher than the general population (as they have, by 
definition, had unprotected sex) while the eligibility criteria for blood donation 
means that the proportion of new blood donors testing positive is generally lower 
than that of the general population. 
Various surveys describing the HIV prevalence in different high risk groups have also 
been carried out in Ireland (Table 1-1). 
Table 1-1. Estimates of HIV prevalence in high-risk populations in Ireland 
Population Subgroup Prevalence rate Year Reference 
A&E attenders  0.29% 2013 [88] 
Prisoners All 
IDU 
Non-IDU 
2.0% (1.3%-3.0%) 
3.5% (2.1%-5.5%) 
0.9% (0.3%-1.9%) 
1998 [89] 
IDUs Needle-exchange 
clients 
14.8% 1991 [90] 
Addiction treatment 
centre attendees 
16.7% 1997 [91] 
Dublin (in treatment 
and not in treatment) 
8.4% 1997 (year of 
publication) 
[92] 
Self-reported 24.8% 2000 [93] 
Addiction treatment 
centre attendees 
11% 2001 [94] 
A&E attendees 13.8% 2010 [95] 
Asylum seekers  2.2% 2000-2003 [87] 
 1.7% 2004-2012 [96] 
MSM 
(self-reported) 
Ever tested for HIV 
All surveyed 
4.8% 
2.5% 
2005-2006 [97] 
Ever tested for HIV 
All surveyed 
9.5% 
6.0% 
2010 [98] 
Homeless  6% 2005 [99] 
Prostitutes Dublin – attending a 
drop-in clinic 
2.5% 1991-1997 [100] 
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Routine morbidity and mortality data 
Between 2005 and 2012 there have been on average 824 (range 664-1,131) 
admissions per year containing a diagnosis of HIV, in 23% of these HIV has been the 
primary diagnosis (average 186 admissions per year, range 139-287) [101]. 
HIV/AIDS has only been recorded as a specific cause of death in routine mortality 
statistics since 2007, since then (up to 2014) 96 deaths have been attributed to 
HIV/AIDS [102-109]. Deaths in people with HIV infection were also reported to the 
Department of Health/HPSC through the voluntary HIV surveillance system. By 
2011 approximately 505 deaths in people with HIV had been reported from the 
start of the epidemic under this system, however not all these deaths were 
necessarily HIV-related (personal communication Dr Kate O’Donnell 22/04/2015). 
Since 2012 surveillance data is only collected on deaths which occur at the time of 
HIV diagnosis. 
1.2.4.2 Development and organisation of HIV care in Ireland 
In the early 1990s two reports were published which influenced how HIV services 
developed in Ireland, one by Comhairle na n-Ospidéal [110] and the other by the 
National AIDS Strategy Committee (NASC) [81]. 
Comhairle na n-Ospidéal 
Comhairle na n-Ospidéal was a statutory body set up under the Health Act 1970 to 
regulate the appointment of consultant medical staff and to specify the 
qualifications for such appointments. It also advised the Minister for health on 
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matters relating to the organisation and operation of hospital services (it was 
dissolved by the Health Act 2004 and its functions were transferred to the HSE) 
[111]. In March 1992 Comhairle na n-Ospidéal published its report “AIDS at 
consultant level” [110]. Its terms of reference included making recommendations 
“…on mechanisms to improve the management of AIDS patients at consultant level 
and to clarify the role of the different specialities in the services for persons who 
are HIV positive and/or who have AIDS” [110]. At this time it was government policy 
that persons with HIV/AIDS should receive care appropriate to their needs in both 
community and institutional settings and that each acute hospital was responsible 
for HIV/AIDS cases requiring hospital care in their catchment area [110]. In practice 
St James’s hospital (SJH) was seeing the vast majority of AIDS cases at the time of 
this report although a small number of cases had been seen in Cork Regional 
Hospital (now CUH), the Mater Misericordiae Hospital, Beaumont Hospital, Our 
Lady’s Hospital for Sick Children Crumlin (OLHSC), and the Coombe and Rotunda 
maternity hospitals. Respite care for AIDS patients was provided in Cherry Orchard 
Hospital. SJH became the de facto HIV centre in Ireland as the only consultant in 
genitourinary medicine (GUM) in Ireland at that time was based there. In addition 
the national haemophilia centre was located in SJH and the hospital’s catchment 
area had a high prevalence of injecting drug users [110]. HIV/AIDS patients in other 
hospitals were seen by a mixture of physicians, mainly general physicians, 
respiratory physicians and gastroenterologists [110]. 
This report concluded that inpatient care for HIV/AIDS patients should be 
concentrated at a small number of large multi-disciplinary general hospitals and 
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recommended the appointment of four additional Infectious Disease (ID) 
consultants in the Dublin area (to be shared between SJH, St Vincent’s Hospital, the 
Mater Misericordiae Hospital and Beaumont Hospital with sessional commitments 
to the public maternity hospitals and Cherry Orchard), as well as ID consultant posts 
in both Cork and Galway with consideration for another ID consultant post in 
Limerick in the future. The report also recommended the appointment of a GUM 
consultant to be based in the Mater Misericordiae Hospital and identified that a 
second GUM consultant may be needed in SJH in the near future. 
National AIDS strategy Committee 
A National AIDS Strategy Committee (NASC) was established in 1991 with a remit 
covering care and management (including primary care), surveillance, education 
and prevention, and discrimination. Four sub-committees were established to look 
at each of these areas, and their first report was published in 1992 [81]. 
The terms of reference of the Care and Management Sub-committee were “To 
consider the development of appropriate arrangements for the care and 
management of persons with HIV/AIDS at primary care and hospital levels including 
the development of liaison arrangements between the prison, health and welfare 
systems. The development of policy recommendations should be carried out in co-
ordination with the Committee on Infectious Diseases in Prisons established by the 
Minister for Justice” [81]. 
The main care-related recommendations of this report were that care for patients 
with less advanced disease should be provided in the community, by general 
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practitioners with appropriate supports and/or in satellite clinics to be established 
outside the hospital setting to provide primary and preventive care for HIV patients 
and drug users. Strengthening of community services and additional resourcing of 
voluntary agencies was also recommended.  
Within a few years of the publication of this report however the landscape of care 
required by HIV patients had completely changed, thanks to the development of 
HAART, and it was no longer considered feasible for HIV patients to be cared for in 
primary care. Routine HIV care needed to be provided in specialist facilities on an 
outpatient basis due to the complex drug-treatments and monitoring required [83]. 
A second NASC report, published in 2000, reviewed the progress on the previous 
reports recommendations and reported that four ID consultants had been 
appointed since the previous report, one each in SJH, OLHSC and CUH and one 
shared between the Mater Misericordiae University Hospital (MMUH) and 
Beaumont Hospital [83]. By 2005 there were nine ID/GUM consultants in Ireland, 
including one in University College Hospital Galway (UCHG) [112], and an infectious 
diseases consultant was appointed in University Hospital Limerick (UHL) in 2008. 
In 2012 in Ireland adult HIV-care was provided by six specialist centres, three in 
Dublin (SJH, MMUH and Beaumont Hospital) and three located around the rest of 
the country (CUH, UCHG and UHL). In 2015 a HIV service was also established in St 
Vincent’s hospital. Paediatric HIV care is provided in Our Lady’s Hospital for Sick 
Children, Crumlin (OLHSC). Routine care is provided on an outpatient basis by 
multidisciplinary teams including at a minimum a consultant in infectious 
disease/genitourinary medicine, non-consultant hospital doctors, nursing staff, and 
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clerical staff. Some of the centres are also supported by HIV pharmacists and other 
allied health professionals (social workers, dieticians etc) [112]. Care is based on 
international best-practice guidelines, which are regularly updated in response to 
emerging evidence on more efficacious treatments, timing of treatment initiation, 
care delivery pathways and cost-effectiveness evaluations. 
1.2.4.3 Treatment 
The European Medicines Agency (EMA), grants marketing approval for all new 
HIV/AIDS treatments through a compulsory centralised procedure which covers all 
EU member states [113]. In addition, the Irish Health Products Regulatory Authority 
(HPRA) can grant national approval for products that are exempt from the 
centralised procedure. The list of drugs currently approved by the EMA and/or the 
HPRA for treatment of HIV infection are shown in Table 1-2. 
There are currently four generic anti-retrovirals (ARVs) approved for use in Ireland 
although only one, nevirapine, appears to be available for sale currently (personal 
communication, CUH HIV pharmacist 15/05/2014). The fixed dose combination of 
Emtricitabine / tenofovir disoproxil fumarate (Truvada®) is also due to come off 
patent in 2017. 
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Table 1-2. List of medications for treatment of HIV infection approved for use in Ireland 
[114,115] 
Active Substance Authorisation date Notes 
First Generic 
Multi-class combinations    
Abacavir sulfate / dolutegravir sodium / lamivudine 01/09/2014   
Efavirenz / emtricitabine / tenofovir disoproxil 
fumarate 
13/12/2007   
Elvitegravir / cobicistat / emtricitabine / tenofovir 
disoproxil fumarate 
24/05/2013   
Emtricitabine / rilpivirine hydrochloride /tenofovir 
disoproxil fumarate 
28/11/2011   
NRTIs    
Abacavir 08/07/1999   
Abacavir / lamivudine 17/12/2004   
Abacavir (as sulfate) / lamivudine / zidovudine 28/12/2000   
Emtricitabine 24/10/2003   
Emtricitabine / tenofovir disoproxil fumarate 21/02/2005   
Lamivudine 08/08/1996 10/12/2009  
Lamivudine / zidovudine 18/03/1998 28/02/2011  
Stavudine 08/05/1996   
Tenofovir disoproxil fumarate 05/02/2002   
Zalcitabine 14/04/1994  Withdrawn 30/11/2005 
Zidovudine 08/06/1987   
NNRTIs    
Didanosine 15/09/2000   
Efavirenz 28/05/1999 09/01/2012  
Etravirine 28/08/2008   
Nevirapine 05/02/1998 30/11/2009  
Rilpivirine hydrochloride 28/11/2011   
Protease Inhibitors    
Amprenavir 20/10/2000  Withdrawn 29/04/2010 
Atazanavir sulphate 02/03/2004   
Darunavir 12/02/2007   
Darunavir / cobicistat 19/11/2014   
Fosamprenavir calcium 12/07/2004   
Indinavir sulphate 04/10/1996   
Lopinavir / ritonavir 20/03/2001   
Nelfinavir 22/01/1998  Withdrawn 23/01/2013 
Ritonavir 26/08/1996   
Saquinavir 04/10/1996   
Tipranavir 25/10/2005   
Integrase inhibitors    
Dolutegravir 16/01/2014   
Elvitegravir 13/11/2013   
Raltegravir 20/12/2007   
Fusion/Entry Inhibitors    
Enfuvirtide 27/05/2003   
Maraviroc 18/09/2007   
Booster    
Cobicistat on silicon dioxide 19/09/2013   
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1.3 Cost of providing HIV care 
The distribution of healthcare costs has changed as patient outcomes have 
improved. The proportion of costs due to in-patient HIV-related care has decreased, 
while outpatient (and non-HIV inpatient) costs have changed little and drugs costs 
have increased [116].  
1.3.1.1 Drug costs 
HAART is the single biggest driver of cost. Although the generic manufacture of 
some ARVs as well international pressure on drug companies has resulted in a 
reduction in the cost of treatment from around US$10,000-15,000 per patient year 
in the early HAART era [117] to US$115 per patient year in 2013 in low and middle-
income countries [118]. However, in high-income countries HAART still costs 
around €10,000-€15,000 per year per patient for first-line regimens [3,119] and 
accounts for between 50%-90% of the total direct healthcare cost of HIV [120-125]. 
The proportion of total costs due to HAART has also tended to increase over time, 
as the proportion of patients on treatment increases and newer (more expensive) 
drugs become available [119,124]. As more ARVs are due to come off patent in the 
coming years [126] the possible reduction in drug costs by replacing branded drugs 
with generic versions appears very appealing [119,127], although concerns exist 
about the possible detrimental effect on treatment adherence if branded single 
tablet regimens are replaced by generic multi-tablet equivalents. 
1.3.1.2 Outpatient costs 
Although the unit costs of an individual outpatient visits are low, because the bulk 
of HIV care is now provided on an ambulatory basis, the total cost of providing 
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ambulatory care often exceeds the cost of in-patient care [123,128]. An effective 
and efficient outpatient service is crucial in providing high quality care for chronic 
diseases such as HIV, in theory enabling the early identification and treatment of 
problems and thereby reducing hospitalisation rates. 
Several extensive literature reviews of the costs of HIV in the HAART era have been 
carried out [122,125,129-131]. The conclusions from these reviews have been 
limited by the difficulties in comparing costs across studies due to differences in 
methodology (e.g. types of care and cost components included) and healthcare 
systems. These reviews have generally called for better reporting of cost data and 
the use of standardised methods [122,125,129,130]. 
The healthcare costs of HIV increase with more advanced disease [122,129], and 
late diagnosis [132,133], age [134] and co-morbidities [135,136] have also been 
associated with increased costs. Evidence regarding the role of other factors 
(gender, risk group, immigrant status) is less clear [121,137-139]. Although 
healthcare factors are also important determinants of health costs, less data are 
available on their impact on the cost of HIV care [140]. 
Modelling studies have projected substantial increases in the cost of providing 
treatment and care for HIV patients in the coming years [141,142] due to the 
increasing number of people living with HIV as well as expected increases in the use 
of second-line and salvage regimens as the patient population becomes more 
treatment experienced. 
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1.3.1.3 Cost of HIV care in Ireland 
One previous study has been carried out reporting the cost of HIV care in Ireland. 
This study looked at HIV healthcare utilisation and cost in the early HAART era 
(1995-1999) in a single centre in Dublin [143] and documented the changes in 
healthcare utilisation patterns associated with the introduction of HAART. They 
estimated the total cost of HIV care to be IR£8,204 per patient year in 1999 
(equivalent to approximately €20,000 in 2012), with approximately 50% of all costs 
in 1999 due to HAART, 30% due to inpatient care, and 20% to outpatient care [143]. 
1.3.2 Challenges for the future 
HIV services are coming under increasing pressure, due to the sheer volume of 
providing routine HIV care combined with the increasing prevalence of age-
associated chronic diseases [144]. HIV services will need to become more efficient 
in order to cope with the anticipated increases in demand without compromising 
patient care. It is currently unclear how this can best be achieved. 
Evidence from resource-limited settings has suggested that HIV treatment can be 
successfully, and potentially cost-effectively, delivered in a variety of settings 
and/or by differing cadres of health care workers [55,145-147]. While in developed 
countries, there have been calls for increased involvement of primary care in the 
routine care of HIV patients [148,149] in line with models of care for non-
communicable chronic diseases [150]. However, a recent review found very limited 
data supporting the clinical effectiveness or acceptability of HIV shared care in 
developed countries and none of the included studies reported comprehensive cost 
implications [50]. Reviews of other HIV health service interventions have reported 
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evidence supporting the effectiveness of some types of interventions aimed at 
medication adherence [151,152], linkage and/or retention in care [153,154] and 
decision support/clinical information systems [155]. Again however data on the 
cost implications of these interventions is very limited [58,146,151,156,157]. 
Other approaches for reducing costs while maintaining existing service 
configurations, have been suggested in terms of both reducing the cost of 
treatment [119,127,158-162] and reducing the cost of laboratory and/or clinical 
monitoring [77,119,146,157]. The underlying assumption of these approaches is 
that patient outcomes would not be affected by changes in regimens prescribed 
and/or reductions in monitoring. In reality full economic evaluations including both 
clinical and cost data need to be performed for the cost-effectiveness of these 
interventions to be established. As data on clinical effectiveness and costs may not 
be generalizable from one setting to another [163] it is important that local data on 
unit costs and current resource use be available in order to accurately assess the 
impact of such changes. 
1.4 Overview of the thesis 
Healthcare providers are now looking for innovative ways of improving the 
efficiency of their HIV services, in order to continue providing high quality care in 
the context of increasing demands but finite resources. In particular interest is 
growing in finding more efficient ways of delivering routine care to the large 
proportion of stable, virally suppressed patients. 
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While clinical need is a major determinant of the resources used by an individual 
patient, factors at all levels, patient, hospital and health system, can influence the 
cost of providing that healthcare.  
High quality information on current service delivery models, resource utilisation 
patterns and cost of providing outpatient HIV care is vital in order to evaluate the 
financial impact of changes in the disease epidemiology and/or organisation of or 
services. Extrapolation from published international costing and burden of illness 
studies to the Irish setting introduces uncertainty into the outcomes, and may 
diminish the validity and rigour of future cost-effectiveness analyses that should 
rely on robust costing inputs specific to this setting. This may have a material 
impact on decision-making. The current, overall cost to the state of HIV disease in 
Ireland is unknown, although reliable individual constituents such as drug costs are 
available. While care in Ireland is based on international best-practice, anecdotal 
information suggests that there are subtle variations in management between 
centres. In light of the changing epidemiology of HIV, and the possibility of changing 
clinical management, it is vital that accurate cost data are available to enable 
appropriate planning of HIV services in Ireland for the future. 
This thesis describes current use and cost of hospital care by HIV patients in Ireland, 
and explores some of the patient and clinic level factors influencing the current cost 
of HIV care. 
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1.4.1 Aim and objectives 
The aim of this study is to describe and explore the determinants of the resource 
use and cost of ambulatory HIV care in Ireland. 
This thesis has five primary objectives. 
Primary objectives: 
1. To estimate the number and age breakdown of HIV patients in care in 
Ireland in 2012, and to generate short-term predictions of the number and 
age breakdown of HIV patients in care up to the year 2020. 
2. To systematically identify and describe the determinants of the use of 
outpatient HIV services in the HAART era. 
3. To identify HIV and non-HIV related hospital utilisation patterns and cost by 
HIV patients 
4. To estimate the total cost of providing an outpatient HIV service from the 
health service provider perspective, and to identify associated patient 
factors. 
5. To generate a national estimate of the annual cost of outpatient HIV care 
taking into account local variation in service delivery. 
1.4.2 Clarification of researcher’s role 
This is an original piece of research, carried out for my PhD with the supervision and 
guidance of Prof Mary Horgan, Prof Colm Bergin and Prof John Browne. 
I was responsible for applying for and receiving ethical approval from the relevant 
hospital ethics committees. 
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For the systematic review, I was responsible for developing search criteria, 
managing search retrievals, screening articles for possible inclusion, critically 
appraising relevant articles, and performing the review. 
I performed the manual data extraction and data entry of the utilisation data for 
the micro-costing study. Data from the activity based costing system of CUH was 
extracted and provided to me in electronic form by Mr Andrew Murphy in CUH 
finance department. 
I performed all statistical analysis reported in this thesis, and I drafted the 
manuscripts for all included papers. 
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2 Estimation of the size and age of the HIV population in care 
in Ireland 
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2.1 Abstract 
Little data are currently available on the number of people accessing HIV care in 
Ireland and the rate at which the population is growing. Although Ireland has had a 
case-based reporting system in place since 2002, modelling of the prevalence of HIV 
infection in Ireland has been hampered historically by a lack of data such as age at 
diagnosis, CD4 count at diagnosis, proportion of patients on treatment and 
mortality data. The aim of this chapter is to estimate the number and age 
breakdown of HIV patients in care in Ireland in 2012, and to generate short-term 
predictions of the number and age breakdown of HIV patients in care up to the year 
2020. 
We developed a simple model based on the numbers of cases diagnosed, mortality 
rates (general and HIV) and loss to follow-up. Four variations of the model were 
developed using different combinations of estimated age at diagnosis and 
published HIV mortality rates. The results of all models were compared with 
observed data. Uncertainty in the model estimates were investigated using one-
way sensitivity analysis. 
The final selected model estimated that there were 3,820 patients in care in Ireland 
in 2012, varying from 3,668 to 4,134 on sensitivity analysis. Assuming the number 
of new cases diagnosed annually remains at current levels the total number of 
patients in care will increase by 20%, to 4,607, by 2020. The age of patients in care 
was estimated to be increasing by nearly 0.5 years annually, and the proportion of 
patients ≥50 years of age will increase from 18% in 2012 to 30% in 2020. 
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Despite considerable limitations in the data available, the estimates generated 
provide a useful basis for estimating the likely epidemiological changes to the 
population of HIV patients in care in the coming years. 
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2.2 Introduction 
The number of new cases of HIV in Ireland has been relatively stable since the early 
2000s, with around 300-400 new cases of HIV being diagnosed each year [164]. The 
prevalence of HIV in the general population is currently estimated to be between 
0.2%-0.6% [165,166]. However this is expected to increase in the coming years due 
to the much improved life-expectancies of HIV patients on HAART. In addition to 
the expected increase in the volume of patients requiring care, it is also anticipated 
that the care required will become more complex due to the high rates of multi-
morbidity and poly-pharmacy associated with ageing of the HIV population. In the 
US it has been estimated that the proportion of people over 50 is increasing by 
1.5% per year, and that by 2020 over half of HIV cases will be over 50 [167], while in 
Australia it has been estimated that over 40% of people living with HIV will be over 
55 by 2020 [141]. A recent modelling study in the Netherlands estimated that by 
2030 73% of HIV patients on treatment will be over 50 and that over 80% of HIV 
patients on treatment will have at least one, and 28% have at least three, non-
communicable chronic diseases [144]. 
There is widespread concern about the consequences such epidemiological changes 
will have, not just on HIV services, but also other services such as those providing 
care for cardiovascular and renal disease [168], cancers [169], organ transplants 
[170,171] and geriatric medicine [172]. 
The aim of this chapter is to estimate the number and age breakdown of HIV 
patients in care in Ireland in 2012, and to generate short-term predictions of the 
number and age breakdown of HIV patients in care up to the year 2020. 
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2.3 Methods 
2.3.1 Model structure 
The number of people in care in any given year is influenced by the number of 
people in care the previous year, the number of new diagnoses that year, the 
number of people who are lost-to-follow-up (temporary or permanent), and the 
number of deaths (both non-HIV and HIV-related mortality).  
A simple deterministic model was created in Microsoft Excel® to calculate the 
number of patients in care at the end of each year in single year age bands, based 
on the numbers of patients diagnosed in each age band, the number of patients 
alive and in care at the end of the previous year for the preceding age band, the 
estimated number of deaths (general mortality and additional mortality due to HIV) 
and the estimated proportion of patients lost-to-follow-up each year. 
Due to limitations in the availability of Irish age at diagnosis and mortality data 
several variations of the model were created using different estimates for age at 
diagnosis and mortality. 
2.3.1.1 Model 1 
This model used published excess HIV mortality rates to estimate the number of 
HIV related deaths. The calculation used in Model 1 was as follows: 
Age band=x 
Year=i 
Rate of loss-to-follow-up = L 
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Number of people diagnosed in year i in age-group x=Dix 
Number of people remaining in care at the end of year i-1 in age group x-1 who age 
into age group x in year i = N(i-1)(x-1)    (1-L) =Pix 
Annual age specific general mortality rate= M 
Annual excess mortality rate= E 
Number of people in care at the end of year = N 
∑         
                  
 
     
 
   
                    
 
2.3.1.2 Model 2 
This model did not estimate the number of HIV deaths using excess mortality rates, 
instead the number of HIV related deaths per year by age group as estimated by 
the Global Burden of Disease project were used [173]. The calculation in Model 2 
was as follows: 
Age band=x 
Year=i 
Rate of loss-to-follow-up = L 
Number of people diagnosed in year i in age-group x=Dix 
Number of people remaining in care at the end of year i-1 in age group x-1 who age 
into age group x in year i = N(i-1)(x-1) × (1-L) =Pix 
Annual age specific general mortality rate= M 
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Age specific number of deaths (GBD)= S 
Number of people in care at the end of year = N 
∑        
         
 
    
 
   
               
2.3.2 Sources of data 
2.3.2.1 Incidence data 
Since tests for HIV antibodies became available in 1985, the majority of 
confirmatory HIV testing in Ireland has been performed by the National Virus 
Reference Laboratory (NVRL) and from 1985-2002 the NVRL collated all confirmed 
HIV diagnoses (including confirmatory testing carried out at other laboratories) and 
reported them to the Department of Health [81,83]. This surveillance was 
performed on a voluntary basis and it is likely that there were issues with duplicate 
reporting of cases in this system (the NVRL laboratory information system is a 
sample-based rather than a person-based system, and samples would frequently 
have been sent without full names for confidentiality reasons). 
In 2001, following a recommendation by the National AIDS Strategy Committee [83] 
a voluntary case-based reporting system was introduced, administered by the 
National Disease Surveillance Centre (now the HPSC). This case-based system 
collected patient level data on the demographic and clinical characteristics of newly 
diagnosed HIV cases (Figure 2-1). 
In 2012 HIV became a statutorily notifiable disease [174]. Named patient data is 
now reported to the HPSC via the computerised infectious disease reporting system 
(CIDR), similar to other notifiable diseases. 
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Figure 2-1. Number of new HIV diagnoses in Ireland, 1985-2014. Sources of data 1985-
1999 NASC[83], 2000-2014 HPSC annual reports. 
 
2.3.2.2 Age distributions at diagnosis 
In order to estimate the age profile of people living with HIV in Ireland it is 
necessary to have the age distribution, in single years, of newly diagnosed cases. 
However complete patient level data including age at diagnosis is only available 
from the HPSC from 2003. 
In order to estimate the age distributions of cases diagnosed before 2003 two 
methods were used. 
2.3.2.2.1 Method A 
Pre-1992 
Although the majority of HIV confirmatory testing has been carried out by the NVRL 
since tests for HIV became commercially available due to changes in the laboratory 
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information system, it is not possible for the NVRL to extract data on tests 
performed before 1992. 
The small number of studies reported in the literature from this time were mostly 
restricted to sub-groups of HIV cases, such as IDUs, and no information was given 
regarding age at diagnosis [90,175]. One survey of HIV positive patients attending 
the GUM clinic in St James Hospital between 1989-1991, reported a mean age of 
participants of 27 years for female IDUs, 29 years for male IDUs and 30 years for 
MSMs [176]. In this study participants had been diagnosed an average of 2 years. In 
the absence of other data, the mean and standard deviation of the age at diagnosis 
was estimated by subtracting the mean number of years since diagnosis from the 
mean age at the time of the study reported by Comiskey [176]. 
To take into account the uncertainty in both the mean age at the time of the study 
and the mean years since diagnosis the mean age at diagnosis was estimated using 
a Monte Carlo simulation (1,000 iterations). The mean age at diagnosis (and 
standard deviation) generated by the Monte Carlo simulation were used to 
estimate the ages of cases diagnosed between 1985 and 1991. 
1992-2002 
Data was obtained from the NVRL on the age of patients at the time of the first HIV 
positive test recorded in their laboratory system between 1992 and 2002. The NVRL 
extracted all positive HIV tests 1992-2002 and this list was de-duplicated keeping 
only first positive sample by date. All positives in babies up to 9 months old were 
also removed as the positive result may have been due to maternal antibodies. 
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Weak HIV positives were manually checked for subsequent confirmed positive HIV 
result. Results with no information on age were excluded. 
The mean age and standard deviation of this NVRL data was used to construct 
estimates of the ages of diagnosed cases 1992-2002 based on the total number of 
new diagnoses notified [83]. 
One important limitation that should be mentioned is that as it was not possible to 
extract data on samples which tested HIV positive before 1992, it is likely that some 
of the patients with positive samples included in this extraction would have been 
diagnosed previously, resulting in an over estimation of the mean age at diagnosis. 
2003-2014 
Data on the number of cases in single year age bands were obtained from HPSC for 
cases diagnosed 2003-2014. 
2014-2020 
The number and age-breakdown of new cases each year 2015-2020 was assumed 
to be an average of the number of cases notified in the previous five years (2010-
2014). 
2.3.2.2.2 Method B 
Due to concerns about the accuracy of these estimated age distributions, 
particularly as the age at diagnosis between 1992 and 2002 data was likely to be 
overestimated, time series analysis of the mean age at diagnosis 2003-2014 was 
used to predict the mean age of diagnosis each year from 1985 to 2020 (Figure 2-2). 
The predicted age in combination with the average standard deviation of ages of 
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cases notified to the HPSC 2003-2014 (mean of the standard deviation was 10.68, 
range 9.13-13.89) were used to construct age distributions of cases in single-year 
age groups for years up to 2002. 
 
Figure 2-2. Observed and predicted mean age at diagnoses 1985-2020, predicted ages 
based on time series analysis. 
 
2.3.2.3 Loss-to-follow-up 
There is no routine data available in Ireland on loss-to-follow-up. In the UK, it was 
found that approximately 10% of patients who attend in a given year do not attend 
care the following year [79], on further investigation 5% of these were considered 
lost-to-follow-up, with 4% subsequently attending care in a subsequent year 
(intermittent attenders), while less than 2% had died. A similar annual loss-to-
follow up was also reported by EuroSIDA, a multi-centre prospective observational 
study of HIV patients in Europe [177]. 
 40 
No national data is available in Ireland on loss-to-follow up. In order to estimate if 
5% would be a reasonable estimate of loss-to-follow-up in Ireland data on the 
number of patients attending each year was extracted from a clinical database of 
viral load results maintained in CUH. Between 1997, when the unit was established, 
and 2012 the proportion of patients who attended in a given year (as indicated by 
the presence of at least one recorded viral load result) but who did not attend care 
the following year was 12% (Table 2-1). On average 7% of patients who attended in 
a given year had no further viral loads recorded (i.e. were lost-to-follow-up in CUH) 
while 5% re-attended in a subsequent year. Although the 7% of patients who no 
longer attended CUH is higher than the estimates of loss-to-follow-up reported in 
the UK [79] and EuroSIDA [177] as these data were from a single centre it was not 
possible to differentiate between patients who transferred to another centre (i.e. 
remained in care) and those who dropped completely out of care (either 
permanently or temporarily). Data from a study in SJH found a cumulative loss to 
follow up (failure to attend the clinic for more than a year) of 11% over the period 
2007-2014 (personal communication Dr Sarah O’Connell, 11/02/2016). 
2.3.2.4 Mortality data 
Data on the number of deaths due to HIV/AIDS in Ireland are not thought to be very 
reliable. Particularly in the early years of the epidemic, when no effective treatment 
was available the number of deaths attributed to HIV/AIDS is thought to be 
underestimated due to the considerable stigma attached to a HIV diagnosis. 
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Table 2-1. Loss-to-follow up in CUH, based on clinic  viral load (VL) database. 
Year Number of 
patients 
with at 
least one 
VL 
Number of 
patients with at 
least one VL 
recorded the 
following year 
% with a VL 
recorded the 
following year 
% with 
subsequent 
VLs 
recorded 
% no 
subsequent 
VLs recorded 
1997 13 13 100% 0% 0% 
1998 42 37 88% 5% 7% 
1999 61 49 80% 15% 5% 
2000 76 56 74% 25% 1% 
2001 91 67 74% 5% 21% 
2002 144 123 85% 6% 9% 
2003 178 156 88% 3% 9% 
2004 187 167 89% 2% 9% 
2005 214 193 90% 2% 7% 
2006 244 216 89% 2% 9% 
2007 261 242 93% 2% 5% 
2008 312 284 91% 2% 7% 
2009 340 322 95% 1% 4% 
2010 367 330 90% 1% 9% 
2011 375 346 92% 0% 8% 
2012 388 - - - - 
Average   88% 5% 7% 
 
2.3.2.4.1 Routine national mortality data 
Routine mortality data including cause of death is collated from death certificates 
by the Central Statistics Office (CSO) in Ireland. Data on age-specific general 
mortality rates in 5-year age groups, 1980-2013 were downloaded from the Health 
Well website [178]. 
HIV/AIDS mortality 
Deaths due to HIV/AIDS have only been specifically coded as an underlying cause of 
death since the introduction of ICD-10 coding by the CSO in 2007. Prior to that, 
HIV/AIDS deaths were coded to an umbrella code (ICD-9 279.8 “Other specified 
disorders involving the immune system”) not specific to HIV/AIDS and which may 
contain non-HIV/AIDS deaths (CSO personal communication, 24/11/2015). 
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Table 2-2. Number of deaths with an underlying code of ICD9 279.8 or ICD10 B20-B24 
(CSO), and number of deaths in people with HIV/AIDS reported to the HSPC 
 Routine mortality data Deaths in people with HIV/AIDS 
Year Number of 
deaths 
Code and source Number of 
deaths 
Notes 
1985 1 Underlying cause of 
death ICD9 279.8 
(other specified 
disorders involving 
the immune 
mechanism) Source, 
personal 
communication 
CSO, 24/11/2015) 
4 Deaths reported 
to HPSC in 
patients with 
HIV/AIDS, death 
may or may not 
be HIV/AIDS 
related. Personal 
communication 
HPSC 10/12/2015. 
 
* deaths at time 
of diagnosis only 
reported 
1986 1 5 
1987 2 13 
1988 6 9 
1989 9 22 
1990 8 18 
1991 16 26 
1992 28 44 
1993 41 38 
1994 29 39 
1995 51 50 
1996 33 33 
1997 15 11 
1998 13 11 
1999 18 17 
2000 5 10 
2001 10 13 
2002 11 10 
2003 17 5 
2004 15 27 
2005 8 25 
2006 7 15 
2007 15 Underlying cause of 
death ICD10 B20-
B24, HIV/AIDS [102-
109] 
14 
2008 14 5 
2009 13 8 
2010 13 6 
2011 14 15 
2012 12 1* 
2013 6 3* 
2014 9 1* 
(Note: for 2001-2006, deaths coded as ICD9 279.8 were reported in the CSO Annual Vital 
Statistics Reports as deaths due to HIV/AIDS) 
 
2.3.2.4.2 Surveillance data 
As part of the voluntary HIV/AIDS surveillance system the Department of Health 
collated the number of HIV/AIDS cases and deaths from 1982 until this function was 
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transferred to the HPSC in 2000 [83]. In the voluntary case-based reporting system 
which operated between 2001 and 2011, clinicians were also requested to report 
the details of deaths in their HIV/AIDS patients. 
Up to 2011 505 deaths (8% of all notifications, including 12 deaths with an 
unknown year of death) in people with HIV had been reported to HPSC (Table 2-2), 
however not all these deaths were necessarily HIV-related (Dr Kate O’Donnell, 
personal communication 22/04/2015). Since 2012 only information on deaths 
reported at the time of diagnosis has been collected by the HPSC [82]. 
2.3.2.4.3 Longitudinal studies 
Many longitudinal studies have reported mortality rates in HIV positive populations 
in developed countries. These mortality rates have dropped dramatically since the 
widespread introduction of HAART from pre-HAART mortality ranging from 50-100 
deaths per 1,000 person years [179-182] to around 10-25 deaths per 1,000 person 
years in the HAART era [179,181-187].  
As no data on the rate of excess mortality in the Irish HIV population are available, 
the excess mortality rates reported by a large multi-national collaboration of HIV 
seroconverter cohorts (CASCADE), mainly located in European countries [188], were 
applied to the Irish HIV population (Table 2-3). This study was chosen as it reported 
excess mortality rates with 95% confidence intervals for a range of years covering 
pre, early and late HAART eras. 
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Table 2-3. Excess mortality rates reported by CASCADE [188] 
 Excess mortality rate 
(per 1,000 py) 
95% CI Years applied 
Pre-1996 40.8 38.5-43.0 All years pre 1996 
1996-1997 31.4 28.5-34.2 1996-1997 
1998-1999 11.9 10.2-13.5 1998-1999 
2000-2001 9.5 8.1-10.9 2000-2001 
2002-2003 8.5 7.1-9.9 2002-2003 
2004-2006 6.1 4.8-7.4 2004-2020 
Total 20.7 19.9-21.6  
 
To assess the likely generalizability of these excess mortality rates to the Irish 
context the age structure of the CASCADE participants were compared to the 
estimated age distributions of the Irish notification data (see Figure 2-3). The age 
composition of the cohort was reasonably similar to the age structure of notified 
cases in Ireland, however, on χ2 testing the proportions in each age group (as 
estimated by both method A and B above) were all significantly different than the 
CASCADE participants for the equivalent time periods. One possible explanation is 
that as the CASCADE collaboration only included seroconverter cohorts, the 
patients included in these cohorts would tend to be diagnosed earlier (therefore 
younger) compared to the general HIV population. 
In addition, a greater proportion of Irish notifications were females compared to 
the proportion of females in the CASCADE cohorts (37% female between 2000-2014 
v 22% female in CASCADE). There were also some differences in risk groups, with 
Irish notification data having comparatively higher proportions of IDUs and a lower 
proportion of MSMs [83,188,189]. 
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      CASCADE  Irish notifications (method A)               Irish notifications (method B) 
Figure 2-3. Comparison of age distribution of CASCADE collaboration and estimated Irish 
notification data 
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2.3.2.4.4 Modelled estimates 
The Global Burden of Diseases, Injuries and Risk Factors Study (GBD) is an 
international collaboration, led by the Institute for Health Metrics and Evaluation 
(IHME) at the University of Washington. Its purpose is to systematically quantify 
levels and trends in mortality, disability, disease burden, life expectancy and risk 
factors at global, regional and national levels. GBD (2013) HIV mortality and 
incidence estimates were based primarily on a modified version of the UNAIDS 
Spectrum model [190], which is a compartmental HIV progression model (an 
illustration of which is shown in Figure 2-4). For countries with concentrated 
epidemics the HIV incidence data required by the Spectrum model have historically 
been generated based on data on specific high risk groups (the percentage of the 
population and the prevalence of HIV in each group). These data, however, are 
often lacking and an alternative is to track the epidemic through deaths reported in 
the vital registration systems. Vital registration data often underestimate the 
number of HIV deaths as deaths may be misclassified or assigned to immediate or 
intermediate causes of death (i.e. garbage codes) rather than the underlying cause 
of death.  
Attempting to address these limitations, the GBD study generates adjusted HIV 
mortality estimates by redistributing the number of deaths coded under “garbage 
codes” (some of the redistribution is proportional, some is based on statistical 
methods, and some is based on evidence from the literature [190]) and correcting 
for misclassification (using a method developed by Birnbaum and colleagues [191]) 
and uses these estimates to calibrate their modified Spectrum model [190]. 
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Figure 2-4. Diagram of Spectrum/Estimation and Projection Package (EPP) model [192].  
 
The estimated cumulative number of HIV deaths in Ireland produced by this 
methodology was around 470 by 2013 (estimated range 338-646)[173] (Figure 2-5). 
GBD estimated the number of HIV/AIDS deaths in Ireland was between 12 and 25 in 
2013 [190] compared to 3 deaths reported to the HPSC [82] and 6 deaths reported 
by the CSO [193]. 
For 2014-2020, the average of the GBD estimated number of deaths per year for 
the preceding 5 years (2009-2013) was used. 
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Figure 2-5. GBD estimated number (range) of HIV/AIDS deaths per year 1980-2013 ([173] 
data downloaded 21/4/2015) 
 
2.3.3 Model validation 
There is currently no routinely collected data on the number of patients in care. A 
prevalence study was carried out in 2009/2010 which identified that there were 
3,254 patients accessing care at that time [85]. The total number and age 
distribution of patients in care in 2009/2010 was compared to the estimated total 
numbers and age distributions generated by the various models. χ2 tests were used 
to test the significance of differences between the proportions of patients in each 
age group as estimated by the various models to the observed data. 
2.3.4 Sensitivity analysis 
Uncertainty in the model estimates were investigated using one-way sensitivity 
analysis varying the mean age at diagnosis and proportion of patients lost-to-
follow-up annually, based on the 95% confidence intervals of source data. The 
annual number of deaths was varied based on the difference between the total 
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number of deaths in Ireland per year as estimated by the GBD and UNAIDS 
(spectrum) estimates. 
2.4 Results 
2.4.1 Model 1a 
Model 1a: the number of deaths per year in each age group estimated using 
published excess mortality rates [188]. The age distributions of cases each year was 
estimated using method A (see section 2.3.2.2.1 above), Figure 2-6. The 95% 
confidence intervals of the published excess mortality rates [188] were used to 
generate alternative estimates given low/high excess mortality (Table 2-4). 
 
 
Figure 2-6. Estimated age distribution of HIV cases in care, 1985-2020 model 1a, mean 
mortality estimate 
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Table 2-4. Estimated total number of people in care, by age group, 2012 and 2020, model 
1a 
Age group 2012 2012 (low 
mortality) 
2012 (high 
mortality) 
2020 2020 (low 
mortality) 
2020 (high 
mortality) 
< 20 59 59 59 54 54 53 
20-29 477 480 474 449 451 447 
30-39 1,419 1,431 1,408 1,347 1,359 1,335 
40-49 1,181 1,196 1,167 1,469 1,490 1,449 
50-59 558 568 547 915 933 898 
60-69 132 134 130 327 349 332 
70+ 18 18 18 79 67 64 
Total 3,845 3,887 3,803 4,641 4,703 4,580 
 
2.4.2 Model 1b 
Model 1b: number of deaths per year in each age group estimated using published 
excess mortality rates [188]. The age distributions of cases each year was estimated 
using method B (see section 2.3.2.2.2 above) Figure 2-7. The 95% confidence 
intervals of the published excess mortality rates [188] were used to generate 
alternative estimates given low/high excess mortality (Table 2-5). 
 
Figure 2-7. Estimated age distribution of cases in care 1985-2020, model 1b, mean 
mortality estimate 
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Table 2-5. Estimated total number of people in care, by age group, 2012 and 2020, model 
1b 
Age group 2012 2012 (low 
mortality) 
2012 (high 
mortality) 
2020 2020 (low 
mortality) 
2020 (high 
mortality) 
< 20 134 135 133 73 73 72 
20-29 570 574 566 413 416 410 
30-39 1,206 1,217 1,195 1,154 1,166 1,143 
40-49 1,204 1,218 1,190 1,555 1,575 1,535 
50-59 580 589 571 1,036 1,054 1,019 
60-69 140 143 137 362 370 354 
70+ 11 11 11 48 50 47 
Total 3,844 3,887 3,803 4,641 4,704 4,581 
 
2.4.3 Model 2a 
Model 2a: number of deaths per year in each age group as estimated by GBD [173]. 
The age distributions of cases each year was estimated using method A (see section 
2.3.2.2.1 above), Figure 2-8. The 95% confidence intervals of the GBD estimates 
were used to generate alternative estimates given low/high estimated number of 
deaths (Table 2-6).  
 
Figure 2-8. Estimated age distribution of cases in care 1985-2020, model 2a, mean 
mortality estimate 
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Table 2-6. Estimated total number of people in care, by age group, 2012 and 2020, model 
2a 
Age group 2012 2012 (low 
mortality) 
2012 (high 
mortality) 
2020 2020 (low 
mortality) 
2020 (high 
mortality) 
< 20 61 61 61 47 47 47 
20-29 388 391 385 364 367 359 
30-39 1,396 1,410 1,370 1,294 1,308 1,274 
40-49 1,260 1,286 1,222 1,547 1,580 1,503 
50-59 671 701 631 1,009 1,045 963 
60-69 150 162 123 423 445 384 
70+ 31 34 28 91 101 77 
Total 3,957 4,045 3,820 4,775 4,893 4,607 
 
2.4.4 Model 2b 
Model 2b: number of deaths per year in each age group as estimated by GBD [173]. 
The age distributions of cases each year was estimated using method B (see section 
2.3.2.2.2 above), Figure 2-9. The 95% confidence intervals of the GBD estimates 
were used to generate alternative estimates given low/high estimated deaths 
(Table 2-7). 
 
Figure 2-9. Age distribution of cases in care 1985-2020, model 2b, mean mortality 
estimate 
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Table 2-7. Estimated total number of people in care, by age group, 2012 and 2020, model 
2b 
Age group 2012 2012 (low 
mortality) 
2012 (high 
mortality) 
2020 2020 (low 
mortality) 
2020 (high 
mortality) 
< 20 124 124 124 60 60 60 
20-29 583 587 576 421 423 417 
30-39 1,237 1,252 1,211 1,183 1,195 1,158 
40-49 1,235 1,262 1,197 1,593 1,622 1,551 
50-59 585 611 542 1,065 1,101 1,018 
60-69 141 159 120 367 390 333 
70+ 18 20 13 70 74 57 
Total 3,923 4,015 3,783 4,759 4,865 4,594 
 
2.4.5 Comparison of model results for 2012 
The use of GBD estimates of the number of deaths (i.e. models 2a and 2b) resulted 
in a slightly higher estimated number of patients in 2012 compared to the models 
using published excess mortality rates (models 1a and 1b), see Table 2-8. While the 
use of data-based age estimates (method A) rather than predicted mean age 
estimates to reconstruct the age breakdown of diagnosed cases (method B) 
resulted in a more pronounced peak of cases in the 30-39 year age group in 2012 
(Figure 2-10). 
Table 2-8. Comparison of estimated number of patients attending care in 2012, produced 
by models 1a, 1b, 2a and 2b. 
Age 
group 
Model 1a (high-
low mortality) 
Model 1b (high-
low mortality) 
Model 2a (high-low 
mortality) 
Model 2b (high-
low mortality) 
< 20 59 (59-59) 134 (133-135) 61 (61-61) 124 (124-124) 
20-29 477 (474-480) 570 (566-574) 388 (385-391) 583 (576-87) 
30-39 1,419 (1,408-1,431) 1,206 (1,195-1,217) 1,396 (1,370-1,410) 1,237 (1,211-1,252) 
40-49 1,181 (1,167-1,196) 1,204 (1,190-1,218) 1,260 (1,222-1,286) 1,235 (1,197-1,262) 
50-59 558 (547-568) 580 (571-589) 671 (631-701) 585 (542-611) 
60-69 132 (130-134) 140 (137-143) 150 (123-162) 141 (120-159) 
70+ 18 (18-18) 11 (11-11) 31 (28-34 18 (13-20) 
Total 3,845 (3,803-3,887) 3,844 (3,803-3,887) 3,957 (3,820-4,045) 3,923 (3,783-4,015) 
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Figure 2-10. Comparison of estimated age breakdown of cases in care 2012, model 1a, 1b 
2a and 2b. 
 
2.4.6 Model Validation 
The only available data on the number and age profile of patients attending HIV 
care in care Ireland is from a national prevalence study carried out in 2009/2010 
[85]. The average age distribution for 2009 and 2010 as estimated by the various 
models were tested against the observed age distribution (Table 2-9) and the age 
distributions were all found to be significantly different, apart from model 2a (high 
mortality). The total number of patients in care in 2009/2010 as estimated by this 
model (the final model) was 3,510 (average of 2009 and 2010) compared to 3,254 
patients identified in the prevalence study carried out by Tuite et al. [85]. While this 
appears to be quite a large difference, 8% higher than the number of patients 
observed in the prevalence study, that study did not include private patients. 
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Table 2-9. Comparison of averaged 2009 and 2010 model results to observed data 
Age 
group 
(years) 
Observed 1a 1a low 
mortality 
1a high 
mortality 
1b 1b low 
mortality 
1b high 
mortality 
2a 2a low 
mortality 
2a high 
mortality 
2b 2b low 
mortality 
2b high 
mortality 
15-25 4.72% 6.48% 6.45% 6.51% 11.32% 11.27% 11.36% 5.05% 4.96% 5.21% 11.26% 11.00% 11.54% 
26-35 30.10% 33.46% 33.33% 33.58% 28.33% 28.26% 28.40% 30.62% 30.14% 31.21% 28.46% 28.07% 28.87% 
36-45 39.36% 35.26% 35.25% 35.26% 34.29% 34.28% 34.29% 35.93% 35.77% 36.26% 34.38% 34.15% 34.74% 
46-55 20.31% 18.90% 19.04% 18.76% 19.79% 19.85% 19.73% 21.85% 22.16% 21.54% 19.65% 19.92% 19.23% 
56-65 4.32% 4.99% 5.01% 4.96% 5.53% 5.57% 5.48% 5.36% 5.65% 4.75% 5.36% 5.85% 4.96% 
66+ 1.17% 0.91% 0.92% 0.91% 0.75% 0.76% 0.74% 1.19% 1.31% 1.02% 0.90% 1.01% 0.65% 
P  <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.041 0.009 0.159 <0.001 <0.001 <0.001 
(Source of observed data personal communication Dr Helen Tuite, 6/12/2015) 
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2.4.7 Final model results 
The age distribution of cases in care each year as estimated by the final model selected is 
shown in Figure 2-11. The model estimates the total number of people in care has been 
increasing by 3%-4% each year between 2010-2014, and that this number will continue to 
increase by about 2% each year from 2015-2020 (Figure 2-12). The average age of patients 
in care has increased by an average of 0.49 years annually over the last 10 years (2005-
2014) (Figure 2-13), and the proportion of patients >50 years is estimated to increase from 
18% in 2012 to 30% in 2020. 
The proportion of patients aged ≥50 years in Ireland appears lower than that reported by 
some other developed countries (Figure 2-14). The differences between countries can be 
explained by variations in the definitions (e.g. patients diagnosed vs patients in care) and 
methodologies (surveys vs modelling) used as well as by underlying differences in the age 
structure of the population and HIV epidemiology. However, it does appear that the rate at 
which the proportion of older patients is increasing is consistent across countries. 
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Figure 2-11. Age distribution of patients in care, final model 
 
 
 
Figure 2-12. Estimated total number of patients in care 1985-2020, final model 
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Figure 2-13. Estimated average age of patients in care by year, final model 
 
 
Figure 2-14. Proportion of people living with diagnosed HIV (US and Australia) or in care for HIV 
(Ireland and UK) aged ≥50 years (Australia ≥55 years), 2001-2013 (Sources of data: US, CDC 
surveillance reports for years 2004, 2008, 2009, 2011, and 2013 [194]; UK, HIV in the UK reports for 
years 2011, 2013 and 2014 available at https://www.gov.uk/government/statistics/hiv-in-the-
united-kingdom ; Australia [195].) 
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2.4.8 Sensitivity Analysis 
One way sensitivity analysis of the final model was performed, varying the mean age at 
diagnosis (pre-2003 only), loss-to-follow-up and annual number of deaths. 
Age at diagnosis 
The lower and upper bounds of the 95% confidence intervals of the mean age at diagnosis 
for the years pre-1991 (based on the results of the Monte Carlo simulation) and 1992-2002 
(based on NVRL first positive samples) were used to construct alternative age distributions 
of notified cases for those years. 
Loss-to-follow-up 
Loss-to-follow-up was varied based on the 95% confidence intervals (4%-6%) of the rate of 
loss-to-follow up, calculated based on data reported by Rice et al. (2011) [79]. 
Number of deaths 
The estimated number of deaths used in the base case model was the higher bound of the 
GBD estimates. The GBD methodology tends to result in a lower number of deaths 
compared to UNAIDS (Spectrum) estimates [190]. For sensitivity analysis the total estimated 
number of AIDS-related deaths in Ireland (1990-2014) as estimated by UNAIDS [26] was 
compared to the total number of HIV/AIDS deaths in Ireland as estimated by the GBD 
project [173] (Figure 2-15). The proportional difference between the upper bound of the 
GBD estimates and the mean UNAIDS estimate were calculated for each year that estimates 
from both sources were available (1990-2013), and the number of deaths in all age groups 
were multiplied by that proportion. The 1990 proportional difference was applied for years 
before 1990 and the proportional difference in 2013 was applied to years after 2013. 
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The results of all the sensitivity analyses performed are shown in Table 2-10. The results 
were most sensitive to variation in the estimate of loss-to-follow up, with a variation of ±1% 
resulting in a difference of ±8% from base case estimates in 2012. The mean age and 
proportion ≥50 years of age varied relatively little on sensitivity analysis. 
 
 
Figure 2-15. Comparison of GBD and UNAIDS (spectrum) estimates of number of HIV/AIDS deaths 
in Ireland 1990-2013 (UNAIDS data downloaded 8/12/2015) 
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Table 2-10. Results of one-way sensitivity analysis 
 Total number 
of patients in 
care 
2009/2010 
Mean age 
of patients 
2009/2010 
% patients 
ages ≥50 years 
2009/2010 
Total number 
of patients 
2012 
Mean 
age of 
patients 
2012 
% 
patients 
ages ≥50 
years 
2012 
Total 
number 
of 
patients 
2020 
Mean age of 
patients 2020 
% patients 
ages ≥50 years 
2020 
Base case 3,510 39.5 16% 3,820 40.8 20% 4,607 44.1 31% 
Lower estimate of mean 
age pre 2003 
3,507 39.1 15% 3,811 40.5 19% 4,605 44.0 30% 
Higher estimate of mean 
age pre 2003 
3,516 39.8 18% 3,824 41.1 22% 4,609 44.3 31% 
Lower estimate of annual 
loss-to-follow-up (4%) 
3,774 39.7 17% 4,134 41.1 21% 5,109 44.6 33% 
Higher estimate of annual 
loss-to-follow-up (6%) 
3,274 39.2 16% 3,530 40.5 19% 4,168 43.6 29% 
Total number of deaths 
decreased/increased to 
UNAIDS estimate 
3,351 39.3 16% 3,599 40.5 20% 4,208 43.6 29% 
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2.4.9 Exploratory modelling by risk group 
Different ageing patterns are likely to occur in the different risk groups due to the 
epidemiological differences between these groups (e.g. in mean age of infection 
and mortality rates etc [188,196-198]).  
In Ireland, individual level data on the risk factor and ages of diagnosed cases has 
only been available since a case-based voluntary reporting system was established 
by the HPSC in 2002 (with 2003 being the first full year of data collection). As can be 
seen in Figure 2-16 the mean age of notified cases differs across risk groups and has 
increased over time, except for the MSM risk group whose mean age at notification 
had decreased from 36.5 years in 2003 to 33.5 years in 2014. 
 
Figure 2-16. Average age of notified cases in Ireland 2003-2014 by risk group (Source of 
data: HPSC) 
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In order to examine possible differences in the ageing of the patients in care by risk 
group we ran the validated model separately for five different groups of cases:  
1. Cases notified before 2003 (pre-2003) 
2. MSM notified from 2003 onwards (MSM) 
3. IDU notified from 2003 onwards (IDU) 
4. Heterosexuals notified from 2003 onwards (Heterosexual) 
5. Other/unknown notified from 2003 onwards (Other/unknown) 
The validated model (model 2a) used number of HIV related deaths as estimated by 
the GBD study, however the estimated number of deaths from the GBD study is 
only broken down by age and not by risk factor. In order to use this model we had 
to assume that HIV-related deaths were distributed proportionally across risk 
groups. In reality this assumption is likely to underestimate deaths in risk groups 
with poorer HIV outcomes (such as IDUs and heterosexuals) and overestimate 
deaths groups with better outcomes (e.g. MSMs). 
As empiric data on the age breakdown of patients in care by risk factor and year of 
notification was not available, it was also not possible to validate the results of this 
modelling, and all results should be interpreted with caution. 
Breakdown of patients in care 
The total number of patients in care by risk group is shown in Figure 2-17. By 2012 
it was estimated that only 27% of patients in care had been diagnosed prior to 
2003, by 2020 it is estimated that this proportion will have decreased to 14%. 
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Figure 2-17. The estimated total number of HIV patients in care in Ireland by year and risk 
group (pre-2003 are cases notified prior to 2003 whose risk factor is not known). 
 
MSMs 
The estimated changes in the age distribution of MSMs in care notified since 2003 is 
shown in Figure 2-18. In 2003 approximately 9% of MSMs in care were ≥50 years of 
age, by 2012 this had increased to 17% and it is estimated to continue to increase 
to 22% by 2020. The mean age of MSM patients in care (also shown on Figure 2-18) 
has also increased by 4.5 years over the same time period (36.5 years in 2003 to 41 
years in 2020). 
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Figure 2-18. Estimated age profile and mean age of MSM HIV patients (notified since 
2003) in care 
 
Heterosexuals 
The estimates of the changing age profile of the patients in the heterosexual risk 
group appear to be more dramatic than in the MSM patients (Figure 2-19) , with an 
increase in mean age of 13 years (from 30 years in 2003 to 43 years in 2020) with a 
10-fold increase in the proportion of patients aged ≥50 years, from 2% in 2003 to 
over 24% in 2020. 
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Figure 2-19. Estimated age profile and mean age of heterosexual HIV patients (notified 
since 2003) in care 
 
IDUs 
The scale of the ageing of the IDU patients is similar to the heterosexual population 
in that we have estimated a 14 year increase in mean age between 2003 and 2010 
(from 29 years to 43 years) and 23% of patients projected to be aged ≥50 years by 
2020 (Figure 2-20). 
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Figure 2-20. Estimated age profile and mean age of IDU HIV patients (notified since 2003) 
in care. 
 
Comparison of risk groups 
The estimated changes in the mean age of patients in care by risk group are shown 
in Figure 2-21. The mean age of MSMs has increased the least (0.3 years annual on 
average between 2003 and 2020), with the mean age of all other groups increasing 
by 0.8-1.1 years annually over the same time period. 
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Figure 2-21. Estimated mean age of patients in care in Ireland by risk group 
 
As would be expected the proportion of patients aged ≥50 years is increasing most 
rapidly in the group of patients diagnosed prior to 2003, with an estimated 65% of 
this group being aged ≥50 years by 2020 (Figure 2-22). The results of this modelling 
also illustrate that patients in the ≥50 year age group are still relatively young. In 
2012 50% of patients estimated to be aged ≥50 years were aged between 50 and 54 
years and only 10% of patients aged ≥50 years were aged ≥65 years (2% of all 
patients) (Figure 2-23). 
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Figure 2-22. The proportion of patients in care in Ireland aged ≥50 years each year by risk 
group 
 
Figure 2-23. The proportion of patients in Ireland aged ≥ 65 years in care each year by risk 
group 
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Although the age profile of the MSM population in care is estimated to be changing 
more slowly than other risk groups, in terms of absolute patient numbers MSMs are 
still projected to account for one quarter of patients aged ≥50 years in 2020 (Figure 
2-24). 
 
Figure 2-24. The estimated number of patients in care aged ≥50 years by year and risk 
group 
 
2.5 Discussion 
Accurate data on the epidemiology of any disease, including data on its prevalence 
and demographic characteristics is essential for health service planning. While there 
has been comprehensive case-based reporting of new HIV diagnoses in Ireland 
since 2003, there is very little data on the prevalence of HIV, the demographic 
characteristics of the national HIV cohort and until recently, on the total number of 
patients accessing services nationally. In the absence of empiric data mathematical 
models can provide useful data on the epidemiology of infectious diseases and the 
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potential impact of control programmes. Some modelling of the HIV epidemic in 
Ireland was carried out in the pre-HAART era based on HIV transmission in the 
injecting drug using population [176,199]. Since then there has been no published 
attempt to model the HIV epidemic in Ireland, due to the lack of many of the key 
pieces of information needed for the accurate modelling of HIV epidemics, such as 
age at infection, mortality data, stage at diagnosis (CD4 or CDC classification) and 
proportion of patients in treatment. 
Despite the lack of available data, we felt it was necessary to attempt to estimate 
the number of patients as accurately as possible to inform the estimated national 
cost of providing outpatient care in 2012. We have also attempted to generate 
estimates of the age distribution of patients due to the resource implications the 
ageing of the HIV population is likely to have, and have used the model developed 
to make short term predictions, up to the year 2020, of the total number and age 
breakdown of patients in HIV care in Ireland. We estimated that the total number 
of people in care in 2012 was approximately 3,820 (ranging on sensitivity analysis 
from 3,668 to 4,134), and if the number of cases diagnosed annually remains stable, 
project that by 2020 4,607 patients will be attending care for HIV in Ireland. The 
mean age of cases was estimated to be 40.8 years, and the mean age had increased 
annually by an average of 0.49 years each year in recent years (2005-2014), with 
the proportion of patients aged ≥50 years increasing by 1.5% each year over the 
same period. When compared to other developed countries, the age profile of HIV 
patients in care in Ireland appears slightly younger [141,144,167,200], although it is 
difficult to make direct comparisons because of differences in the definitions and 
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methods used to generate these estimates. In reality, in some cases the difference 
may be even greater, as estimates of the proportion of people living with diagnosed 
HIV who are in the older age groups are likely to be lower than the proportion of 
people in care in the same age groups as engagement in care increases with age 
[201]. For example, in the US it was estimated that 35% of people living with 
diagnosed HIV in 2012 were ≥50 years [202] but data from a survey of patients in 
care for the same year (the Medical Monitoring Project) estimated that 40% of 
adult patients (>18 years) in care were ≥50 years [203]. Despite the differences in 
the proportion of older patients across countries, however, the rate at which HIV 
populations are ageing appears consistent across jurisdictions (Figure 2-14).  
Although the results of the exploratory modelling of the ageing of patients in care 
stratified by risk group are unvalidated and should be interpreted with caution, it is 
interesting to see the possible differences in age trends – with the MSM population 
ageing at a slower rate than the other risk groups. This is somewhat different to 
what has been described in the literature in the US where the rate of ageing of 
MSMs in care appears similar to other risk groups [134], and is a reflection of the 
ongoing transmission of HIV in young MSMs in Ireland [82]. 
2.5.1 Strengths and limitations 
Due to the lack of data available, only very rudimentary calculations were used to 
model the numbers of patients in care each year, and it was unclear which 
estimates of age and deaths were the most appropriate to use. In light of this, 
several variations of the model were performed and the results of all the models 
were validated against observed data from a prevalence study of patients in care in 
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2009/2010 [85]. Only one model was found not to result in estimates significantly 
different from the observed data. This model was selected as the final model and 
uncertainty in the final model was investigated using one-way sensitivity analysis, 
varying the mean age (pre 2002), loss-to-follow-up and number of deaths. The level 
of variation of the input variables in the sensitivity analysis was informed by the 
data available. 
There are also major limitations to the estimates generated. A lack of data on age at 
diagnosis made it necessary to construct age distributions for years pre 2003 based 
on mean ages of diagnoses. For years before 1992 the mean age was based on a 
single study of attenders at one Dublin clinic [176], while between 1992 and 2002 
age information from first positive samples sent to the NVRL was used, which was 
likely to overestimate the mean age at diagnosis. Reliable routine data on deaths in 
HIV patients is also limited in Ireland and we had to use the estimated number of 
deaths from a modelling study, which had its own assumptions and limitations 
[190]. 
We relied on a published estimate of 5% loss-to-follow-up each year in the UK, 
however, this rate may not be appropriate for use in Ireland, as several factors may 
have resulted in higher out-migration of HIV patients in Ireland compared to the UK 
or other developed countries. At the beginning of the HIV/AIDS epidemic in the 
1980s and early 1990s Ireland had a comparatively low proportion of MSM cases. 
This may have been due to underreporting of MSM as a risk factor as a result of the 
particular cultural and religious factors present in Ireland at that time (e.g. illegality 
of homosexual activity) [204], however these same factors also resulted in high 
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emigration rates (either permanent or temporary) of MSMs [205], and HIV positive 
MSMs in particular may have travelled abroad for HIV diagnosis and/or treatment 
particularly in the early years of the epidemic, when stigma was high and expertise 
in Ireland was limited (the first infectious disease consultant was appointed in 
Ireland in 1993, previously there had been a single consultant in genitourinary 
medicine appointed in 1987 providing care for HIV patients). In addition, starting in 
the late 1990s there was a large rise in notified HIV in heterosexuals the majority of 
whom originated from sub-Saharan Africa [206]. A substantial proportion of these 
cases were likely to have been asylum seekers as there was a sharp increase in the 
number of people seeking asylum in Ireland around that time [207] and the 
prevalence of HIV in asylum seekers is 1.7% [96]. It is unclear what proportion of 
HIV positive asylum seekers remain in the county, given that the success rate for 
asylum applications generally is low (around 10% [207]). A further complication is 
the possibility of patients choosing to attend a consultant privately for their routine 
HIV care, and so be “lost” to the public system. The number of patients attending 
private HIV care nationally is unknown. Temporary loss-to-follow-up was also not 
included in the model. 
The model used was a very simple deterministic model, using population averages 
and did not take into account changes in individual patients’ status over time. The 
main model was not stratified for any clinical (e.g. CD4 counts, AIDS diagnosis, 
treatment status) or demographic (e.g. gender, risk group) factors, apart from age 
at diagnosis. We did attempt to explore possible differences be risk group for cases 
notified since 2003, however it was not possible to validate the results of the 
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stratified modelling, and the assumption was made that HIV-related deaths were 
distributed evenly across risk groups, which is unlikely to be the case in reality. 
There was also only one year of empiric data to validate the results of the main 
model against, it is possible that the final model selected produced an age-
distribution similar to the observed data by chance, and if further years of observed 
data had been available the model would have been proved to produce invalid 
results. 
In conclusion, we estimate that in 2012 there were approximately 3,820 HIV 
patients in care in Ireland, and that approximately 20% of the patients in care were 
≥ 50 years of age. Unless the new number of diagnoses decreased we estimate that 
by 2020 the total number of patients in care will have increased by approximately 
20% and nearly one third of patients in care will be ≥50 years of age. This is the first 
attempt to quantify the size and age breakdown of the HIV patients in care in 
Ireland in the HAART era, and as such will feed into our estimation of the current 
cost of outpatient care at a national level. In the absence of the data required to 
allow more sophisticated modelling of the HIV epidemic here these results provide 
a basis for assessing the potential rate of ageing of the HIV population in Ireland. 
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3.1 Abstract 
Demands on HIV services are increasing as a consequence of the increased life-
expectancy of HIV patients in the HAART era. Understanding the factors that 
influence utilization of ambulatory HIV services is useful for planning service 
provision. This study reviewed factors associated with utilization of hospital based 
HIV out-patient services. Studies reporting person-based utilization rates of HIV-
specific outpatient services broken down by patient or healthcare characteristics 
were eligible for inclusion. The Andersen Behavioural Model was used to organise 
the information extracted into pre-disposing, enabling and need components. Ten 
studies were included in the final review. Older age, private insurance, urban 
residence, lower CD4 counts, a diagnosis of AIDS, or anti-retroviral therapy (ART) 
were associated with higher utilization rates. The results of this review are 
consistent with existing knowledge regarding HIV patients’ use of health services. 
Little information was identified on the influence of health service characteristics 
on utilization of out-patient services. 
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3.2 Introduction 
The emergence of HAART for the treatment of HIV infection in the mid-1990s has 
had profound consequences for both those living with HIV and the healthcare 
systems providing care for them. A person diagnosed with HIV today can have a 
near normal life expectancy [208]. A recent modelling study estimated that the 
median life expectancy of people living with HIV after entry to healthcare is over 40 
years [9]. Continuing transmission of HIV, combined with the reductions in 
mortality and increased life-expectancy resulting from HAART, means that both the 
overall size and the age profile of the HIV population are increasing. These changes 
will inevitably increase the demands placed on HIV services worldwide. 
Utilization of healthcare services is influenced by many factors which operate at 
individual, healthcare provider and societal levels. Examination of healthcare 
utilization patterns can be used to identify sub-groups of patients who are either 
under- or over-utilizing services. Under-utilization of services has consequences for 
the patient, as it has been shown that patients not fully engaged in care have 
poorer outcomes [76], while over-utilization is an inefficient use of health system 
resources. International guidelines for the care, management and treatment of HIV 
patients recommend that patients are monitored 2-4 times per year, depending on 
the individual needs of the patients [3,41,75]. However there is still debate on the 
optimal frequency of monitoring [77,78]. While quality indicators, such as the 
recent HIV/AIDS Bureau performance measures [209] have been developed which 
include measures of visit frequency, these measure the proportion of patients 
meeting a minimum standard and do not provide information on the volume of 
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care being provided.  It is necessary to have information on the volume of resources 
used by patients, and the most important factors which influence patients’ 
utilization of services, to accurately estimate the consequences of the changing 
population characteristics on future service demand and cost.  
The Behavioural Model was originally developed by Andersen in the 1960s to 
explain why people use healthcare services [210]. The model initially categorised 
explanatory factors into three components: predisposing, enabling and need 
factors. Later versions of the model also incorporated health behaviour and 
outcomes, with feedback loops to reflect the dynamic relationships between 
outcomes, use of services and explanatory factors [211]. It has been widely used 
since both as a theoretical framework for explaining why people use health services 
[212], and as an organizational framework for reviewing determinants of health 
service utilization in a variety of settings and diseases [213-215]. 
A previous comprehensive review of HIV healthcare utilization performed by 
Uphold and Mkanta (2005) described some variation in use of out-patient services 
[216]. However, their review did not focus specifically on outpatient services, was 
not systematic and many of the articles reporting out-patient utilization pre-dated 
or were from the early HAART era. Other reviews have focused on specific aspects 
of HIV care such as retention and engagement [217], cost [130] or use of specific 
services such as prevention services [218]. To our knowledge no review of the 
determinants of HIV out-patient utilization has been carried out to date. 
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The aim of this review was to identify any patient and/or healthcare related factors 
reported in the literature to be associated with HIV outpatient utilization in the 
HAART era. 
3.3 Methods 
The methodology for carrying out this review was based on published guidance for 
conducting and reporting systematic reviews [219-221]. 
The electronic databases PubMed, EMBASE, EconLit and CINAHL (EconLit and 
CINAHL via EBSCO) were searched for articles published between 01/01/1997 and 
01/03/2013. Keyword searches combined common terms for HIV (Human 
immunodeficiency virus OR HIV OR AIDS), healthcare (ambulatory care OR hospital 
OR out-patient OR outpatient), utilization (utilization OR utilisation OR cost OR 
expenditure), and patient characteristics (patient characteristics OR determinants 
OR predictors). An example of the full search strategy can be seen in Appendix 2. In 
addition, the reference lists of articles which underwent full review were manually 
searched. 
Any article which reported person-based utilization rates, or rate-ratios, of adult 
hospital-based HIV outpatient services, broken down by patient or healthcare 
factors were eligible to be included, regardless of study design. Due to the impact 
of HAART on patterns of healthcare utilization, only articles published since 1997 or 
reporting data for a time period when HAART was routinely available were 
reviewed. 
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Studies were excluded if they reported utilization of out-patient care which was not 
hospital-based (e.g. community, general practitioner, dental, complementary, 
prevention or home care services); or was not HIV specific (e.g. included outpatient 
visits to non-HIV services). Studies solely reporting utilization data of sub-groups of 
patients with specific co-morbidities (e.g. tuberculosis patients, haemophiliacs) and 
data on patients participating in clinical trials were excluded unless relevant 
information was reported on patients receiving usual care. Modelling studies were 
excluded unless they reported original utilization data. Studies which did not 
contain original utilization data (reviews/opinion pieces), were not peer-reviewed, 
or were published only in abstract form or in a language other than English, were 
also excluded. 
Data forms for extraction of study characteristics and quality assessment were 
developed based on published guidelines [219]. Data was extracted from included 
articles by a single reviewer (AB) and independently checked for completeness and 
accuracy by a second reviewer (DM). 
Information was extracted on general characteristics as well as analysis and 
reporting of the study results. The risk of bias (selection, information, other bias), 
choice of outcome measure, statistical analysis, quality of reporting, generalizability 
of results, and statements of funding/conflicts of interest were extracted and used 
to assess the overall quality of each study. 
The behavioural model for vulnerable populations was used as a framework for 
categorizing the results of this review into predisposing, enabling and need factors 
using traditional and vulnerable domains [222]. 
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3.4 Results 
3.4.1 Study characteristics 
A total of 10 articles were included in the final review. The number of articles 
excluded at each stage and reasons for exclusion are shown in Figure 3-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Flow chart of study selection 
*Other: Mother-to-child-transmission prevention (n=4), data only relating to a specific 
subgroup of patients (n=3), not hospital based (n=2), same/overlapping data as another 
article (n=3), non-English (n=1), clinical trial, no usual care arm (n=2) 
 
Records identified through 
database searching 
PubMed (n=1299) 
EMBASE  (n=1234) 
EconLit  (n=14) 
CINAHL (n=88) 
Additional records 
identified through 
other sources 
(n=87) 
Records after duplicates removed 
(n=2101) 
Records screened 
(n=2101) 
Records excluded (n=1912) 
Clearly not relevant (n=1653) 
Published before 1997 (n=244) 
Abstract/not peer reviewed (n=15) 
Full-text articles assessed for 
eligibility 
(n=189) 
Full-text articles excluded (n=179) 
Outpatient visits not reported (n=97) 
No breakdown by subgroups (n=23) 
Not HIV specific outpatients or unclear 
(n=28)  
Pre-HAART (n=8) 
No original utilisation data (n=8) 
Other* (n=15) 
Studies included in qualitative 
synthesis (n=10) 
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A summary of the study characteristics can be seen in Table 3-1. Four of the studies 
included were carried out in the United States (US) [223-226]. Of these, two 
reported on data collected as part of the HIV Research Network (HIVRN) [223,225], 
however as these studies reported data from different years both were retained in 
this review. The remaining studies were spread across Europe [138,227,228], Africa 
[229,230], and Asia [231]. 
The quality of seven of the articles reviewed was assessed as average or good, while 
three were assessed to be of poor quality (Table 3-2). The main issues affecting 
methodological quality were a lack of information on the sources of data used, and 
a low level of statistical analysis. Only two papers reported multivariate analysis 
[223,226]. 
A summary of the results of the studies can be seen in Table 3-3 and Table 3-4. 
3.4.2 HIV outpatient use 
3.4.2.1 Predisposing characteristics 
Three of the 10 articles included in the review reported utilization rates by the 
traditional predisposing demographic characteristics of gender, age and ethnicity 
[223,226,228]. Additional predisposing characteristics specific to vulnerable 
populations reported in the included studies were residency/immigration status 
[138,228], and route of infection [223,226,228]. 
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Table 3-1. Characteristics of included studies 
Reference Country Patient characteristics 
Type of 
study 
Data 
collection Source of data 
Time period of 
data 
Number of 
patients 
included 
Duration of 
follow-up: 
Bikilla et al., 
2009 [229] Ethiopia No ART  OR ART, >= 15 years old 
Comparison 
of 2 cohorts 
overlapping 
in time Retrospective 
Existing clinic 
database 
Non-ART: Jan 2003-
Apr 2004 
ART: Aug 2003-Mar 
2006 
Before: 
203 
After: 209 
before : up to 
15.2 months 
after: up to 31.2 
months 
Cook et al., 
2009 [228] UK All attendees Cohort 
Retrospective 
(every 6 
months) 
Enhanced HIV 
surveillance 
system Jan 2005-Jun 2006 3,983 up to 18 months 
Fleishman et 
al., 2005 
[223] US 
>=18 years old, in longitudinal 
HIV primary care 
Repeat 
cross-
sectional Retrospective 
Existing 
admin/hospital 
database & 
medical records 
2000 
2001 
2002 
13,392 
15,211 
14,403 1 year 
Garattini et 
al., 2001 
[227] Italy AIDS or Non-AIDS by CD4 Cohort Prospective 
Physician 
collected Aug 1997-Jul 1998 483 1 year 
Howe et al., 
2010 [226] US 
>= 18 years attending care, 
attended at least 1 appointment 
subsequent to baseline with 
laboratory measurements 
available Cohort Prospective 
Existing 
admin/hospital 
databases & 
medical records, 
patient 
interview 2001-2007 1,636 up to 7 years max 
Larson et al., 
2013 [230] Kenya 
1st year of ART, >=18 years old, 
not pregnant, files available Cohort Retrospective Medical records 2007-2008 360 12 months 
Paton et al., 
2006 [231] Singapore 
all attendees with at least 3 
months of follow-up, who either 
never had ART, or had only dual 
or only HAART. Singaporeans or 
permanent residents. Cohort Not specified 
Existing clinical 
database 1996-2001 764 up to 5 years max 
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Reference Country Patient characteristics 
Type of 
study 
Data 
collection Source of data 
Time period of 
data 
Number of 
patients 
included 
Duration of 
follow-up: 
Siddiqui et 
al., 2009 
[224] US 
Commercial health plan 
members, 2 medical claims with 
HIV diagnosis, or 1 medical claim 
and 1 prescription for ARV, 12 
months continuous enrolment Cohort Retrospective Claims database Jan 2005-Jul 2007 12,189 1 year 
Velasco et 
al., 2012 
[138] Spain All attendees Cohort Retrospective 
Existing 
admin/hospital 
database 2003-2005 372 up to 3 years 
Wilson et al., 
2011 [225] US 
>=18 years, in longitudinal 
primary care 
Cross-
sectional Retrospective 
Existing 
admin/hospital 
database & 
medical records 2005 8,824 1 year 
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Table 3-2. Quality assessment of included studies 
Reference 
Assessment 
of selection 
bias 
Assessment of 
Information 
bias 
SE, SD or 95%CI 
of means 
reported 
Multivariate 
analysis 
Other quality issues 
Overall assessment 
of quality 
Bikilla et al., 2009 
[229] Unlikely Unlikely Yes No 
The cohort of patients not on ART was earlier (but 
overlapping) in time than the cohort on ART. The 
ART cohort contained a much greater proportion 
of AIDS patients. Average 
Cook et al., 2009 
[228] Unclear Unlikely Yes No 
Time period used for calculation of rates not 
clearly reported Average 
Fleishman et al., 2005 
[223] Unclear Unlikely Yes Yes   Good 
Garattini et al., 2001 
[227] Unlikely Unlikely Yes No   Good 
Howe et al., 2010 
[226] Unlikely Unlikely Yes Yes  Good 
Larson et al., 2013 
[230] Likely Unlikely No No 
Rates specific to individual sites, would not be 
generalizable Poor 
Paton et al., 2006 
[231] Unlikely Unlikely No No No details given about recruitment of participants Poor 
Siddiqui et al., 2009 
[224] Unlikely Unlikely Yes No 
Overall generalizability may be an issue as all 
participants were employees Average 
Velasco et al., 2012 
[138] Likely Unlikely Yes No Time period of utilization data unclear Poor 
Wilson et al., 2011 
[225] Unclear Unlikely Yes No   Average 
SE, standard error SD standard deviation CI, confidence interval 
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Table 3-3. Summary of results of included studies 
Reference Predisposing Enabling Need 
Bikilla et al., 2009 [229]     ART: patients on ART (AIDS and non-AIDS) had 
significantly more outpatient visits per year than 
non-ART patients 
AIDS patients: no significant differences between 
the number of visits of AIDS patients compared to 
non-AIDS patients within the groups of patients 
either on ART or not on ART 
Cook et al., 2009 [228] Gender: no significant difference in 
number of visits. 
Age group: younger and older age groups 
had significantly more visits than 25-34 
year olds. 
Ethnicity: black Africans had significantly 
fewer visits than whites. 
Route of infection: mother to child and 
MSM had significantly more visits than 
heterosexuals. 
Residency: Asylum seekers and overseas 
students had significantly fewer visits than 
UK and other non-UK residents. 
Deprivation & urban category: No 
significant differences. 
Level of ART: those on quadruple therapy had 
significantly more visits than those on 
mono/dual/triple therapy, who had significantly 
more visits than those not on ART. 
Fleishman et al., 2005 
[223] 
Gender: females had significantly more 
visits than males. 
Age group: number of visits increased 
significantly with age group.  
Ethnicity: Hispanic patients had 
significantly more visits then whites. 
Route of transmission: Heterosexuals and 
IDUs had significantly fewer visits than 
MSMs. 
Insurance: compared to those with 
private insurance those with medicaid and 
medicare had significantly more visits and 
those uninsured had significantly fewer 
visits. 
CD4: number of visits increased significantly as CD4 
decreased. 
VL: those with VL < 10,000 had a significant, but 
slight, decrease number of visits compared to those 
with VL > 100,000.  
HAART: those on HAART had significantly more visits 
than those not receiving HAART. 
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Reference Predisposing Enabling Need 
Garattini et al., 2001 
[227] 
    ADI and CD4 category: No significant differences. 
Howe et al., 2010 [226] Gender: no significant difference. 
Age group: visits increased significantly 
with age. 
Ethnicity: no significant difference. 
Risk factors: no significant differences. 
Insurance: no significant differences. 
Urban area: no significant difference. 
Distance to clinic: no significant 
difference. 
Care first initiated in the study center: no 
significant difference. 
CD4: those with CD4 > 350 had significantly fewer 
visits than those with CD4 < 200. 
VL: no significant difference. 
AIDS: those with a clinical diagnosis of AIDS had 
significantly more visits than those not diagnosed 
with AIDS. 
ART: those on cART had significantly more visits than  
those not on cART 
Larson et al., 2013 [230]   Site: utilization varied by site, unable to 
assess if differences were significant. 
  
Paton et al., 2006 [231]     CDC stage A: visits increased from no ART to dual 
ART to HAART groups (unable to assess significance 
of differences). 
CDC stage B: More frequent visits in all categories 
compared to stage A patients (unable to assess 
significance of differences). Those receiving dual ART 
had highest utilization, followed by patients on 
HAART and then patients not on ART (unable to 
assess significance of differences). 
CDC stage C: similar patter to stage B patients, but 
rates higher in each category (unable to assess 
significance of differences). 
Siddiqui et al., 2009 
[224] 
    HIV associated weight loss: those with weight loss 
had significantly more visits than those without 
weight loss. 
Velasco et al., 2012 [138] Immigrant: no significant difference.     
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Reference Predisposing Enabling Need 
Wilson et al., 2011 [225]   Area of residence: utilization increased 
significantly from rural to peri-urban to 
urban area of residence for all patients. 
HAART patients only: more frequent visits on 
average than all patients combined, same pattern of 
utilization for area of residence (unable to assess 
significance of differences). 
S, significant. NS, not significant. U, unable to assess significance. IDU, injection drug use. VL, viral load. ADI, AIDS defining illness. OI, opportunistic infection. (c)ART, 
(combined) anti-retroviral therapy. 
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Table 3-4. HIV outpatient visit rates and relative rates by patient subgroup reported by included studies 
Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Predisposing characteristics 
Gender Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
Male 6.1 (5.9-6.2)     
 Female 5.8 (5.6-6.1)    
 Fleishman et al., 2005 [223] 2000-2002 Calendar 
year 
Male 5.46-5.90   ref 
 Female 5.86-6.44   1.12 (1.09-1.14) 
 Howe et al., 2010 [226] 2001-2007 Person-
months 
Female   0.96 (0.92-1.00) 1.01 (0.96-1.07)* 
Age Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
0-14 6.8 (5.9-8.0)     
 15-19 7.4 (5.6-9.8)    
 20-24 5.5 (4.9-6.2)    
 25-29 5.6 (5.2-6.0)    
 30-34 5.4 (5.1-5.7)    
 35-39 5.7 (5.5-6.1)    
 40-44 6.5 (6.1-6.8)    
 45-49 6.9 (6.5-7.3)    
 50-54 6.4 (5.8-6.9)    
 55-59 6.2 (5.5-7.0)    
 60+ 6.7 (6.0-7.4)    
 Fleishman et al., 2005 [223] 2000-2002 Calendar 
year 
18-30 4.12-4.87   ref 
 31-49 5.55-6.04   1.13 (1.10-1.16) 
 50+ 6.39-6.86   1.27 (1.22-1.31) 
 Howe et al, 2010 [226] 2001-2007 Person-
months 
per 10 years   1.07 (1.05-1.09) 1.06 (1.04-1.09)* 
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Ethnicity Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
White 6.1 (6.0-6.3)     
 Black Caribbean 6.5 (5.2-8.2)    
 Black African 5.8 (5.5-6.0)    
 Black Other 6.5 (4.7-9.0)    
 Indian/Pakistani/Bangladeshi 5.5 (4.6-6.6)    
 Other Asian/Oriental 5.5 (4.2-7.1)    
 Other/Mixed 6.0 (5.1-7.1)    
 Unknown 3.6 (2.5-5.1)    
 Fleishman et al., 2005 [223] 2000-2002 Calendar 
year 
White 5.28-6.02   ref 
 Black 5.10-5.68   1.02 (0.99-1.04) 
 Hispanic 6.74-7.02   1.11 (1.08-1.14) 
 Other 5.93-6.17   1.04 (0.97-1.12) 
 Missing ethnicity 3.59-6.27   0.93 (0.87-1.00) 
 Howe et al., 2010 [226] 2001-2007 Person-
months 
African American   0.95 (0.91-0.99) 0.96 (0.92-1.00)* 
Residency/immi
gration status 
Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
UK 6.1 (6.0-6.3)     
 Asylum seeker 5.5 (5.1-6.0)    
 Overseas student 5.2 (4.5-6.0)    
 Other non UK 6.4 (5.8-6.9)    
 Unknown 5.3 (4.8-5.9)    
 Velasco et al., 2012 [138] 2003-2005 study 
duration 
Spaniard 5.8 (SD 4.7)     
 Immigrant 5.6 (SD 4.5)     
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Route of 
transmission 
Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
MSM 6.3 (6.3-6.5)     
IDU 5.3 (4.5-6.2)    
Heterosexual 5.7 (5.5-6.0)    
Blood/tissue 5.9 (5.0-7.0)    
Mother to child 7.2 (6.2-8.3)    
Other/unknown 4.9 (3.9-6.1)    
Fleishman et al., 2005 [223] 2000-2002 Calendar 
year 
MSM 5.34-5.89   ref 
IDU 6.07-6.38   0.96 (0.93-0.99) 
Heterosexual 5.60-6.12   0.95 (0.93-9.8) 
MSM-IDU 6.62-6.79   1.06 (1.00-1.12) 
Heterosexual-IDU 5.77-6.10   1.04 (0.99-1.09) 
Other 4.35-5.42   0.87 (0.83-0.92) 
Missing 5.35-6.65   0.84 (0.81-0.88) 
Howe et al., 2010 [226] 2001-2007 Person-
months 
Intravenous drug use  1.05 (0.99-1.12) 1.03 (0.96-1.11) 
MSM   1.04 (1.00-1.08) 1.05 (1.00-1.11)* 
Enabling characteristics 
Insurance Fleishman et al., 2005 [223] 2000-2002 Calendar 
years 
Private 4.53-4.95   ref 
 Medicaid 6.36-6.76  1.12 (1.09-1.15) 
 Medicare 6.25-7.38  1.22 (1.19-1.26) 
 Ryan white/uninsured 4.28-5.32  0.97 (0.94-0.99) 
 Missing insurance 2.04-4.42  0.59 (0.55-0.62) 
 Howe et al., 2010 [226] 2001-2007 Person-
months 
None/other  ref ref 
 Private  1.07 (1.02-1.12) 1.04 (0.99-1.09)* 
 Public   1.06 (1.00-1.11) 1.05 (1.00-1.11)* 
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Area of 
residence 
Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
Not urban, least deprived 5.4 (4.8-6.0)     
 Urban, least deprived 6.1 (5.9-6.4)    
 Urban, average deprivation 6.1 (5.8-6.3)    
 Urban, most deprived 5.9 (5.7-6.2)    
 Wilson et al., 2011 [225] 2005 Calendar 
year 
Rural 3.95    
 Peri-urban 4.4    
 Urban 5.24    
 Rural  (patients on HAART) 4.02    
 Peri-urban  (patients on 
HAART) 
4.48    
 Urban  (patients on HAART) 5.83    
 Howe et al., 2010 [226] 2001-2007 Person-
months 
Urban area   1.03 (0.98-1.08) 1.02 (0.97-1.07)* 
 Distance to clinic per 50 
miles 
  0.97 (0.94-1.00) 0.97 (0.94-1.01)* 
Site Larson et al., 2010 [230] 2007 Patient in 
care/year 
Government District Hospital 8.3     
 Private company hospital 9.5    
 Mission hospital 8.9     
Care first 
initiated at 
study site 
Howe et al., 2010 [226] 2001-2007 Person-
months 
Yes   1.00 (0.96-1.07) 1.03 (0.98-1.07)* 
Need characteristics 
AIDS Howe et al., 2010 [226] 2001-2007 Person-
months 
AIDS   1.17 (1.12-1.22) 1.13 (1.08-1.18)* 
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
AIDS & CD4 Garattini et al., 2001 [227] 1997-1998 Person-years ADI 5.9 (5.3-6.7)     
 no ADI, CD4 < 200 6.6 (5.1-8.6)    
 no ADI, CD4 200 - 500 6 (4.8-7.7)    
 no ADI, CD5 >500 5.6 (4.1-7.9)     
CD4 Fleishman et al., 2005 [223] 2000-2002 Calendar 
years 
CD4 < 51 6.36-7.37   1.26 (1.21-1.31) 
 CD4 51-200 6.13-6.68   1.15 (1.12-1.18) 
 CD4 201-500 5.48-5.92   1.05 (1.04-1.07) 
 CD4 > 500 5.07-5.33   ref 
 Howe et al., 2010 [226] 2001-2007 Person-
months 
CD4 <200   ref ref 
 CD4 200-350   0.97 (0.92-1.03) 0.97 (0.92-1.04)* 
 CD4 >350   0.90 (0.86-0.95) 0.93 (0.88-0.98)* 
Viral load Fleishman et al., 2005 [223] 2000-2002 Calendar 
years 
Viral load < 10,000 5.50-5.94   0.97 (0.94-0.99) 
 Viral load 10,000-100,000 5.58-6.04  0.98 (0.95-1.01) 
 Viral load > 100,000 5.99-6.92  Ref 
 Missing 2.32-2.66  0.49 (0.44-0.54) 
 Howe et al., 2010 [226] 2001-2007 Person-
months 
Viral load <400   ref ref 
 Viral load 400-10,000   0.97 (0.92-1.01) 0.99 (0.95-1.04)* 
 Viral load >10,000   0.99 (0.94-1.04) 0.99 (0.94-1.04)* 
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Anti-retroviral 
therapy 
Cook et al., 2009 [228] 2005-2006 Annualised 
rate (based 
on 6 month 
periods) 
No ART 4.7 (4.5-4.9)     
 Mono/dual/triple ART 6.4 (6.2-6.6)    
 Quadruple ART 8.1 (7.7-8.5)    
 Fleishman et al., 2005 [223] 2000-2002 Calendar 
years 
No HAART 3.77-4.58   ref 
 HAART 5.99-6.36   1.39 (1.36-1.42) 
 Missing 5.70-6.95   1.02 (0.98-1.07) 
 Bikilla et al., 2009 [229] 2003-2006 Person-years No ART 4.6 (4.3-5.0)    
 ART 11.4 (11.0-11.7)    
 Howe et al., 2010 [226] 2001-2007 Person-
months 
cART   1.22 (1.15-1.28) 1.14 (1.08-1.20)* 
Clinical 
categories & 
anti-retroviral 
therapy 
Bikilla et al., 2009 [229] 2003-2006 Person-years Non-ART, non AIDS 4.5 (4.1-4.9)     
 Non-ART, AIDS 5.9 (4.0-7.9)    
 ART, non AIDS 11.4 (11.0-11.8)    
 ART, AIDS 11.3 (10.5-12.1)    
 Paton et al., 2006 [231] 1996-2001 Person-years CDC stage A- no ART 3.33     
 CDC stage A- Dual ART 6.69     
 CDC stage A - HAART 7.73     
 CDC stage B - no ART 5.7     
 CDC stage B - Dual ART 8.24     
 CDC stage B - HAART 7.62     
 CDC stage C - no ART 8.31     
 CDC stage C - Dual ART 9.18     
 CDC stage C - HAART 9.11     
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Group Reference Year(s) Denominator Category Rate (95% CI) RR (95% CI) RRadj (95% CI) 
Weight loss Siddiqui et al., 2009 [224] 2005-2007 Person-years Weight loss 9.7 (SD 12.9)     
No weight loss 5.9 (SD 5.0)     
*RRadj also weighted for inverse probability of censoring of drop-out and death. SD standard deviation, ref reference category. 
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Gender 
In the studies which reported utilization rates by gender, the majority of 
participants were male (68%-74%) [223,226,228]. Reported rates ranged between 
5.46 and 6.44 visits per year [223,228]. 
Two of the studies (from the USA and the UK) found no significant differences in 
utilization rates, although unadjusted female utilization tended to be lower than 
male [226,228]. In contrast, the results of a repeat cross-sectional study by 
Fleishman et al. (2005) found utilization rates of females to be greater than males 
(7%-9% in each of the three years reported), with an overall significant increase of 
12% found on multivariate analysis of the three year pooled data [223]. 
Age group 
The age breakdown of participants in the three studies was broadly similar with the 
majority of patients being between the ages of 30 and 50 years [223,226,228]. 
Reported rates ranged between 4.12 and 7.4 visits per year [223,228]. 
All three articles reported age-groups differently, making comparisons difficult. 
Fleishman et al. (2005) reported three broad age categories (≤30 years, 31-49 years 
and 50+ years). Compared to those 30 years and under, utilization rates were 13% 
higher in 31-49 year olds and 27% higher in those aged 50 years and over [223]. 
Cook et al. (2009) reported data in five-year age bands, allowing a more detailed 
pattern of utilization by age emerge. They found that people in younger and older 
age groups had higher rates of outpatient visits than people between 20 and 39 
years [228]. If their data is re-categorised into the three broad age groups reported 
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by Fleishman et al. (2005), the increased use in the younger age groups is masked, 
and a similar pattern appears (an increase of 5% and 11% in the middle and older 
age groups respectively). 
Howe et al. (2010) did not report utilization by age group, but reported an increase 
of 6% in scheduled attendances with each 10 year increase in age [226]. 
Ethnicity 
The largest group of patients in both US papers that reported ethnicity were of 
black ethnicity (47%-58%), with a smaller proportion (27%) of patients categorised 
as white [223,226]. In the UK 67% of patients were white and 27% were black 
Africans [228]. One of the US studies also reported a large proportion of Hispanic 
participants (18%-23%) [223]. Reported rates ranged between 5.1 and 7.02 visits 
per year [223,228]. 
Compared to whites, black patients tended to have fewer visits [223,226,228], but 
this finding was not significant in any of the studies following adjustment. In 
contrast, Hispanics were found to have significantly increased use compared to 
whites [223]. 
Residency/Immigrant status 
The studies which reported utilization by residency/immigration status found no 
significant differences in utilization compared to native residents in either the UK 
[228] or Spain [138], with reported rates ranging between 5.2 and 6.4 visits per 
year. 
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Route of infection 
Route of infection provides information on several vulnerable domains including 
sexual orientation and substance abuse. The categorization of risk groups varied 
between studies making comparisons difficult, however overall the rates of 
utilization varied ranged from 4.35 to 7.02 visits per year [223,228]. 
The most common routes of transmission were men who have sex with men (MSM) 
(36%-55%), followed by heterosexual acquisition (32%-38%) [223,226,228]. 
Heterosexuals were consistently found to have lower utilization rates than MSMs 
[223,226,228], although the difference was only significant in one of the studies 
[223]. 
People who had acquired their infection through injection drug use (IDU) also had 
slightly lower utilization rates than MSMs, with a 4% reduction on multivariate 
analysis of US data [223]. This was supported by data from the UK although the 
findings were not significant [228]. Another US study which compared IDUs to non-
IDUs found IDUs to have slightly higher utilization rates, but the difference was not 
significant [226]. 
3.4.2.2 Enabling characteristics 
Insurance 
Two studies carried out in the US, reported utilization by insurance status, rates 
varied from 4.28-7.38 [223]. Both studies found uninsured patients to have fewer 
visits than privately insured patients on multivariate analysis, although this 
difference was not significant in one of the studies [226]. However, the data 
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regarding publically insured patients differed, with one study reporting no 
difference between public and no/other insurance [226], and the other reporting 
significant increases of 12% for Medicaid, and 22% for Medicare patients compared 
to those with private insurance [223]. 
Area of residence 
The variation in categories used again made meaningful comparisons of rates 
difficult. One study included in this review specifically examined the relationship 
between rural/urban residence and use of HIV services [225]. They found utilization 
rates varied significantly by area of residence. Rural residents had the lowest 
utilization rates (3.95 visits/year), with utilization rates of urban residents and peri-
urban residents being 33% (5.24 visits/year) and 11% (4.4 visits/year) higher than 
rural residents respectively. When restricted to patients on HAART, the difference 
was even greater with urban residents on HAART having utilization rates 45% (5.83 
visits/year) higher than rural residents on HAART (4.02 visits/year). However, these 
rates were not adjusted for possible confounding variables [225]. 
The other studies reporting a breakdown by area of residence did not find any 
significant differences in utilization rates by rural/urban residence [226,228], or 
with distance to HIV clinic [226]. 
Health service resources 
One study included in this review compared utilization across three sites in one 
province in Kenya: a government district hospital; a private company hospital; and a 
mission hospital [230]. All sites receive PEPFAR (US President’s emergency plan for 
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AIDS relief) support and provide free out-patient ART. The public hospital had the 
lowest average number of outpatient visits per year (8.3 visits/year), while the 
private hospital had the highest average number of visits per year (9.5 visits/year). 
The differences between these rates were not tested statistically, and were not 
adjusted for any confounding factors. However the median baseline CD4 cell count 
was highest in the private hospital and lowest in the public hospital. 
Source of first HIV care 
Howe et al. (2010) found no difference in utilization by people who had initiated 
their care in their study centre compared to those had initiated their care 
elsewhere [226]. 
3.4.2.3 Need characteristics 
Evaluated Health (AIDS status/CD4 count) 
Five articles reported utilization rates broken down by some measure of disease 
severity. The individual measures used varied, however they were all based on 
some combination of CD4 cell count and/or clinical indicators of AIDS. Utilization 
rates ranged from 3.3 to 11.4 visits per year [223,227,229,231]. 
All studies found that as the measure of severity increased, the annual number of 
outpatient visits also tended to increase [223,226,227,229,231]. In studies that 
reported adjusted results, a clinical diagnosis of AIDS was found to be associated 
with a significant increase in visits (13% on multivariate analysis), and although 
categorization of CD4 counts varied across studies, there was a consistent and 
significant increase in utilization with decreasing CD4 count [223,226]. 
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One study reported a decrease in outpatient utilization by those with most severe 
disease (as use of inpatient care increased) [227]. 
ART/HAART 
The reporting of ART varied, with some studies reporting treatment (either ART or 
HAART) compared to no treatment [223,226,229], and others reporting levels of 
treatment [228,231]. 
In general, people on treatment tended to have more visits than patients not on 
treatment [223,226,228,229,231], with some evidence that utilization varied less in 
patients on treatment regardless of disease severity [229,231]. Two articles 
reported analyses adjusted for CD4 category, and both found patients on HAART 
attended significantly more frequently (14%–39%) than those not on HAART 
[223,226]. 
Utilization rates also vary by level of ART. In Singapore, Paton et al. (2006) found 
that in patients with less severe disease (CDC stage A) those on dual therapy had 
less frequent visits than those on triple therapy, but in patients with more severe 
disease (stage B and C) patients on triple therapy had lower utilization rates than 
those on dual therapy [231].  
Cook et al. looked at quadruple therapy compared to any other ART 
(mono/dual/triple) and found that those on quadruple therapy have significantly 
more outpatient visits [228], reflecting the fact that quadruple therapy is likely to 
be a surrogate for HIV drug resistance and be related to an advanced and prolonged 
clinical history.  
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Viral Load 
Viral load (VL) is a measure of response to therapy. Two studies reported utilization 
by viral load [223,226]. One of them found that utilization decreased significantly 
(p=0.05) as viral load decreased, but the difference was small (3% decrease in those 
with VL < 10,000 copies RNA/ml compared to VL > 100,000 copies RNA/ml) [223]. 
Other indicators of need 
A study of pharmacy and claims data from a large database of commercial health 
plan members by Siddiqui et al. (2009) found that patients with HIV associated 
weight loss had significantly increased outpatient visits (9.7 visits/year) compared 
to those with no evidence of weight loss (5.9 visits/year) [224]. 
3.5 Discussion 
This systematic review sought to identify determinants of HIV outpatient service 
utilization, using the behavioural model for vulnerable populations as an 
organizational framework to present and discuss the findings. The behavioural 
model has been used to present the results of numerous previous systematic 
reviews, and the use of a common framework facilitates the comparison with 
previously published papers across subject areas. 
A review of the predictors of healthcare utilization in chronically ill populations 
using the behavioural model concluded that need characteristics (physical and 
psychological) were the strongest predictors of use, while predisposing and 
enabling characteristics were of little predictive value in chronically ill populations 
[215]. In contrast, we found that age was clearly associated with increased use of 
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outpatient services, with evidence from some studies that MSM acquisition, 
white/Hispanic ethnicity, private insurance and urban residence were also 
associated with increased utilization rates. The need component of the behavioural 
model covers both evaluated health and perceived health. As would be expected 
evaluated health factors (such as CD4 count and/or AIDS diagnosis) were found to 
be important in determining utilization patterns, with utilization increasing with 
severity of disease. Patients on antiviral therapy generally tend to attend clinic 
more frequently than people not on treatment, and their utilization rates also 
appear to be subject to less variation. The reasons for this are unclear, patients on 
treatment may simply be scheduled to visit more frequently than those not on 
treatment, however it is also possible that patients who attend regularly for care 
could be more likely to be started on treatment (i.e. health behavior influencing 
outcome), or alternatively, being on treatment may make patients more likely to 
attend care (i.e. outcome influencing subsequent healthcare use). There was a 
notable lack of studies on the relationship between utilization of outpatient 
services and perceived health. 
There are several important limitations to this review. The search was restricted to 
four databases and to articles published in the English language. Non-peer reviewed 
literature, and articles that were only published in abstract form were not included. 
In order to allow comparability of results, studies were only included if they 
reported on use of hospital based HIV outpatient clinics which may limit the 
generalizability of the findings. In addition, the lack of information on patient 
outcomes and utilization of other (emergency and in-patient) services, make it 
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difficult to identify the health consequences, if any, associated with variation in 
utilization rates. The majority of studies, regardless of their design, obtained 
utilization data retrospectively from existing clinical or administrative databases. 
Retrospective database studies are a useful source of data on healthcare utilization, 
however there are methodological challenges associated with their use [232]. The 
studies included in this review generally gave little detail on the databases used, 
making assessment of the quality of the data sources challenging. The calculation of 
rates also varied between studies, limiting the interpretation of results to the 
relative use of services by different subgroups. 
Few articles were identified that reported data outside the US and Western Europe, 
with only two studies from sub-Saharan Africa, one from Southeast Asia, and none 
from any other region of the world (e.g. Latin America, Eastern Europe/Central Asia, 
or East Asia). Two of the US studies reported data collected as part of the HIV 
Research Network (HIVRN), a consortium of sites across the US that provide 
primary and subspecialty HIV care, with some patient overlap possible. The purpose 
of the HIVRN is to obtain, analyse and disseminate data on HIV service utilization in 
order to provide information for planning and quality assessment of HIV services in 
the US [233]. No equivalent source of information exists in any other region of the 
world however, and extrapolation from US data to other regions is difficult, as the 
structures of healthcare systems as well as the patients cohorts differ considerably. 
Differences in the categorization of subgroups reported also made comparisons 
across studies difficult, and can influence the actual rates reported (as was 
illustrated by the differing age categorizations [223,228]. Future publications should 
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look to the literature to inform their choice of subgroups, and should report as 
detailed a breakdown as is practicable, preferably including raw numbers so that if 
needed, rates could be recalculated for different categorizations. 
While little can be concluded about the absolute visit rates reported (Table 3-4), it is 
worthwhile noting that the rates were of a similar magnitude across all studies 
(possibly a reflection of the inclusion criteria for this review), and interestingly, 
virtually all groups had rates above 4 visits/year, i.e. all groups appear to attend at 
least as frequently, on average, as is recommended in international guidelines. It is 
likely that the inclusion criteria of individual studies means that these rates are for 
people actively engaged in care and have, intentionally or unintentionally, excluded 
poor attenders which would reduce the averages. In any case, average rates may 
not by the most appropriate measure of visit data as the data are likely to be very 
skewed and may be influenced by a minority of high-frequency users (e.g. newly 
diagnosed/starting or switching treatment). Previous studies have identified 
subgroups of patients who do not attend as regularly as recommended and/or who 
have higher missed-appointment rates [76,234,235] but this was not reflected in 
the results of this review. As previously mentioned, this could be a consequence of 
the inclusion criteria of individual studies, or could be a result of looking at average 
rates as opposed to proportional measures. At the other end of the spectrum, many 
groups appear to be attending well in excess of the recommended frequency, 
although again, due to the limitations of this review the reasons behind this cannot 
be elucidated. 
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This review has identified several factors which influence use of HIV services and 
which should be considered when developing future models projecting the future 
burden or cost of care for people living with HIV. The increased use of HIV out-
patient services associated with older age groups described in this review is 
consistent with the reported increase in prevalence of co- and multi-morbidity in 
older HIV patients [236,237]. As the proportion of older HIV patients rises, the 
increasing prevalence of co- and multi-morbidity means that demands on health 
services will multiply accordingly. Anticipating future demands is an essential part 
of healthcare planning, ensuring adequate provision and allocation of whatever 
resources are available to provide the most efficient and effective health service 
possible. In the case of HIV, models predict not only an increase in the total number 
of patients, but also substantial increases in the proportion of older patients, and in 
the numbers of patients requiring second-line and subsequent therapies in the 
coming years [195]. The resource implications of these changes are considerable, 
not only for the HIV services themselves, but also for the other chronic disease (e.g. 
oncology [169], cardiac [238], renal [239], and transplant services [170,240]) and 
geriatric care [172] specialties that will be seeing more and more HIV-infected 
patients, and for the co-ordination of care across these multiple providers. 
While the changing age profile of HIV patients is the most obvious, and probably 
the most important factor, several of the other factors are also likely to change in 
the future, for example increasing health insurance coverage as a result of the 
affordable health care act in the USA [241], and increasing levels of urbanization 
[242]. Modelling studies estimating the future cost/burden of HIV should at least 
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consider the possible effects that changing patient, health service and societal 
changes could have on service use in the future. To date, estimates have been 
based on current rates of service usage, and have only taken clinical factors, such as 
severity and ART into account [142,243]. This review has also highlighted several 
areas, including patient outcomes, health beliefs and treatment status, where 
specific research is needed to elucidate their relationship with utilization of 
outpatient services. Further work on the relationship between patient outcomes 
and utilization of outpatient services could shed some light on what constitutes 
under- and over-utilization. Research examining the role of health beliefs in 
utilization may provide useful insights for the development or implementation of 
patient engagement interventions. Information on the direction and magnitude of 
the relationship between treatment and utilization may also provide insights into 
the possible role of treatment as a tool for improving engagement, but is also 
needed to estimate potential increases in service demand as the numbers of people 
on treatment increase.  
In conclusion, several factors were found to be associated with utilization of 
outpatient HIV services. As the HIV epidemic evolves these factors may play an 
increasing role in the demands placed on HIV services, and the most important 
factors need to be identified and taken into account in future modelling and/or 
cost-effectiveness studies. 
In terms of the relevance of the results of this literature review to the overall thesis, 
this review was performed in order to identify important patient and/or healthcare 
characteristics associated with use of outpatient HIV services to inform the 
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variables collected as part of the costing studies reported subsequently in this 
thesis. Possibly due to the small number of articles meeting the inclusion criteria, 
the differing time periods of the studies included and/or the differences in 
healthcare systems across jurisdictions this review did not identify any variables 
which were clearly associated with use of outpatient services, relevant to an Irish 
context, other than those which would have been included anyway as part of the 
basic patient demographic and clinical data (e.g. age, CD4 count, treatment status, 
suppression status etc). 
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4.1 Abstract 
Background 
It is anticipated that demands on ambulatory HIV services will increase in coming 
years as a consequence of the increased life expectancy of HIV patients on HAART. 
Accurate cost data are needed to enable evidence based policy decisions be made 
about new models of service delivery, new technologies and new medications. 
Methods 
A micro-costing study was carried out in an HIV outpatient clinic in a single regional 
centre in the south of Ireland. The costs of individual appointment types were 
estimated based on staff grade and time. Hospital resources used by HIV patients 
who attended the ambulatory care service in 2012 were identified and extracted 
from existing hospital systems. Associations between patient characteristics and 
costs per patient month, in 2012 euros, were examined using univariate and 
multivariate analyses. 
Results 
The average cost of providing ambulatory HIV care was found to be €973 (95% 
confidence interval €938-€1,008) per patient month in 2012. Sensitivity analysis, 
varying the base-case staff time estimates by 20% and diagnostic testing costs by 
60%, estimated the average cost to vary from a low of €927 per patient month to a 
high of €1,019 per patient month. The vast majority of costs were due to the cost of 
HAART. Women were found to have significantly higher HAART costs per patient 
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month while patients over 50 years of age had significantly lower HAART costs using 
multivariate analysis. 
Conclusions 
This study provides the estimated cost of ambulatory care in a regional HIV centre 
in Ireland. These data are valuable for planning services at a local level, and the 
identification of patient factors, such as age and gender, associated with resource 
use is of interest both nationally and internationally for the long-term planning of 
HIV care provision. 
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4.2 Background 
The availability of effective treatment since the mid-1990s, has transformed HIV 
infection into a chronic disease [244]. Nowadays, with timely diagnosis and 
engagement in care, people living with HIV can have a life-expectancy that 
approaches that of the general population [9,208]. However, HAART is not a 
curative treatment and most newly diagnosed HIV patients face the daunting 
prospect of decades of medication use and regular healthcare visits. It has also 
become apparent that long term HIV infection and medication use is associated 
with increased non-AIDS morbidity [24,244,245]. 
Since HIV testing began in the early 1980s over 6,600 people have been diagnosed 
with HIV in Ireland [246]. A prevalence study of patients in care found 3,254 
patients accessed HIV care in Ireland in the 12-month period from July 2009 to June 
2010, with 25% over 45 years of age [247]. Of these patients, 80% were on 
treatment and 94% of those had a viral load < 500 copies/ml [85], figures that 
compare favourably with other developed countries [248-250]. In Ireland, as in 
many other countries, policy makers and clinicians are now faced with the 
challenge of continuing to provide high quality care in the context of increasing 
demand and within on-going financial constraints. 
Data on the use and cost of services are needed to estimate the potential impact 
the changing HIV epidemiology will have on the health service in Ireland, as well as 
to support evidence based decisions about new models of service delivery, 
technologies and medications [251]. It is not generally appropriate to extrapolate 
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costs from studies in different countries due to variation in how health services are 
provided and organised.  
There are two general approaches to costing healthcare: top-down and bottom up. 
A top-down approach estimates the cost of an individual service on average, usually 
using routinely available data e. g. average per diem costs. Top-down costing 
studies tend to be relatively quick and easy to carry out, however they are also less 
precise and cannot provide information on individual factors driving the costs [252]. 
A bottom-up approach (micro-costing) generates a more precise estimate, but is 
more difficult to perform. In micro-costing all resources used are identified and 
then the unit costs of the resources are multiplied by the quantities used [252]. 
Studies examining the differences between the cost estimates produced by the two 
approaches have concluded that bottom-up approaches are preferable for 
estimating cost components which have a large impact on total costs (e.g. labour, 
drugs), for services where there is wide variation in costs between patients and for 
centres which are integrated within a larger hospital compared to stand-alone 
centres [253-255]. 
Existing data on the cost of outpatient care in Ireland are limited. The national 
average cost of an outpatient visit in Ireland was estimated to be €130 in 2011 
using a top-down methodology [256], however no information is available on how 
this cost may vary across specialties. A previous study looking specifically at the 
pharmacoeconomics of HIV in Ireland carried out in the early HAART era reported 
an average outpatient cost of IR£493 per active patient month in 1999 which would 
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be equivalent to €1,184 in 2012 (inflated using the Irish consumer price index for 
health) [143,257]. 
Ireland is currently in the process of restructuring its healthcare funding system 
from one where hospitals are funded based on historical levels of funding adjusted 
for activity and patient mix to a prospective case based payment system (“Money 
Follows the Patient”) [258]. While it is initially planned to implement this change for 
in-patient and day-case activity, the new funding system will also encompass 
outpatient services [258]. It is proposed that prices in the new system will be set 
initially with reference to average prices, but with a view to implementing best 
practice prices on an incremental basis [258]. 
The aim of this study was to estimate the total cost of providing an outpatient HIV 
service in a single centre in 2012 from the health service provider perspective, and 
to identify associated patient factors. We also compare our results with other 
available sources of cost data. 
4.3 Methods 
Ethics 
Ethical approval for this study was obtained from the Clinical Research Ethics 
Committee of CUH. 
Description of service 
CUH is one of the largest university teaching hospitals in Ireland, and provides HIV 
care for the counties of Cork, Kerry, Waterford, and South Tipperary (covering 
approximately 20% of the Irish population). The ID department holds two routine 
outpatient clinics specifically for HIV patients: the main HIV clinic (“HIV clinic”) held 
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once a week and a joint ID-maternity clinic (“antenatal-HIV clinic”) held once a 
month in the adjoining maternity hospital. Patients attending the antenatal-HIV 
clinic attend both obstetric and ID services during their appointment. 
Local clinical guidelines, based on international best-practice [3,41,42], recommend 
that a CD4 count, viral load (VL), full blood count (FBC) and biochemistry patient 
profile (renal, liver and bone profiles) are performed every 3-4 months. Additional 
and/or more frequent testing is recommended at initiation of care and at initiation 
of HAART until suppression is achieved. Antenatal HIV patients are monitored on a 
monthly basis. 
Study participants 
All patients who attended for HIV care in 2012 were identified from a pre-existing 
clinical database which contains the results of all viral load tests performed in CUH. 
The database also contains basic demographic and risk factor information on the 
patients who have attended the public HIV clinic in CUH. Patients who attended the 
public HIV clinic at least once in 2012 were eligible to be included in the study. 
Patients who attended for private HIV outpatient care, who did not attend any 
outpatient appointment in 2012, or who routinely attended another HIV centre for 
their HIV care were excluded. 
For new patients to the clinic in 2012 (newly diagnosed or transferred from another 
clinic) the date of their first appointment attended or admission was taken as the 
start date of their care, for all other patients the start date of care was 01/01/2012. 
Patients were considered to be in care until 31/12/2012 if they used any hospital 
service (outpatient/in-patient/emergency department) at least once between 
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01/07/2012 and 31/12/2012. The files of patients who did not use any hospital 
service in the last 6 months of 2012 were manually checked, and these patients 
were censored at the date of their last scheduled appointment where appropriate. 
Patients who had either a CD4 count < 350 cells/µl or an AIDS defining illness at the 
time of diagnosis recorded in their medical notes were categorised as late 
diagnoses. 
Resource use 
Information on the number and dates of all outpatient appointments and 
diagnostic tests (laboratory, radiology and cardiology) were extracted from the 
hospital information system. Data on the total number of months of each HAART 
regimen dispensed, as well as any relevant start and/or stop dates, were extracted 
from pharmacy patient files. The medical records of patients with no pharmacy files 
were cross-checked to confirm the patient did not receive HAART in 2012. In 
addition, information on the number of doses of prophylactic antibiotics 
(azithromycin, dapsone, sulfamethoxazole/trimethoprim and pyrimethamine) 
dispensed to HIV patients was provided by the hospital pharmacy. Diagnostic tests 
were linked with patient appointments on the basis of matching test and 
appointment dates. Radiology and cardiology tests, which may not occur on the 
date of the outpatient appointment where the test was ordered, were linked with 
the nearest previous outpatient appointment attended. 
Costs 
A micro-costing study was carried out to estimate the cost of typical HIV outpatient 
appointments from the service-provider perspective in 2012. Staff routinely 
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involved in providing or supporting the HIV clinic (clerical, nursing, medical, 
phlebotomy, and pharmacy) were interviewed to assess the HIV-clinic related tasks 
performed by the staff member and the estimated patient-facing and non patient-
facing time involved. Doctors and nurses self-recorded their patient-facing times at 
six consecutive HIV clinics in March and April 2013 (127/153 appointments timed). 
Pharmacy staff self-recorded their HIV related patient-facing and non patient-facing 
time for the month of April, 2013. The accuracy of self-timed doctor patient-facing 
times was confirmed by independent observation of approximately 50% of 
appointments. Average costs per appointment were then calculated based on 
estimated time and salary of relevant staff using recommended national guidelines 
[259,260].  
The total annual staff cost per grade was calculated as follows: 
Pay = Mid-point of pay range 
Direct Salary Cost = Pay + Employers PRSI (10.75%) 
Total Salary Cost = Direct Salary Cost + Imputed Pension Cost (4% of Pay) 
Total Staff Cost = Total salary cost + Overheads (25% of Pay) 
This method includes adjustments for non-pay costs associated with hiring 
additional staff including employers’ PRSI, superannuation, as well as general 
overheads such as costs for accommodation, utilities, support and back-office staff, 
training, travel etc [259]. Total staff cost was converted to hourly rates using the 
formula: annual cost for grade/((249- annual leave entitlement) x 6.95)) [259]. 
 119 
Eight basic types of appointment were identified: 1) did not attend scheduled 
outpatient appointment (DNA), patient was not on HAART at the time (“DNA, not 
on HAART”); 2) DNA, patient was on HAART at the time (“DNA, on HAART”); 3) 
attended the HIV-clinic, patient was not on HAART at the time (“Attended HIV 
clinic, not on HAART”); 4) attended the HIV-clinic, patient was on HAART at the time 
(“Attended HIV clinic, on HAART”); 5) attended the antenatal HIV-clinic, patient was 
not on HAART at the time (“Attended antenatal-HIV clinic, not on HAART”); 6) 
attended the antenatal-HIV clinic, patient was on HAART at the time (“Attended 
antenatal-HIV clinic, on HAART”); 7) first attended appointment with the ID service 
for HIV care, patient was not on HAART at the time (“Baseline visit, not on HAART”); 
and 8) first attended appointment with the ID service for HIV care, patient was on 
HAART at the time (“Baseline visit, on HAART”). Appointments were categorised as 
DNA if the patient did not attend their scheduled appointment without cancelling 
or rescheduling the appointment prior to the start of the clinic they were due to 
attend. The cost of a DNA appointment was estimated based on the same non 
patient-facing administrative and pharmacy staff time (where applicable) as 
attended appointments as well as the time incurred rescheduling an appointment. 
In general, a patient is considered lost to follow-up if they DNA three consecutive 
appointments. For the antenatal-HIV clinic appointments only the cost of the care 
delivered by the ID team was included in the micro-costing. 
Unit costs 
The unit costs of diagnostic tests were obtained from the finance department of the 
hospital and the National Virus Reference Laboratory. The monthly costs of ARVs 
and prophylactic antibiotics were provided by the hospital pharmacy. In Ireland, the 
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price of all prescribed drugs are set at a national level [261,262], although individual 
hospitals can negotiate discounts with wholesalers. The number of months of 
regimens dispensed was used in the calculation of HAART costs to allow for possible 
wastage due to regimen switching. 
The hospital finance department also provided outpatient costs per patient for 
comparison purposes from a newly implemented activity based costing system. 
These data were broken down into direct and indirect costs by category (clinical 
salaries, nursing salaries, non-clinical salaries, imaging, pathology etc), but 
contained little information on individual patient characteristics, appointment types 
or diagnostic tests. Drug costs (with the exception of a few very high cost drugs) 
were not assigned at a patient level in the hospital activity based costing system in 
2012. 
The unit costs of individual appointment types, common diagnostic tests and 
regimen types are shown in Table 4-1. 
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Table 4-1. Unit costs (in 2012 euros) and frequency of appointment types, most common 
diagnostic tests and most common HAART regimens dispensed. 
Cost category Unit cost Resource use Source of cost data 
Appointment type Staff cost/ 
appointment 
Number of 
appointments 
 
DNA, not on HAART €12.68 32 Micro-costing study 
DNA, on HAART €21.25 127 Micro-costing study 
Attended HIV clinic, not on HAART €174.89 89 Micro-costing study 
Attended HIV clinic, on HAART €194.88 997 Micro-costing study 
Attended antenatal-HIV clinic, not 
on HAART 
€174.26 2 Micro-costing study 
Attended antenatal-HIV clinic, on 
HAART 
€194.25 42 Micro-costing study 
Baseline appointment, not on 
HAART 
€244.46 14 Micro-costing study 
Baseline appointment, on HAART €264.45 12 Micro-costing study 
Most common diagnostic tests Cost per test Number of tests  
CD4 €47.29 1,013 Hospital Finance Dept 
Viral load €92.94 995 National Virus 
Reference Laboratory 
Full Blood Count €6.79 1,036 Hospital Finance Dept 
Biochemistry profiles, weighted 
average cost 
€18.63 1,042 Hospital Finance Dept 
All other tests, weighted average 
cost 
€28.39 1,262 Hospital Finance Dept 
HAART regimens (regimen class) Cost per 
month 
Number of 
months dispensed 
 
Efavirenz/Emtricitabine/Tenofovir 
(NNRTI) 
€816.61 1,515 Hospital pharmacy 
Emtricitabine/Tenofovir, Darunavir, 
Ritonavir (PI) 
€1,097.51 864 Hospital pharmacy 
Emtricitabine/Tenofovir, Atazanavir, 
Ritonavir (PI) 
€1,084.84 389 Hospital pharmacy 
Emtricitabine/Tenofovir, 
Lopinavir/Ritonavir (PI) 
€1,148.79 99 Hospital pharmacy 
Emtricitabine/Tenofovir, Nevirapine 
(NNRTI) 
€747.98 75 Hospital pharmacy 
Lamivudine/Zidovudine, 
Lopinavir/Ritonavir (PI) 
€953.16 53 Hospital pharmacy 
All other regimens, weighted 
average cost 
€923.70 327 Hospital pharmacy 
Prophylactic antibiotics Cost per 
dose 
Number of doses 
dispensed 
 
Azithromycin €0.42 330 Hospital Pharmacy 
Sulfamethoxazole and trimethoprim €0.15 2,047 Hospital Pharmacy 
Dapsone €0.69 344 Hospital Pharmacy 
DNA, did not attend. “Staff cost” is the estimated total patient and non patient-facing staff costs per 
appointment. Diagnostic tests includes laboratory, radiology and cardiology tests. “Biochemistry 
profiles” refers to the number and weighted average cost of the following biochemistry profiles: 
“patient”, “ward”, “bone”, “renal/bone”, “patient & lipid”, “patient & lipoprotein”, “urea, 
electrolytes & creatinine” and “liver function tests”.  
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Data analysis 
All information was entered into a Microsoft Access® database. Data were analysed 
using Microsoft Excel® and STATA 12 (College Station, Texas). Weighted average 
costs per patient month (ppm) were calculated to account for differences in patient 
lengths of follow-up. χ2 tests were used to test for differences in proportions. 
Logistic regression was used to estimate the odds ratios of being treated with PI-
based regimens compared to NNRTI-based regimens in patients receiving a single 
type of regimen. Generalised linear models were used to model costs ppm on 
HAART as they are suitable for modelling cost data, which tend to be skewed, 
without the need for transformation [263]. The most appropriate family was chosen 
using the modified Parks test, and the link was chosen using the Pearson 
Correlation Test, the Pregibon Link Test and the modified Hosmer and Lemeshow 
test to evaluate power links in increments of 0.1 between 0 and 1 [264]. 
Sensitivity analysis 
To reflect the uncertainty in the estimates of staff time and laboratory costs staff 
times were varied by 20% and unit costs of diagnostic testing by 60% in a sensitivity 
analysis. The 20% variation in staff time was based on the approximate width of the 
confidence intervals of the average doctor and nurse patient-facing times, while the 
choice of 60% variation for diagnostic testing costs was based on the difference in 
the weighted average test costs calculated using alternative unit costs which were 
available for a limited number of the tests. 
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4.4 Results 
4.4.1 Study population 
In total 326 patients (3,659 patient months) were included in this study. The 
characteristics of the patient population can be seen in Table 4-2. The majority of 
patients (59%) were men and the average age of patients was 40 years. Co-
infection with hepatitis C virus (HCV) was recorded for 7% of patients, Hepatitis B 
Virus (HBV) in 2% of patients and both HBV and HCV in 1% of patients. Eight percent 
(26/326) of patients were new to the service in CUH in 2012, most of whom were 
newly diagnosed in 2012 (n=17). The CD4 profile of patients improved with the 
number of years since diagnosis (χ2 test, P=0.001). 
Three patients died in 2012, two of these were considered HIV-related deaths both 
of which were of people who were newly diagnosed with advanced illness (CD4 < 
50 cells/μl) at the time of diagnosis. 
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Table 4-2. Number and proportion of patients and patient-months by patient 
characteristics 
Characteristics Patients (%) Patient months (%) 
Patient type Existing patient 300 (91%) 3,506 (95%) 
New patients 26 (8%) 153 (4%) 
Gender Male 192 (59%) 2,148 (58%) 
Female 134 (41%) 1,511 (41%) 
Age <50 years 284 (87%) 3,172 (86%) 
50+ years 42 (13%) 487 (13%) 
Risk factor COHP 133 (41%) 1,501 (41%) 
Heterosexual 63 (19%) 721 (20%) 
MSM/Bisexual  95 (29%) 1,067 (29%) 
IDU 18 (5%) 185 (5%) 
Other 8 (2%) 96 (3%) 
Unknown 9 (3%) 89 (2%) 
Late diagnosis No 135 (41%) 1,535 (42%) 
Unknown 77 (23%) 840 (23%) 
Yes 114 (35%) 1,284 (35%) 
Years since diagnosis 11+ years ago 95 (29%) 1,107 (30%) 
6-10 years ago 107 (33%) 1,231 (34%) 
1-5 years ago 100 (30%) 1140 (31%) 
diagnosed in 2012 17 (5%) 105 (3%) 
Lowest CD4 count in 2012 
(cells/μl) 
500+ 168 (51%) 1,894 (52%) 
350-499 85 (26%) 973 (26%) 
200-349 52 (16%) 581 (16%) 
50-199 14 (4%) 146 (4%) 
<50 7 (2%) 65 (2%) 
Treatment and viral load 
statusb 
On HAART, suppressed 211 (64%) 2,469 (67%) 
On HAART, not suppressed 37 (11%) 438 (12%) 
On HAART, unable to 
determine status 
7 (2%) 75 (2%) 
Started/Stopped HAART 49 (15%) 440 (12%) 
Not on HAART 22 (7%) 237 (6%) 
Overall   326 (100%) 3,659 (100%) 
 
4.4.2 Resource use 
There were a total of 1,315 HIV outpatient appointments scheduled during 2012, 
with an average of 4.1 (median 4, range 1-15) scheduled appointments per patient 
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and 3.6 (median 3, range 1-11) attended appointments per patient. The frequencies 
of each type of appointment are shown in Table 4-1. 
In total 304 patients were on HAART for 3,272 patient-months, with 3,322 months 
of HAART dispensed in total. The majority of regimens dispensed consisted of a 
nucleoside reverse-transcriptase inhibitor (NRTI) backbone combined with either a 
protease inhibitor (PI) or a non-nucleoside reverse-transcriptase inhibitor (NNRTI). 
NNRTI-based regimens were the most frequently dispensed (164 patients, 1,755 
months dispensed) followed by PI-based regimens (145 patients, 1,477 months 
dispensed), with a small number of patients being dispensed other regimens types 
(10 patients, 90 months dispensed). Fifteen percent (n=45) of patients had more 
than one regimen prescribed during the study period, most of which were within 
the same class, although a small number of patients were prescribed regimens from 
different classes during the study period (n=15). 
4.4.3 Total costs 
The overall average cost of providing HIV outpatient care was estimated to be €973 
ppm in 2012 (median €940, interquartile range €938-€1,008). As the cost of HAART 
accounted for the majority (88%) of total costs, varying the staff time estimates and 
unit costs of diagnostic testing did not result in substantial changes to the average 
costs ppm in the sensitivity analysis, with total costs ppm only varying by about 5% 
(Table 4-3). When costs were stratified by whether the patient was on HAART or not 
at the time, the average cost ppm not on HAART was €107 (95% CI €65-€150) 
compared to €1,085 (95% CI €1,060-€1,111) ppm on HAART. 
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Table 4-3. Average base-case cost, in 2012 euros, per patient month (ppm) and results of 
sensitivity analysis. 
 Base case (95% CI) Lower estimate (95% CI) Upper estimate (95% CI) 
Staff costs ppm (+/- 20%) €62 (€59-€65) €50 (€47-€52) €75 (€71-€78) 
Diagnostic test costs ppm 
(+/-60%) 
€55 (€52-€59) €22 (€21-€23) €89 (€83-€94) 
Total non-drug cost ppm €117 (€111-€124) €72 (€68-€76) €163 (€154-€172) 
Total cost ppm (including 
drug costs) 
€973 (€938-€1,008) €927 (€893-€962) €1,019 (€983-€1,054) 
 
4.4.4 Patient factors 
The mean total cost ppm generally differed little across patient groups (Table 4-4). 
However, patients who were on HAART for the duration of their time in the study 
and were categorised as suppressed were found to have lower average total 
monthly costs compared to those who were not suppressed (mean €1,043 ppm 
compared to €1,189 ppm respectively). 
HAART accounted for the vast majority of outpatient costs. The unit cost of 
individual regimens varied from a minimum of €552/month to a maximum of 
€1,600/month. Although NNRTI-based regimens tend to be less expensive than PI-
based regimens (the weighted average cost of NNRTI-based regimens in this study 
was €809/month compared to €1,091/month for PI-based regimens), there are 
many other factors apart from cost which influence regimen choice, including 
patient (e.g. demographic, behavioural), clinical (resistance, adverse reactions, co-
morbidities) and health system factors (drugs available for prescription, clinician 
preferences). Significantly lower proportions of new patients and newly diagnosed 
patients received HAART in 2012 compared to existing and previously diagnosed 
patients (χ2 test, P=0.008 and P=0.017, respectively). While a significantly higher 
proportion of those diagnosed late (i.e. with a CD4 count <350 cells/µl or an AIDS 
 127 
defining illness at diagnosis) received HAART (χ2 test, P=0.003). On multivariate 
logistic regression of these three factors late diagnosis was the only factor that 
remained significant with an odds ratio (OR) of 15.5 (95% CI 2-120). Logistic 
regression of regimen type (analysis restricted to patients only prescribed PI-based 
regimens or only prescribed NNRTI-based regimens, n=283) found women were 
significantly more likely to be prescribed a PI-based regimen (OR 6.6, 95% CI 3.3-
13.2, p<0.001), while those over 50 years were less likely to be prescribed a PI-
based regimen (OR 0.34, 95% CI 0.14-0.85, p=0.022) when adjusted for risk factor, 
patient type, years since diagnosis, CD4 <350 cells/µl and late diagnosis. 
The cost of HAART is the main driver of total costs, so any analysis of the factors 
associated with total costs in effect just identifies the factors associated with 
HAART cost. In order to try and identify the factors associated with outpatient 
service use multivariate analyses was carried out separately on the non-HAART 
costs, the HAART costs and the total cost ppm on HAART (3,272 patient months). 
The results of these multivariate analyses are shown in Table 4-5. Female patients 
were significantly more expensive compared to male patients and patients who 
were not suppressed were more expensive compared to those who were 
suppressed, reflecting the fact that more expensive PI-based regimens were more 
commonly dispensed in these groups of patients (67% months of HAART dispensed 
to females were PI based regimens vs 30% of months dispensed to males, and 61% 
of months of HAART dispensed to patients on HAART not suppressed/other vs 37% 
of months dispensed to suppressed patients). Patients over aged ≥50 years on the 
other hand had significantly decreased total costs ppm on HAART compared to 
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patients under 50 years of age, again reflecting the regimens used in these groups 
(50% of months of HAART dispensed to patients <50 years were NNRTI-based 
regimens vs 72% of months dispensed to those ≥50 years). 
In terms on non-HAART costs, older patients had significantly lower non-HAART 
costs ppm on HAART, while patients diagnosed between 1 and 5 years ago were 
more expensive than those diagnosed more than 10 years previously, and patients 
who had a CD4 count < 350 cells/µl were more expensive than those with a higher 
cell count. 
 
Table 4-4. Costs per patient month (ppm) by patient subgroup 
 N Mean drug cost ppm 
(95% CI) 
Mean non-drug 
costs ppm (95% CI) 
Mean total cost ppm 
(95% CI) 
Patient type 
Existing patient 300 €863 (€829-€897) €112 (€107-€116) €975 (€940-€1,010) 
New patients 26 €678 (€503-€853) €253 (€206-€300) €931 (€732-€1,130) 
Gender 
Male 192 €844 (€805-€882) €117 (€109-€124) €960 (€921-€999) 
Female 134 €873 (€812-€934) €118 (€108-€129) €991 (€927-€1,055) 
Age group     
<50 years 284 €859 (€821-€897) €121 (€114-€128) €980 (€941-€1,019) 
50+ years 42 €833 (€773-€894) €94 (€85-€104) €928 (€871-€984) 
Risk factor 
COHP 133 €878 (€826-€931) €117 (€106-€127) €995 (€940-€1,050) 
MSM/Bisexual 95 €826 (€769-€884) €122 (€110-€134) €948 (€889-€1,007) 
Heterosexual 63 €835 (€745-€925) €113 (€101-€125) €948 (€856-€1,041) 
IDU 18 €931 (€834-€1,027) €124 (€103-€144) €1,054 (€942-€1,166) 
Other 8 €982 (€733-€1,231) €92 (€59-€125) €1,075 (€817-€1,332) 
Unknown 9 €697 (€383-€1,012) €125 (€92-€159) €823 (€514-€1,132) 
Late diagnosis 
No 135 €810 (€748-€871) €120 (€111-€130) €930 (€867-€993) 
Unknown 77 €868 (€797-€939) €115 (€103-€126) €983 (€908-€1,058) 
Yes 114 €902 (€862-€942) €116 (€104-€127) €1,018 (€974-€1,062) 
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 N Mean drug cost ppm 
(95% CI) 
Mean non-drug 
costs ppm (95% CI) 
Mean total cost ppm 
(95% CI) 
Years since diagnosis 
11+ years ago 95 €879 (€830-€929) €102 (€95-€108) €981 (€930-€1,032) 
6-10 years ago 107 €890 (€833-€947) €107 (€99-€115) €997 (€938-€1,056) 
1-5 years ago 100 €831 (€762-€899) €130 (€119-€141) €961 (€889-€1,033) 
diagnosed in 2012 17 €581 (€349-€812) €275 (€208-€342) €855 (€582-€1,128) 
Lowest CD4 count in 2012 (cells/μl) 
500+ 168 €888 (€844-€932) €104 (€98-€110) €993 (€947-€1,038) 
350-499 85 €807 (€734-€879) €120 (€108-€132) €927 (€852-€1,002) 
200-349 52 €830 (€735-€925) €129 (€114-€145) €960 (€861-€1,058) 
50-199 14 €839 (€725-€953) €179 (€115-€244) €1,018 (€873-€1,164) 
<50 7 €903 (€706-€1,100) €218 (€118-€319) €1,121 (€842-€1,401) 
Treatment and viral load status 
On HAART, 
suppressed 
211 €939 (€915-€964) €104 (€100-€109) €1,043 (€1,017-€1,069) 
On HAART, not 
suppressed 
37 €1,035 (€987-€1,083) €154 (€134-€175) €1,189 (€1,133-€1,245) 
On HAART, 
undetermined 
status 
7 €914 (€776-€1,052) €84 (€55-€113) €998 (€845-€1,151) 
Started/Stopped 
HAART 
49 €660 (€578-€742) €169 (€141-€197) €829 (€733-€924) 
Not on HAART 22 - €103 (€79-€128) €103 (€79-€128) 
Overall 326 €856 (€822-€889) €117 (€111-€124) €973 (€938-€1,008) 
COHP, person from a country of high prevalence with no other identifiable risk factor available. IDU, 
current/former injecting drug user. Late diagnosis defined as CD4 count < 350 cells/μl at diagnosis or 
AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire 
duration of the study, “suppressed” was defined as all viral loads in 2012 <50 copies/ml, with one 
test result of 50-499 copies/ml allowed if previous and subsequent viral load results were < 50 
copies/ml. 
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Table 4-5. Results of multivariate analysis of non-HAART, HAART and total costs ppm on 
HAART. 
  
Non HAART cost ppm on HAART 
HAART cost ppm 
Total cost ppm 
on HAART 
  Coefficient1 Coefficient2 Coefficient2 
New patient -6.555 -0.03 -0.004 
Female 1.464 0.138* 0.139* 
Age 50+ years -3.113* -0.101* -0.117* 
Risk factor 
COHP ref ref ref 
MSM 1.308 0.033 0.037 
Heterosexual 0.32 0.054 0.054 
Other/unknown -0.737 0.05 0.054 
Late diagnosis 
No ref ref ref 
Unknown -0.354 -0.012 -0.015 
Yes -0.515 -0.035 -0.04 
Years since diagnosis 
11+ years ago ref ref ref 
6-10 years ago -0.267 0.053 0.05 
1-5 years ago 1.825* 0.041 0.059 
diagnosed in 2012 4.504 0.078 0.128 
Min CD4 < 350 cells/μl 3.432* 0.02 0.054 
On HAART, not 
suppressed/other 2.051 0.059 0.089* 
Constant 31.314 3.896 4.026 
1) Generalised linear model with Inverse Gaussian family and link power 0.5. 2) Generalised linear 
model, with Gaussian family and link power 0.2. * p<0.05. PPM, per patient month. COHP, person 
from a country of high prevalence with no other identifiable risk factor available. IDU, 
current/former injecting drug user. Late diagnosis defined as CD4 count < 350 cells/μl at diagnosis or 
AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire 
duration of the study, “suppressed” was defined as all viral loads in 2012 <50 copies/ml, with one 
test result of 50-499 copies/ml allowed if previous and subsequent viral load results were < 50 
copies/ml. “On HAART, other” includes patients on HAART who were not suppressed or had 
undetermined status and those who started/stopped HAART in 2012. 
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4.4.5 Comparisons of total costs with other sources of cost data 
Patient level costs for the HIV patients included in the micro-costing study were 
provided by the hospital finance department. The data are activity based costing 
data, the cost components of which are generated using a top-down methodology. 
The total number of HIV outpatient appointments in the finance dataset was very 
similar to the total scheduled number of appointments from the utilisation study 
(1,310 vs 1,315) which would be expected given that the finance costs are based on 
information recorded in the same hospital information system as the utilisation 
data were extracted from. As the costs of most drugs were not assigned at a patient 
level in this system in 2012, it was not appropriate to compare drug costs, however 
the estimated non-drug cost ppm based on the hospital activity-based cost data 
was €63 ppm (95% CI €59-€67) compared to €117 (95% CI €111-€124) in the micro-
costing study. Use of the national average outpatient appointment cost (€130.56 in 
2012) would have resulted in an even lower estimate of €47ppm (95% CI €44-
€49ppm). While our estimate is greater than the estimates generated using routine 
data, the estimated total cost (€973 ppm) is about 20% lower than the IR£493 per 
active patient month in 1999 reported by a previous micro-costing study 
(equivalent to €1,184 in 2012). Although that study was carried out in the early 
HAART era and the patient population was quite different to the patient population 
in this study [143]. 
4.5 Discussion 
This study reports the results of a bottom-up costing study of routine HIV 
outpatient care performed in a regional referral centre in the south of Ireland. The 
total estimated cost of the service in 2012 was €973 ppm, nearly 90% of which was 
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due to the cost of HAART. While it is difficult to compare costs across countries, 
HAART is reported to account for 60%-80% of the total cost of HIV care (including 
inpatient care) in many studies in developed countries [121,128,134,265-268]. 
Despite its cost, HAART is considered a very cost-effective treatment [117,269], and 
also has the important population-level benefit of reducing onward transmission 
[270]. HAART also offers the greatest opportunity for reducing costs, for example, 
in this study the total non-drug spend would have to be reduced by over 35% to 
save the same amount as could be achieved by a 5% reduction in HAART costs. 
Possible strategies for reducing HAART costs do exist, such as increased use of 
generic drugs or less expensive regimens where available and appropriate 
[119,127,159], though efforts to reduce drug spend should not come at the cost of 
increased risk of poorer outcomes and reduced quality of care [269]. As regimen 
choice is influenced by patient factors, such as age, gender and risk factor, variation 
in costs between centres at a national level is likely to be a reflection of differences 
in patient populations, although clinician preference may also play a role. With 
time, as more patients switch onto newer treatments, the drug costs are likely to 
increase unless savings can be made through increased use of generic drugs 
[119,127,159] or other rationalisation measures. In any case, further research is 
warranted into the patient and healthcare factors influencing regimen choice, such 
as the acceptability and potential impact of a preferred medicine scheme. 
The most important factor on multivariate analysis which influenced total costs 
ppm on HAART was gender, with women being 15% more expensive than men. It 
was also interesting to note that patients over 50 years of age had significantly 
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reduced costs ppm on HAART. This was due to a combination of older patients 
tending to be on less expensive NNRTI-based regimens, as well as having fewer 
scheduled appointments (0.26 ppm compared to 0.37 ppm, p<0.001). The lower 
appointment rate in older patients contrasts with previous studies which have 
found older patients have higher utilisation rates [271], and may be a reflection of 
the particular characteristics of this patient cohort. As the total number of older 
patients increase, it will be possible to perform more nuanced analysis by age, 
which may identify particular age groups with higher resource use (e.g. 50-65 year, 
65-75 year, 75+ year age groups). Late diagnosis has been reported in the literature 
to be associated with sustained increased healthcare costs [133], in this study there 
was some evidence that those diagnosed late had higher mean outpatient costs 
(Table 4-4), however the differences were not significant using multivariate analysis.  
There are several limitations to this study. The data collection was restricted to one 
year, so changes over time cannot be examined. The usage and cost of other 
services (inpatient, emergency, and non-ID outpatient care) were not included in 
this analysis. While the majority of HIV-related care is now provided on an out-
patient basis by the ID team, a small minority of patients use a substantial amount 
of other services [272]. Newly diagnosed patients with low CD4 counts in particular 
can have very complex care needs, in this study the inpatient costs of two newly 
diagnosed patients who were diagnosed late and subsequently died were not 
captured by this micro-costing study. CUH has a smaller proportion of injecting drug 
users than the national HIV patient population (5% vs 21%), however the 
population served is similar in terms of age, gender, CD4 count and viral load to the 
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national cohort in care [247]. Diagnostic tests were linked to specific outpatient 
appointments on date and mis-matching may have occurred which could have led 
to either an under- or over-estimate of the diagnostic testing ordered by the HIV 
clinic. Private patients were not included in the study. While private patients do not 
attend the public outpatient clinic so would not generate appointment costs, the 
health service provider may incur costs as a result of diagnostic tests and/or HAART. 
The additional cost of obstetric care for HIV patients (i.e. additional to the three 
consultant visits that antenatal patients are routinely entitled to [273]) was not 
included in the cost estimates. As the numbers of women attending antenatal care 
was very small in this study it was not possible to investigate this fully, but to give 
an indication of the scale of the possible additional costs the average number of 
antenatal-HIV appointments attended in this study was 3.2 per woman. This study 
also does not include the cost of medications prescribed to HIV patients other than 
HAART and prophylactic antibiotics, as these are dispensed outside the hospital 
setting. The total cost of vaccines (influenza, pneumococcal, hepatitis A, hepatitis B, 
and combined hepatitis A and B) and tuberculin dispensed to the HIV clinic was 
available, however as these costs could not be assigned at a patient level. The total 
estimated cost of vaccines and tuberculin in 2012 was €3,734 (including 
consumables) and even though this is probably an underestimate as patients may 
be vaccinated in other healthcare settings, overall it is likely to account for a 
relatively small proportion of the total costs of ambulatory HIV care in this centre.  
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4.6 Conclusion 
Accurate cost data are essential for ensuring HIV services are effective, efficient, 
and equitable and cost information should be used to guide policy, planning and 
implementation [251]. This is particularly pertinent in the current situation in 
Ireland, as healthcare funding is undergoing restructuring. We have found that HIV 
outpatient costs were substantially underestimated by routine hospital cost data, 
and we feel that this information will be vital for the development of realistic 
setting of HIV outpatient appointment prices in the new funding system. In 
addition, as demands on the service increase due to greater numbers of patients 
and more complex care these cost data will be available for cost-effectiveness 
evaluations of new drugs, technologies and models of care. 
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5.1 Abstract 
Data on the pattern and cost of health service use by HIV patients are required for 
evaluations of the cost-effectiveness of new drugs and technologies as well as being 
essential for service planning. The aim of this study was to identify the utilisation 
patterns and cost of hospital care for HIV patients in a single centre in Ireland in 
2012. Data on the frequency and non-drug costs of all hospital resources used by 
HIV patients were extracted from a hospital activity based costing system. Cost data 
were analysed using a generalised linear model. A total of 328 patients, 3,672 
patient months, were included in this study. Patients had a mean of 4.4 scheduled 
infectious disease outpatient appointments per patient year. 33% of patients also 
used another outpatient service, 10% in-patient services, 4% day-case service, and 
14% emergency department services in 2012. Patients with very advanced HIV 
disease continue to incur a disproportionate amount of the total cost of providing 
care. This study provides baseline utilisation and cost data for use of both 
infectious-disease and non-infectious disease hospital services, and will be useful 
for service planning in light of the likely increases in resource demands.  
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5.2 Introduction 
The epidemiology of HIV infection has changed with the availability of highly-active 
antiretroviral therapy (HAART). Mortality rates in those who initiate treatment early 
and who are highly adherent approach that of the general population [208], making 
HIV infection not only a chronic disease, but one with a relatively long duration and 
a high per-capita cost compared to other chronic diseases [9,136,244,274]. 
It has also become apparent that long-term infection with HIV and/or long-term 
ART is resulting in increasing levels of non-AIDS morbidity [245], and the prevalence 
of many non-infectious chronic diseases is higher in people living with HIV than in 
the general population [275,276]. 
Historically, healthcare systems have been designed to provide acute, episodic care 
and so tend to be less equipped to deal with chronic conditions [277]. The care 
needs of patients with multiple chronic conditions is particularly complex as these 
patients tend to have high healthcare utilisation and polypharmacy rates requiring 
co-ordination across multiple specialties both within and across healthcare 
providers. While there is currently little consensus in the literature on how to 
improve care integration, it is clear that in order to provide a service that improves 
patients outcomes and satisfaction, it is essential that the needs and characteristics 
of the patient population are taken into account when designing services and 
information management systems [278,279]. 
While many studies have published utilisation and/or cost data on all healthcare 
resources used by HIV patients, fewer studies have reported results broken down 
by whether the care was HIV related or not. In one study that did, the overall 
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admission rates of HIV patients for non-HIV related conditions were twice that of 
HIV-related admissions, with HIV-related admissions being more frequent than non-
HIV admissions only in patients with a CD4 count < 75 cells/μl [280]. 
Increasing demands on HIV services have stimulated interest in the identification of 
more efficient means of providing those services. In developed countries, research 
has mainly focussed on methods of decreasing drug costs through such methods as 
the use of centralised procurement [162], generic drugs [127,159,160], and single 
tablet regimens [158,161], but reducing the frequency of visits and/or laboratory 
monitoring of stable, suppressed, patients have also been suggested as means of 
increasing efficiency without affecting patient outcomes [77,119,281,282]. 
In the era of widespread HAART use a large proportion of patients in care in 
developed countries are suppressed and may be suitable for reductions in the 
frequency of visits and/or laboratory monitoring [62,283]. In Ireland at least 68% of 
all patients in care (87% of patients on treatment) in 2009/2010 had a viral load <50 
copies/ml [85]. Although stable patients are a group of particular interest, little has 
been published on either their use of HIV outpatient services or their use of wider 
health services. As postulated efficiency measures may target this group of patients 
in particular, data on the proportion of patients who fall into this category and their 
current level of health service usage would provide information on the potential 
savings that could be made if suggested efficiency measures were implemented. 
We have previously reported utilisation rates and cost of the ambulatory HIV care 
service [284]. The cost of outpatient care reported in that study (based on micro-
costing methodology) was estimated to be between €927-€1,019 per patient 
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month, 90% of which was due to the cost of HAART. On multivariate analysis, care 
for males and older people (≥50 years of age) was found to be significantly less 
expensive. This variation was mostly explained by variations in HAART regimens 
across groups, although older patients were also found to have significantly fewer 
appointments [284]. However that study focussed only on patients’ use of HIV 
clinics and did not evaluate their use of inpatient care, emergency medicine or 
other outpatient clinics. The aim of this study was to identify HIV and non-HIV 
related hospital utilisation patterns and cost by HIV patients attending a single 
regional centre in Ireland in 2012. 
5.3 Methods 
5.3.1 Setting 
We carried out a descriptive study of direct and indirect non-drug healthcare costs 
in CUH in 2012. CUH is a tertiary referral centre, and was one of only six adult HIV 
specialist centres which provided HIV care in Ireland in 2012 (the other centres are 
located in Dublin, Galway and Limerick). HIV care is provided solely by hospital-
based practitioners, primary care physicians do not provide specialist HIV care. HIV 
care provided in the public system is free for Irish residents; however patients may 
choose to attend a consultant privately, in which case they pay a consultancy fee 
for their visit. The catchment area for the HIV service in CUH covers most of the 
southern region of Ireland (counties Cork, Kerry, Waterford and south Tipperary, a 
population of approximately 860,000 people). While the total number of people 
living with HIV in this region is unknown, as the catchment area is mainly rural it is 
likely that the prevalence of HIV in the region is lower than the 0.1%-0.2% 
estimated nationally by UNAIDS [23]. It is likely that most patients resident in the 
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region access HIV care in CUH as the nearest alternative HIV centre is located in 
Limerick (approximately 100km away).  
5.3.2 Patient population 
All HIV positive patients who attended the HIV centre in CUH in 2012 were 
identified from a pre-existing clinical patient database. Patients who attended the 
public HIV clinic located in CUH, or who were admitted to CUH in 2012 were eligible 
to be included in this study. Patients who attended any private HIV outpatient care 
in 2012 (full or partial year) were excluded. Patients who attended another HIV 
centre for their routine care (i.e. visitors to the area who attended CUH on a 
temporary basis) were also excluded. Patients were considered to be in-care from 
01/01/2012, or the date of their first visit if they were a new patient, until 
31/12/2012. Local clinical guidelines recommended monitoring of HIV patients 
every 3-4 months (although a small number of stable patients are monitored on a 
6-monthly basis). The files of patients who did not attend any HIV clinic 
appointments in the last 6 months of 2012 were manually checked, and these 
patients were censored at the date of their last scheduled visit where appropriate. 
5.3.3 Data 
Information on admissions (inpatient and day-case, both public and private), 
outpatient appointments and emergency department (ED) visits in 2012 by the 
included patients was extracted from the hospital finance system (in 2012 euros) 
which covers both CUH and Cork University Maternity Hospital (CUMH). This 
system is an activity based costing (ABC) system (“Power Performance Manager”) 
which uses top-down methodology to generate patient level hospital costs based 
on hospital accounting and activity data. The cost estimates include both pay and 
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non-pay (e.g. drugs, consumables, utilities, capital expenditure etc) costs, based on 
best accounting practice and in compliance with statutory requirements and Health 
Service Executive policies and procedures. In 2012 the finance system did not assign 
drug costs at an individual patient level, so this analysis was limited to non-drugs 
costs. Data on the cost of appointments with allied health professionals (social 
workers, dieticians, physiotherapists) were not included in the finance data due to 
concerns about the completeness of these data. Outpatient visits recorded on this 
system included “missed visits” (scheduled appointments which the patient did not 
attend without cancelling/rescheduling in advance of the clinic) but did not include 
cancelled appointments. While in general patients’ appointments are scheduled in 
advance, a small number of patients may “walk-in” to a clinic without an 
appointment, these visits are recorded on the hospital administration system and 
were indistinguishable from pre-scheduled appointments in the data extracted. 
Healthcare contacts for obstetric care were excluded from analysis, as maternity 
care is considered a normal physiological process and not an illness (attendances 
for joint HIV-antenatal care were not excluded). Obstetric care contacts were 
identified as follows: 
 Admissions (inpatient or day case) with a primary diagnosis coded O00-O99 
(childbirth, childbirth and puerperium) 
 ED attendances at the CUMH emergency room 
 Outpatient visits at the following CUMH clinics: obstetrics, ultrasound, fetal 
assessment, antenatal and post natal. 
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Utilisation data from a previous micro-costing study (Chapter 4) [284] was used to 
cross-check utilisation data and to provide information on whether an outpatient 
visit was attended or missed, as well as to provide information on the diagnostic 
tests linked with each outpatient ID appointment. Data on diagnoses associated 
with all inpatient episodes were obtained from the HIPE department of CUH. In-
patient diagnoses are coded using the International Classification of Diseases 10th 
revision Australian Modification [285]. Up to 30 diagnoses codes can be recorded 
for each admission. Diagnoses codes for each in-patient episode were reviewed 
independently by two infectious-disease consultants (AJ and CB), and categorised 
subjectively as “HIV-related”, “HIV-associated” or “unrelated to HIV”. HIV-related 
diagnoses were diagnoses that were known to be related to HIV infection (e.g. 
candidal oesophagitis, adverse reactions to antiviral medication, Kaposi sarcoma), 
HIV-associated diagnoses were diagnoses for conditions associated with HIV 
infection (e.g. anal carcinoma), or diagnoses which were possibly related to the 
underlying HIV infection but which couldn’t be definitely attributed to HIV infection 
(e.g. unspecified acute lower respiratory tract infection in a virally suppressed 
patient with a high CD4 count). Episodes where categorisations differed or were not 
possible to determine on the basis of diagnoses codes alone were re-checked by 
the consultant in CUH (AJ) in conjunction with a Clinical Nurse Specialist and patient 
notes. Admissions which occurred within 1 day of an ED visit were assumed to be 
linked to that ED visit. In-patient episodes admitted and discharged on the same 
day were given a length of stay of 1 day. The CD4 counts reported are the minimum 
CD4 counts recorded in 2012. A list of the variables included in this analysis and 
their source is shown in Table 5-1. 
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Table 5-1. List of variables included in analysis and source of data 
Variable Source of variable Notes 
Patient level 
Age ABC/Micro-costing  
Gender ABC/Micro-costing  
Risk factor Micro-costing  
Minimum CD4 count in 
2012 
Micro-costing  
Late diagnosis Micro-costing  
Years since diagnosis Micro-costing  
Treatment status Micro-costing  
Suppression status Micro-costing  
Healthcare contact level 
Date ABC Date of healthcare contact/admission 
Type of contact ABC Inpatient/day case/emergency 
dept/outpatient 
Hospital ABC CUH/CUMH 
Clinic name ABC  
Cost ABC Total cost, excluding drug costs 
Date of discharge ABC Inpatient admissions only 
Length of stay ABC Inpatient admissions only 
Number of ICU days ABC Inpatient admissions only 
Diagnosis HIPE Inpatient admissions only, up to 30 
recorded per admission 
Procedure HIPE Inpatient admissions only, up to 30 
recorded per admission 
Attended Micro-costing study Outpatient appointments only 
CD4 count Micro-costing study ID outpatient appointments only 
FBC Micro-costing study ID outpatient appointments only 
Viral Load Micro-costing study ID outpatient appointments only 
Biochemistry profile Micro-costing study ID outpatient appointments only 
ABC, activity based costing system; HIPE, Hospital inpatient enquiry; FBC, Full blood count 
5.3.4 Ethical considerations 
Ethical approval for this study was obtained from the Research Ethics Committee of 
CUH. 
5.3.5 Data analysis 
5.3.5.1 Patient categorisation 
There is no definition of what constitutes a “stable” patient, however patients who 
are newly diagnosed, require antenatal care, are on HAART but not suppressed, are 
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not on HAART or have CD4 counts <350 cells/µl are all groups of patients who 
would not be suitable for less frequent monitoring [3,40,41,75]. Therefore in this 
analysis patients were categorised as “stable” if they met all of the following 
conditions: 
• They were on HAART and categorised as suppressed for their entire 
study period in 2012 (“suppressed” defined as all viral loads in 2012 <50 
copies/ml, with one test result of 50-499 copies/ml allowed if previous 
and subsequent viral load results were < 50 copies/ml)  
• They were diagnosed before the start of 2011 
• Their lowest CD4 count recorded in 2012 was ≥ 350 cells/µl 
• They did not attend for antenatal care in 2012 
5.3.5.2 Statistical analyses 
All information was entered into a Microsoft Access® database and analysed using 
Microsoft Excel® and STATA 12 (College Station, Texas). Mean numbers of 
appointments per year were calculated weighted by the number of months in care. 
Differences in proportions were tested using χ2 tests, as patients had different 
length of follow-up during which an episode of care could happen χ2 tests for 
differences in proportions were limited to the sub-group of patients who were in 
care for 12 months (n=287) where applicable. Differences in means of normally 
distributed variables were tested using the Student’s t-test. Differences in non-
normally distributed variables (e.g. mean costs per patient month) were tested 
using either Wilcoxan rank-sum or Kruskal-Wallis rank tests. A binomial generalised 
linear model was used to test the association between HAART status and missed 
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infectious disease outpatient visits, taking into account length of follow-up and 
patient clustering.  
For comparison of stable and non stable patients, the average number (and 95% 
CIs) of visits and tests per patient were estimated using Poisson regression with 
robust standard errors. Relative risks for use of services were calculated using a 
modified Poisson approach with robust error variances [286]. 
Multivariate analysis of cost data was performed using a generalised linear model 
(inverse Gaussian family, identity link). The family was selected using a modified 
Parks test, while the link was identified by evaluating the results of the Pearson, 
Pregibon and modified Hosmer and Lemeshow tests for power links between 0 and 
1 in increments of 0.1 [264]. 
5.4 Results 
5.4.1 Description of cohort 
A total of 328 patients (3,672 patient-months) were included in the study. The 
characteristics of the patient cohort has been reported previously [284]. The 
majority of patients (59%) were male and the average age was 40 years. 13% (n=42) 
were ≥50 years of age. Most patients had a minimum CD4 count in 2012 >350 cells 
(77%), and were on HAART for 100% of their study period (79%), a further 14% 
were on HAART for <100% of their study period, most of whom were patients who 
initiated HAART in 2012. A small proportion of patients were co-infected with 
hepatitis C (7%), hepatitis B (2%) or with both hepatitis B and C (1%). Three patients 
died, two of these were newly diagnosed in 2012 and died of HIV-related causes. 
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In total 61 patients were excluded. Limited data were available on the age and sex 
of excluded patients. Excluded patients were significantly older (mean 47 years vs 
40 years, t-test p<0.0001) and more likely to be male (77% vs 59%, χ2 p=0.005). 
5.4.1.1 Stable vs non-stable patients 
Of the 328 patients included in this study, 166 (51%) were classified as stable and 
162 (49%) as non-stable. The characteristics of the two groups are shown in Table 
5-2. Stable patients tended to be older (mean age 43 years vs 37 years, t-test p < 
0.0001), and diagnosed longer (9.1 years vs 5.5 years, Mann-Whitney p <0.0001). 
Stable patients also contributed significantly more patient months (mean 11.6 vs 
10.8 months per patient, Mann-Whitney p <0.0001). 
 
Table 5-2. Patient characteristics of stable and non-stable patients 
  Stable (%) Non-stable (%) Total Chi2, P 
Total patient 
months 
 1,929 1,743 3,672  
Gender Male 101 (61%) 93 (57%) 194 0.527 
 Female 65 (39%) 69 (43%) 134 
Age group <50 years 134 (81%) 152 (94%) 286 <0.001 
 ≥50 years 32 (19%) 10 (6%) 42 
Years since diagnosis >10 years 68 (41%) 28 (17%) 96 <0.001 
 6-10 years 62 (37%) 45 (28%) 107 
 1-5 years 36 (22%) 64 (40%) 100 
 Diagnosed in 2012 - 18 (11%) 18 
Risk factor MSM 48 (29%) 48 (30%) 96 0.829 
 COHP 66 (40%) 67 (41%) 133 
 Heterosexual 36 (22%) 28 (17%) 64 
 IDU 9 (5%) 9 (6%) 18 
 Other/unknown 7 (4%) 10 (6%) 17 
Late diagnosis No 65 (39%) 72 (44%) 137 0.237 
 Unknown 36 (22%) 41 (25%) 77 
 Yes 65 (39%) 49 (30%) 114 
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5.4.2 Use of outpatient ID services 
Infectious disease. There were 1,338 infectious-disease outpatient appointments 
scheduled in the 3,672 patient months in 2012 giving an average of 4.4 scheduled 
visits per patient year (median 4, interquartile range 3-5). While some of these 
appointments may have been for infectious diseases other than HIV the opinion of 
the clinicians providing the clinic was that the vast majority of appointments were 
likely to have been HIV-related. It is also worth noting that in CUH the hepatology 
service provides care and treatment for hepatitis C infection, and co-infected 
patients attend both services separately. 
Missed visits. The overall missed visit rate for scheduled infectious disease clinic 
appointments was 12% (158/1,338), however missed visits were concentrated in a 
minority of patients, as 75% of patients missed no visits, 15% missed a single visit 
and 10% missed two or more visits. Patients not on HAART at the time of the 
scheduled visit were significantly more likely (odds ratio 2.7, 95% CI 1.3-5.6) to miss 
their appointment. 
Overall stable patients had fewer visits in 2012 (average 3.30 scheduled visits per 
patient, 95% CI 3.13-3.36) than non-stable patients (4.95 scheduled visits per 
patient, 95% CI 4.57-5.33). Stable patients also attended significantly more of their 
scheduled visits 90% attended vs 86% attended (χ2 p=0.025). Stable patients 
attended an average of 2.98 visits in 2012 (95% CI 2.86-3.10 visits per patient) while 
non-stable patients attended 4.28 visits in 2012 (95% CI 3.95-4.61 visits per 
patient).  
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Of the patients who were considered to be in care for the entire of 2012 (n=287), 
15% attended twice, 59% attended 3 times, 18% attended 4 times and 8% attended 
5 or more visits in 2012 (Figure 5-1). 
 
 
Figure 5-1. Number of attended HIV outpatient appointments per patient in 2012 in 
patients in care for all of 2012, by patient type (n=287) 
 
Routine laboratory testing 
There were 1,180 attended outpatient appointments in 2012, and 91% of these had 
at least one associated laboratory test. Local clinical guidelines in 2012 (Appendix 3) 
recommended patients receive CD4, viral load, FBC and biochemistry profile testing 
every 3-4 months. 
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The average number of these routinely recommended tests that patients received 
in 2012 is shown in Table 5-3. The distribution of the number of tests per patient 
(for patients in care for all of 2012) by patient type can be seen in Appendix 4. 
 
Table 5-3. Total number of tests and mean number of tests per patient (n=328) by patient 
type, in 2012 
 Stable patients Non-Stable patients 
Test name Total 
number 
Average per patient 
(95% CI) 
Total 
number 
Average per patient 
(95%CI) 
CD4 466 2.71 (2.61-2.81) 548 3.56 (3.33-3.78) 
Viral Load 469 2.73 (2.63-2.83) 527 3.42 (3.19-3.65) 
FBC 473 2.75 (2.65-2.85) 564 3.66 (3.41-3.91) 
Biochemistry profile 483 2.81 (2.69-2.93) 560 3.63 (3.38-3.88) 
 
5.4.3 Use of other hospital services 
The overall proportions of patients with any non-ID outpatient appointment, any 
emergency department (ED) attendance or any inpatient admission in 2012 are 
shown in Table 5-4. 
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Table 5-4. Proportion of patients with any non-ID outpatient appointment, any ED 
attendance or any inpatient admission (including day-cases) in 2012 
  Non-ID 
outpatient 
appointment  
ED 
attendance 
Inpatient 
admission (HIV 
related/associated, 
HIV unrelated) 
Stable Yes 39% 17% 15% (6%, 9%) 
 No 27% 11% 6% (1%, 5%) 
Gender Male 35% 13% 11% (4%, 7%) 
 Female 31% 15% 10% (2%, 7%) 
Age group <50 years 34% 15% 11% (4%, 7%) 
 ≥50 years 29% 10% 7% (0%, 7%) 
Years since 
diagnosis 
>10 years 
33% 14% 7% (1%, 6%) 
 6-10 years 37% 13% 8% (2%, 7%) 
 1-5 years 27% 11% 10% (3%, 7%) 
 Diagnosed in 2012 22% 39% 39% (22%, 17%) 
Risk factor MSM 31% 10% 9% (3%, 6%) 
 COHP 34% 17% 8% (2%, 6%) 
 Heterosexual 27% 11% 13% (5%, 8%) 
 IDU 56% 11% 11% (6%, 11%) 
 Other/unknown 35% 29% 24% (6%, 18%) 
Late diagnosis No 36% 15% 12% (1%, 11%) 
 Unknown 36% 16% 9% (4%, 6%) 
 Yes 26% 11% 9% (5%, 4%) 
Minimum CD4 
category 
500+ 
28% 11% 7% (1%, 6%) 
 350-499 26% 11% 6% (1%, 5%) 
 200-349 48% 17% 15% (4%, 12%) 
 50-199 64% 14% 14% (7%, 7%) 
 <50 57% 86% 86% (71%, 29%) 
HAART and 
Viral load 
category 
On HAART, suppressed 
33% 13% 8% (1%, 7%) 
 On HAART, not 
suppressed/undetermined 41% 5% 9% (5%, 5%) 
 Started/stopped HAART 31% 24% 20% (10%, 12%) 
 Not on HAART 25% 21% 17% (8%, 8%) 
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5.4.3.1 Other outpatient specialties 
One third of patients (n=108) had at least one outpatient appointment scheduled 
with a specialty other than infectious diseases (272 appointments). The most 
frequently scheduled non-ID outpatient appointments were gynaecology (14% of 
appointments), psychiatry (11%), gastroenterology (11%), haematology (8%), 
ophthalmology (8%) and orthopaedics (8%). Although use of non-ID outpatient 
specialities might be expected to be more frequent in older patients, the total 
proportion of patients ≥50 years of age with scheduled non-ID outpatient 
appointments did not differ significantly from younger patients (χ2=0.41, p=0.52). 
The missed visit rate for scheduled appointments with non-ID specialties was 25%. 
On univariate analysis, non-stable patients, IDUs and patients in lower CD4 
categories had significantly higher risks of having any scheduled non-ID outpatient 
appointments (see Table 5-5). Stable categorisation and IDU remained significant 
on multivariate analysis, adjusting for gender, age, number of years diagnosed, risk 
factor and late diagnosis (CD4 category was not included as stable patients by 
definition had a CD4 count ≥350 cells/µl). 
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Table 5-5. Relative risk (RR) from univariate analysis and adjusted RR from multivariate 
analysis of any scheduled non-ID outpatient appointment in 2012, by patient 
characteristic 
Patient characteristics Any non-ID outpatient appointment(s) 
  RR RR adj 
Stable patient Yes - - 
 No 1.55* 1.64* 
Female Male - - 
 Female 0.88 0.71 
Age (per year) 1.00 1.00 
Years since diagnosis (per year) 1.01 1.03 
Risk factor MSM - - 
 COHP 1.08 1.35 
 Heterosexual 0.85 0.95 
 IDU 1.94* 2.13* 
 Other/unknown 1.17 0.94 
Late diagnosis No - - 
 Unknown 1.03 0.73 
 Yes 0.72 0.69 
Min CD4 category 500+ -  
 350-499 0.89  
 200-349 1.70*  
 50-199 2.43**  
 <50 2.43**  
HAART and Viral 
load category 
On HAART, suppressed -  
 On HAART, not 
suppressed/undetermined 
1.26  
 Started/stopped HAART 1.22  
 Not on HAART 0.86  
Model used for both univariate and multivariate analyses was a generalised linear model with 
Poisson family, log link and robust standard error. *P<0.05, **P≤0.001, RR relative risk. COHP, 
person from a country of high prevalence with no other identifiable risk factor available. IDU, 
current/former injecting drug user. Late diagnosis defined as CD4 count < 350 cells/μl at diagnosis or 
AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire 
duration of the study, “suppressed” was defined as all viral loads in 2012 <50 copies/ml, with one 
test result of 50-499 copies/ml allowed if previous and subsequent viral load results were < 50 
copies/ml. 
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5.4.3.2 Admissions 
There were 43 inpatient episodes (in 34 patients) in 2012, of which 28% (n=12) 
were categorised as HIV-related and a further 9% (n=4) as HIV-associated. The 
overall in-patient admission rate was 0.14 admissions per patient year, with the 
average length of stay 7.5 days per admission. Eight inpatient days (2%) were 
intensive care days (2 patients). The primary diagnosis coded for each inpatient 
episode can be seen in Table 5-6. Of note was that 8 admissions (19%, 95% CI 8%-
33%) did not have a HIV related diagnosis code (B20-24) recorded in any of the 30 
available diagnoses fields. Nearly all of these admissions were classed as unrelated 
to HIV, however one was classed as HIV-associated. 
Table 5-6. Number (days) of inpatient episodes by primary diagnosis code and HIV 
category 
Primary diagnosis (ICD-10 AM chapter) Codes HIV-related HIV-
associated 
Unrelated to 
HIV 
Infectious and parasitic diseases A00–B99 7 (88)   
of which, HIV diagnoses B20-24 4 (35)   
Neoplasms  C00–D48 1 (33)   
Diseases of the blood and blood-
forming organs and immune mechanism 
D50–D89   1 (1) 
Endocrine, nutritional and metabolic 
diseases 
E00–E90   1 (1) 
Mental and behavioural disorders F00–F99   1 (1) 
Diseases of eye and adnexa  H00–H59 1 (3)   
Circulatory system diseases  I00–I99   3 (6) 
Respiratory diseases J00–J99  1 (3) 1 (1) 
Digestive diseases  K00–K93   3 (18) 
Diseases of the skin and subcutaneous 
tissue  
L00–L99 2 (5)  1 (1) 
Diseases of the musculoskeletal system 
and connective tissue  
M00–M99 1 (11)  2 (2) 
Genitourinary system diseases N00–N99  1 (1) 5 (13) 
Symptoms, signs not elsewhere 
classified  
R00–R99  2 (7) 4 (20) 
Injury, poisoning and certain other 
consequences of external causes 
S00–T98   5 (110) 
Total  12 (140) 4 (11) 27 (174) 
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There were also 197 day-case admissions (defined as planned admissions not 
requiring an overnight stay [285]) in 2012. The vast majority of these were incurred 
by two patients, one on haemodialysis (158 day-case admissions) and the second 
undergoing radiotherapy for a HIV-associated condition (27 day-case admissions). 
Of the remaining 12 day-case admissions, 4 were considered HIV-related and 2 HIV-
associated. 
Not being categorised as stable was significantly associated with risk of any 
inpatient admission and any HIV-related/associated inpatient admission (but not 
HIV-unrelated admission) on multivariate analysis, with non-stable patients being 
more than twice as likely as stable patients to be admitted and over 5 times more 
likely to have a HIV-related/associated admission (Table 5-7). Having a risk factor of 
“other/unknown” was also significantly associated with an increased risk of any 
admission. This risk group is comprised of mixture of patients including those with 
an unknown risk factor as well as those who acquired HIV through exposure to 
blood/blood products, and vertical transmission. The elevated risk of admission in 
this group may possibly be explained by the likelihood of co-morbidities in these 
patients, particularly the patients who acquired HIV through exposure to blood 
products. 
5.4.3.3 Emergency department visits 
There were 65 ED visits by 46 patients (14% of patients), giving an average ED visit 
rate of 0.2 visits per patient year. 51% of these visits resulted in admission, one 
third of which were considered HIV-related admissions.  
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Having a very low CD4 count and having started/stopped treatment were 
significantly associated with an ED attendance on univariate analysis, however on 
multivariate analysis only having a risk factor of other/unknown remained 
significant (Table 5-8). 
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Table 5-7. Relative risk (RR) from univariate analysis and adjusted RR from multivariate 
analysis, of any admission (including day-case admissions), HIV-related/associated 
admissions, and HIV unrelated admissions in 2012, by patient characteristics 
Patient characteristics Any inpatient 
admission 
HIV-
related/associated 
admission 
HIV unrelated 
admission 
  RR RR adj RR RR adj RR RR adj 
Stable Yes - - - - - - 
 No 2.66* 2.23* 11.07* 5.04* 1.84 1.81 
Female Male - - - - - - 
 Female 0.89 0.86 0.54 0.35 1.02 1.06 
Age (per year) 0.98 0.99 0.96 0.98 0.98 1.00 
Years since diagnosis (per year) 0.94 0.96 0.72 0.80 1.00 1.00 
Risk factor MSM - - - - - - 
 COHP 0.88 0.89 0.72 1.16 0.96 0.87 
 Heterosexual 1.33 1.48 1.49 3.10 1.25 1.11 
 IDU 1.30 1.56 1.94 2.91 1.94 1.90 
 Other/unknown 2.60 3.81* 1.94 3.63 2.92 2.96 
Late diagnosis No - - - - - - 
 Unknown 0.76 0.79 2.76 4.60 0.61 0.60 
 Yes 0.71 0.83 3.62 4.16 0.32* 0.36 
Minimum CD4 
category 
500+ -  -  -  
 350-499 0.81  0.97  0.78  
 200-349 2.17  3.26  1.96  
 50-199 2.16  6.49  1.30  
 <50 14.58**  72.88**  5.83*  
HAART and 
Viral load 
category 
On HAART, 
suppressed 
-  -  -  
 On HAART, not 
suppressed/ 
undetermined 
1.20  4.81  0.69  
 Started/stopped 
HAART 
3.51*  14.03*  2.40  
 Not on HAART 2.47  9.88*  1.41  
Model used for both univariate and multivariate analyses was a generalised linear model with 
Poisson family, log link and robust standard error. *P<0.05, **P≤0.001, RR relative risk. COHP, 
person from a country of high prevalence with no other identifiable risk factor available. IDU, 
current/former injecting drug user. Late diagnosis defined as CD4 count < 350 cells/μl at diagnosis or 
AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire 
duration of the study, “suppressed” was defined as all viral loads in 2012 <50 copies/ml, with one 
test result of 50-499 copies/ml allowed if previous and subsequent viral load results were < 50 
copies/ml. 
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Table 5-8. Relative risk (RR) from univariate analysis and adjusted RR from multivariate 
analysis, of any ED attendance in 2012, by patient characteristics 
Patient characteristics Any ED attendance 
  RR RR adj 
Stable Yes - - 
 No 1.57 1.33 
Female Male - - 
 Female 1.10 0.84 
Age (per year) 0.99 1.00 
Years since diagnosis (per year) 0.97 0.96 
Risk factor MSM - - 
 COHP 1.58 1.66 
 Heterosexual 1.05 1.12 
 IDU 1.17 1.19 
 Other/unknown 2.92* 3.87* 
Late diagnosis No - - 
 Unknown 1.05 1.15 
 Yes 0.75 0.76 
Minimum CD4 
category 
500+ -  
 350-499 0.92  
 200-349 1.54  
 50-199 1.37  
 <50 9.21**  
HAART and Viral 
load category 
On HAART, suppressed -  
 On HAART, not 
suppressed/undetermined 
0.36  
 Started/stopped HAART 2.49*  
 Not on HAART 1.83  
Model used for both univariate and multivariate analyses was a generalised linear model with 
Poisson family, log link and robust standard error. *P<0.05, **P≤0.001, RR relative risk. COHP, 
person from a country of high prevalence with no other identifiable risk factor available. IDU, 
current/former injecting drug user. Late diagnosis defined as CD4 count < 350 cells/μl at diagnosis or 
AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire 
duration of the study, “suppressed” was defined as all viral loads in 2012 <50 copies/ml, with one 
test result of 50-499 copies/ml allowed if previous and subsequent viral load results were < 50 
copies/ml. 
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5.4.4 Costs 
The non-drug cost to the hospital of providing care for the HIV patients included in 
this study in 2012 can be seen in Table 5-9. 
As would be expected, the type of costs incurred differed by CD4 category, with 
patients with lower CD4 counts having a higher proportion of their costs due to 
HIV-related inpatient care, while those with higher CD4 counts had little HIV-related 
inpatient care. Most notably, the 2% of patients with a CD4 count < 50 cells/µl 
accounted for 61% of inpatients costs (€194,369/€317,892) and 31% 
(€209,725/€669,591) of the total cost of providing care for HIV patients in 2012. 
The overall mean non-drug cost per patient month (PPM) was €180 (€95-€265). On 
univariate testing (Wilcoxan rank-sum or Kruskal-Wallis tests) the total non-drug 
costs per patient month differed significantly by age group (p<0.0001), risk factor 
(p=0.04), stable categorisation (p<0.0001), CD4 category (p=0.0001), year of 
diagnosis (p<0.0001), and HAART/suppression category (p=0.0001). However on 
multivariate analysis of total non-drug costs the only predictors that remained 
significant on adjustment were CD4 < 50 cells/μl and not being on HAART (Table 
5-10). 
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Table 5-9. Proportion of non-drug costs by type of care, proportion of patients who used 
each care type (n=328), and for those who used each type of care the mean, median and 
inter-quartile range (IQR) of non-drug costs per patient month, 2012. 
 
% of total 
non-drug 
costs 
% of patients 
incurring cost 
(95% CI*) 
Non drug cost per patient month 
 
Mean Median IQR 
Outpatient appointments 
    Infectious diseases 35% 100% € 63 € 54 €45-€72 
Other specialties 11% 33% (28%-38%) € 59 € 18 €10-€32 
Outpatient subtotal 46% 100% € 84 € 60 €46-€87 
Inpatient episodes 
     HIV related 19% 3% (2%-6%) € 1,584 € 656 €291-€1,968 
HIV associated 1% 1% (0.2%-3%) € 207 € 159 €146-€317 
Unrelated to HIV 27% 7% (5%-11%) € 722 € 138 €66-€358 
Inpatient subtotal 47% 10% (7%-14%) € 958 € 182 €75-€879 
Day case admissions 
     HIV related 0% 1% (0.2%-3%) € 55 € 47 €18-€97 
HIV associated 1% 1% (0.2%-3%) € 258 € 57 €56-€661 
Unrelated to HIV 3% 2% (1%-4%) € 251 € 46 €16-€60 
Day case subtotal 5% 4% (2%-7%) € 212 € 56 €24-€60 
Emergency Department visit 
    All ED visits 2% 14% (11%-18%) € 27 € 17 €14-€25 
Total 100% 
 
€ 180 € 61 €46-€93 
*Agresti-Coull 95% Confidence Interval. 
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Table 5-10. Mean HIV related/associated, HIV unrelated and total non-drug costs ppm 
2012, by subgroups, and significance of differences in total non-drug costs on 
multivariate analysis. 
Patient subgroup N Mean cost ppm Multivariate 
analysis of 
total nondrug 
costs, P 
HIV 
related/ 
associated 
HIV 
unrelated 
Total 
Gender Male 194 121 111 235 ref 
Female 134 79 24 101 0.86 
≥50 years No 286 112 84 197 ref 
Yes 42 48 18 68 0.11 
Risk 
factor 
MSM 96 151 49 203 ref 
COHP 133 78 33 112 0.46 
Heterosexual 64 73 32 104 0.11 
IDU 18 94 530 629 0.64 
Other/unknown 17 170 275 453 0.46 
Minimum 
CD4 
count in 
2012 
500+ 169 58 22 82 ref 
350-499 85 67 58 122 0.49 
200-350 52 103 119 223 0.20 
50-199 14 176 143 323 0.06 
<50 7 1840 1340 3227 0.02 
Late 
diagnosis 
No 137 75 61 136 ref 
Unknown 77 76 173 251 0.08 
Yes 114 156 28 186 0.11 
Years 
since 
diagnosis 
11+ years 96 57 81 140 ref 
6-10 years 107 69 98 168 0.97 
1-5 years 100 108 20 126 0.66 
diagnosed 2012 18 918 380 1319 0.28 
HAART & 
Viral load 
category 
On HAART suppressed 211 64 46 111 ref 
On HAART not 
suppressed/undetermined 
44 
137 55 187 0.71 
Started/stopped HAART 49 293 293 591 0.37 
No HAART 24 98 26 128 0.03 
PPM, per patient month. Total non-drug costs ppm includes the cost of ED visits. Generalised linear 
model with inverse Gaussian family and identity link. Ref, reference category. COHP, person from a 
country of high prevalence with no other identifiable risk factor available. MSM, men who has sex 
with men. IDU, current/former injecting drug user. Late diagnosis defined as CD4 count < 350 
cells/μl at diagnosis or AIDS defining illness at diagnosis. “On HAART” means the patient was on 
HAART for the entire duration of the study, “suppressed” was defined as all viral loads in 2012 <50 
copies/ml, with one test result of 50-499 copies/ml allowed if previous and subsequent viral load 
results were < 50 copies/ml. 
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5.5 Discussion 
This study reports the range, frequency and cost of healthcare services used by HIV 
patients in a single centre in the south of Ireland in a single calendar year (2012). 
We have previously reported the cost of HAART for this cohort in 2012 was €856 
per patient month [284], making HAART costs over 80% of the total cost of 
providing care in 2012 (excluding other drug costs). This is a similar proportion to 
what has reported previously in other countries [121,134,266,267]. Although 
HAART is expensive, it is a very cost-effective treatment [42,269,287], and not only 
vastly improves individual outcomes, but also has population level benefits, 
reducing onward transmission [270]. In this cohort, 77% of patients were on HAART 
for the entire period of the study with a further 11% initiating HAART during 2012, 
just 7% of patients received no HAART in 2012 (their average CD4 count was 510 
cells/μl). Of patients who were on HAART for more than 6 months, the most recent 
viral load result was <50 copies/ml for 90% of patients, treatment and response 
figures which are comparable to other developed countries [248-250]. 
Unsurprisingly outpatient infectious disease care was the most frequently used 
service by this group of patients, accounting for 35% of all non-drug costs in 2012 
(Table 5-9). One third of patients also had outpatient appointments with other 
specialties, and while the overall cost of non-ID outpatient appointments was 11% 
of total non-drug costs, within the subgroup of patients using other services nearly 
half (47%) of their outpatient costs were due to use of non-ID services. It is well 
established in the literature that as patients age they are experiencing increasing 
levels of non-HIV morbidity [237], rates of which are higher than in comparable HIV 
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negative populations [275,288]. It is a limitation of our study that we do not have 
information on patient co-morbidities, and can only use other services as an 
indicator of possible non-HIV morbidity. Hospital outpatient appointments are likely 
to underestimate the burden of non-HIV morbidity as infectious disease specialists 
may be dual trained or patients may attend other hospitals/primary care services 
for their non-HIV care. Conversely patients may also be referred to other specialties 
for investigations that subsequently prove negative. There were relatively few 
patients ≥50 years of age in this cohort in 2012 so unfortunately it was not possible 
to carry out any meaningful analysis of their use of specific non-ID services. In 
contrast to what has previously been reported in the literature [134] the cost of 
care for older patients in this study was lower than that for younger patients, 
although this was no longer significant when adjustment was made for confounding 
factors (Table 5-10). We previously reported a similar finding for the cost of HIV 
outpatient care alone, and postulated that this result was due to the particular 
characteristics of the cohort attending CUH [284]. However this study does provide 
baseline data which will be useful to assess potential changing resource use with 
the ageing of the patient cohort. 
An interesting finding was that 19% (95% CI 8%-33%) of admissions had no HIV 
diagnosis coded in any of the 30 available diagnoses fields. There are two possible 
reasons for this discrepancy, HIV diagnoses may not have been documented in the 
medical records available to the coders (as doctors may not have asked about, or 
patients may not have disclosed their HIV status), or errors may have occurred 
during the coding process. Previous studies examining the accuracy of diagnostic 
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coding in Irish public hospitals have highlighted the limitations of such data for 
research purposes [289-291]. The benefits of clinician awareness of and 
involvement in the coding process has previously been demonstrated [290] and as 
healthcare funding structures in Ireland change, from block grant budgets to an 
activity based “money follows the patient” approach [258], clinician education on 
the importance of clear and complete documentation as well as regular auditing of 
coding and detailed analysis of local data to identify possible data quality issues 
[292-294] are likely to become critical factors in hospital funding. 
Approximately half of the patients attending CUH in 2012 for HIV care were 
categorised as stable. Although 64% of patients in our study were on HAART and 
suppressed for the study period 16% of those patients had CD4 <350 cells/µl, and 
so were not categorised as stable in this analysis. Over half of these patients were 
known to have been diagnosed late, and baseline CD4 count is one of the most 
important factors determining the CD4 recovery of patients on treatment [295-
300]. This illustrates one of the longer-term consequences of late diagnosis for the 
health service, as patients diagnosed late will on average take longer to achieve the 
required CD4 levels necessary for reduced monitoring. 
In terms of the use of the outpatient HIV service, as would be expected stable 
patients were found to have significantly fewer outpatient ID appointments (both 
scheduled and attended), and significantly fewer routine tests per year than 
patients who were not categorised as stable. A small proportion of patients had 
more frequent attendances than would be expected for truly stable patients, 
indicating that perhaps these patients had additional clinical needs which were not 
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covered in the criteria used to categorise patients in this analysis, and perhaps 
would not, in reality, be suitable candidates for reduced clinical and/or laboratory 
monitoring. An audit carried out in CUH in 2013 reported a similar proportion (50%) 
of patients were suppressed with a CD4 count > 350 cells/µl, but only 52% of those 
patients in that study were deemed eligible to be scheduled for 6-monthly review 
[301]. 
On average, stable patients attended nearly 3 visits per year, and accounted for 
44% of all attended HIV outpatient visits in 2012 (n=514), assuming the average 
number of visits per patient could be reduced to 2 visits per year, there would be 
approximately 180 fewer visits, equivalent to around a 15% reduction in the total 
number of attended outpatient infectious disease visits. If this reduction was only 
possible in 52% of the stable patients (as suggested by the audit in CUH), then there 
would be an equivalent reduction in total visits of less than 9%. 
Laboratory monitoring is another area where it has been suggested that cost-
savings could be made through the reduction in the number of tests performed. In 
recent years, evidence has emerged the CD4 counts of stable patients change little, 
leading to international guidelines reducing their recommended frequency of 
monitoring in stable patients on treatment , in particular in those which high CD4 
counts (see Appendix 5) [3,41,302]. This cohort of patients, had an average of 
around 2.7-2.8 of each of the four routinely recommended tests (CD4, viral load, 
FBC, biochemistry profile) performed per year. Within current guidelines CD4 
testing and FBCs could theoretically be performed annually, while VL and 
biochemistry profiles could be performed 2/year (Appendix 5). A reduction in 
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testing of that magnitude would result in a saving of approximately 40% of routine 
test costs in stable patients, and routine tests account for over 80% of the total 
laboratory testing costs associated with HIV outpatient visits (see Chapter 4). 
On multivariate analysis non-stable patients were found to have a significantly 
higher risk of using any non-ID outpatient service (RR 1.64), and were also over five 
times as likely to have a HIV related/associated inpatient admission compared to 
stable patients (see Table 5-7). 
We recognise that there are several important limitations to this study. The study 
was carried out in a single centre which has a lower proportion of injecting drug 
users than the total HIV population in care in Ireland (6% vs 21% nationally), 
however the study population was similar to the national HIV population in care in 
terms of age (mean age 40 years for both), gender (59% male CUH vs 62% male 
nationally) and clinical characteristics (80% on HAART nationally) [85]. No 
information was collected on patients’ use of other hospitals, while the nearest 
alternative HIV centre is 100km away, there are four other hospitals in the region 
providing emergency care which patients could have accessed and which would not 
have been included in this study. The cost of appointments with allied health 
professionals within CUH was not included nor was any patient use of non-hospital 
health services (GPs, community care). It was also not possible to distinguish HIV-
morbidity associated use of non-ID outpatient hospital services. As a clinical 
database routinely updated with viral load results was used to initially identify all 
patients who attended in 2012, eligible patients may have been missed if a patient 
attended and did not have a viral load test performed or if the viral load was not 
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entered on the database. As the possibility of a patient who had attended in 2012 
but who had no corresponding viral load result in the database would be more 
likely to happen if a patient only attended once in 2012, this could be a source of 
selection bias in this study. Probably the biggest limitation, however, is the lack of a 
HIV negative comparison group, meaning it was not possible to estimate how much 
healthcare use in this cohort was additional to what would be normally used by 
similar patients without HIV infection. National surveys have reported the 12-
month prevalence of use of hospital services by the general population to be 10% 
for emergency services, 20% for outpatient services, 9% for day patient admissions, 
and 10% for in-patient admissions [303,304]. The overall prevalence of ED and non-
ID outpatient clinic use were higher in our study (14% and 33% respectively) as 
were the age-specific rates. The proportion of patients admitted following an ED 
episode (51%) was also higher than the reported proportion of ED episodes that 
result in admission overall in Ireland (25%) [305]. The prevalence of non-HIV 
admissions (7%) and day-case admissions (4%) was slightly lower than the 
prevalence in the general population, although this difference may be explained by 
the exclusion of obstetric care from our analyses. 
Data on the use and cost of health service use by HIV patients is very useful for both 
planning of health services and for use in health technology assessments and cost-
effectiveness studies. The prevalence approach to costing, as used in this study, is 
particularly informative for policy makers and planners as it provides a snapshot of 
the total cost for a particular year given the mix of patients present, whereas an 
incidence approach, which would be better at identifying and estimating the costs 
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for particular types of patients, or particularly resource intensive periods of patient 
care (e.g. following diagnosis, approaching death etc) does not necessarily provide 
the type of information that can be easily used for planning. Information on the 
range and frequency of other specialties accessed by this population can also be 
used to inform the long-term organisation of services and co-ordination and 
integration of care across specialties. 
There is no agreed definition of what constitutes a “stable” patient, British [42], 
European [41] and WHO[40] guidelines give no definition of how long a patient 
should be suppressed to be considered “stable” while US guidelines specify 2 years 
[3]. We did not have data on the suppression status of patients before the start of 
data collection in 2012, so our categorisation may have over-estimated the 
proportion of patients who were stable. Data on patient co-morbidities, which 
would require more frequent clinical follow-up, were not available, again possibly 
inflating the proportion of stable patients in this analysis. In addition, laboratory 
tests were linked to outpatient appointments based on matching dates, the use of 
the data as a linking variable may have missed some laboratory results, 
underestimating the number of laboratory tests performed. 
While our study provides baseline information on the frequency and type of 
hospital services used by HIV patients, further work to estimate the costs and 
resource use during intensive phases of care, such as following diagnosis, or 
approaching death would be useful for making more accurate estimates for health 
technology assessments and cost-effectiveness analyses. As Ireland’s healthcare 
financing structures are reformed, it is particularly important that the costs of 
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complex patients, such as HIV patients, are adequately accounted for in new 
financing structures. 
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6 Cost and variation of ambulatory HIV care in Ireland 
  
 171 
6.1 Abstract 
It is anticipated that demands on ambulatory HIV services will increase in coming 
years due to increases in both the size and age profile of the patient population. 
Data on current service delivery patterns and costs are needed to allow evaluation 
of the estimated impact of the changing epidemiology and/or changes to 
international clinical guidelines, as well as to facilitate health technology 
assessments of new drugs and models of care. Differences in organisation of care as 
well as economies of scale make national extrapolation of cost data generated in a 
single centre problematic. The aim of this research was to generate a national 
estimate of the annual cost of outpatient HIV care taking into account local 
variation in service delivery. 
Visit costs were based on results of a single centre micro-costing study. In order to 
account for variation in organisation of care across centres information collected 
through expert interviews with key staff was used to adjust the staff portion of 
visits costs for each centre. A decision tree was developed based on groups of 
patients with different visit rates (antenatal patients, new patient patients, patients 
who started or switched HAART regimens) and populated using data from the 
micro-costing study and average annual staff costs weighted by centre. Uncertainty 
was explored using both one-way and probabilistic sensitivity analysis.  
The average base-case annual non-drug cost of care in 2012 was estimated to be 
€1,127 per patient (IQR on PSA €1,008-€1,230). On one-way sensitivity analysis, 
uncertainty associated with staff costs and diagnostic tests resulted in the greatest 
variation in estimated costs (±9% and ±34% respectively). The estimated annual 
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non-drug cost for individual centred varied by up to 20% from the base-case 
estimate. 
The results of this research show the importance of taking variation in service 
delivery into account when generating cost of illness estimates at a national level. 
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6.2 Introduction 
The micro-costing study described in Chapter 4 resulted in an estimate of the 
monthly cost of outpatient HIV care per patient in a single centre (CUH). As unit 
costs and utilisation patterns in any specific location may be related to each other 
as well as being affected by the complex interplay of local (e.g. disease, patient and 
clinician characteristics) and higher level factors (e.g. health system and socio-
economic characteristics), the generalisability of cost estimates generated in a 
single centre can be limited [163].  
The majority of the literature examining cost variability between centres has 
focused on the problem of cost data generalisability at an international level 
[163,306,307]. However, the same issues exist between centres within countries 
[163]. Information on the variability of outpatient costs within countries is 
particularly limited. Data from a European project (HealthBASKET) examining the 
variation of costs for 10 healthcare services (both inpatient and outpatient), both 
within and between countries using case-vignettes, found that the within-country 
correlation of costs (as measured by the intra-cluster correlation coefficient, ICC) 
varied between 0.43 and 0.94 for outpatient care [308]. While a study of outpatient 
first-visits for oral-contraceptives found the cost of what was considered a very 
standard type of outpatient visit ranged from $42-$206 (mean $90) between sites 
in the United States [309].  
That the unit costs of outpatient visits vary between centres within individual 
countries is not surprising, given that outpatient visits may occur in a variety of 
settings (tertiary referral centre, district hospital etc) and each visit consists of a 
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number of different steps performed by a variety of staff. Variation can occur in the 
individual steps that make up an outpatient visit, the type of staff involved in each 
step, as well as the diagnostic tests ordered and medications. 
In the case of ambulatory HIV care in Ireland, while all care is provided by the ID 
Departments of tertiary hospitals following international best practice guidelines 
[3,41,42], local variation in the organisation of HIV services is likely to affect the per 
patient cost of providing ambulatory HIV care in each centre. When estimating 
average costs as a national level how costs are dealt across centres can affect the 
average cost estimates generated and variation in costs between centres should be 
taken into account where possible [310]. 
The aim of this chapter was to generate a national estimate of the annual cost of 
outpatient HIV care taking into account local variation in service delivery. 
6.3 Methods 
6.3.1 Ethical considerations 
Ethical approval to collect data on the organisation and characteristics of the adult 
HIV outpatient centres using expert interviews was obtained (Appendix 6) from the 
research ethics committees of: Beaumont Hospital, MMUH, SJH, UCHG, and UHL. 
6.3.2 National data collection 
Data was gathered using surveys and face-to-face group interviews with key staff at 
each centre. Any issues requiring clarification were followed up by 
email/telephone. 
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6.3.2.1 Survey 
A short survey was designed to collect data on the number and type of staff 
involved in providing HIV care, and the characteristics of out-patient clinics 
(Appendix 7). This survey was emailed to the consultant at each participating 
centres prior to the face-to-face interview. The participants had the option of 
completing and returning the survey prior to the meeting or at the time of the 
interview. 
6.3.2.2 Expert interviews 
Contact was made with each centre and a meeting arranged with the consultant 
and key members of HIV team (as nominated by the consultant). The interviews 
were semi-structured as the primary aim was to elicit information on how the 
services were organised in 2012.  
The interviews were loosely structured as follows: 
1) A brief introduction was given to the staff on the background to the study. 
2) Discussion on the patient population and the services provided and 
numbers of staff in 2012 (e.g. the total patient population, the number, types and 
frequency of clinics, the approximate number of patients attending each clinic, the 
number of whole time equivalent (WTE) staff members working on outpatient HIV 
care, non patient-facing time etc). In cases where the number of staff differed in 
2012 from the usual staffing levels (e.g. due to staff not being replaced while on 
maternity leave) the usual staff staffing level was used. 
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3) Discussion on the individual visit steps in 2012 for each type of clinic 
identified. To aid this process, visit flow-charts were developed prior to the 
meetings, based on the steps of an outpatient visits in CUH (Appendix 8), were 
presented and similarities/differences noted and discussed.  
4) Discussion on breakdown of patient populations, based on patient groups 
with significantly different outpatient visit rates as identified in the micro-costing 
study (new patients, antenatal patients, patients starting/switching HAART). 
Following each site visit, centre-specific visit flow-charts were developed based on 
the expert opinion based information gathered during the interviews and fed back 
to the key staff in each centre for approval. 
The centre specific flow-charts, (along with information on non patient-facing times 
where available) were used to generate centre-specific estimates of unit costs of 
typical HIV outpatient visits in 2012. Where participants were not able to provide a 
local estimate, estimates were taken from the micro-costing study in CUH. It was 
not possible to collect specific details of staff and visits in clinics held off-site (e.g. in 
prisons, drug-treatment clinics and antenatal hospitals) as ethical approval was not 
sought for these other sites which were identified during the data collection 
process. 
6.3.3 Cost model 
Decision modelling is a widely used method in economic evaluations. Decision 
models provide a structured framework for decision making, and have the benefits 
of being able to incorporate data from a wide range of sources, as well as 
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facilitating the assessment of uncertainty through either probabilistic or 
deterministic sensitivity analysis [252]. 
A simple decision tree was developed using Microsoft Excel® (Figure 6-1). The 
branches of the tree represented groups of patients with differing utilisation rates 
as identified in the micro-costing study (Table 6-1). Each branch was then 
associated with an annual cost, generated by combining average annual visit cost 
for each group of patients (i.e. the centre specific unit cost per visit multiplied by 
the average number of visits per arm) and the average annual cost of diagnostic 
testing for the same groups of patients. The decision tree was then used to 
calculate the overall average annual cost per patient. 
The same perspective and cost year were used for the cost model as were previously used 
in the micro-costing study: the healthcare provider in 2012. 
 
Table 6-1. Mean number of ID outpatient visits per month, by patient group (with 
Poisson 95% CI) 
Patient group Mean number of ID outpatient 
visits per month 
New patient No 0.30 (0.29-0.32) 
Yes 0.59 (0.47-0.72) 
Antenatal care No 0.31 (0.29-0.33) 
Yes 0.52 (0.41-0.64) 
Started/switched HAART No 0.28 (0.26-0.30) 
Yes 0.45 (0.41-0.50) 
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Figure 6-1. Structure of cost model 
 
4% Antenatal care
20% Routine care only
HIV outpatient population
8% New patient
80% Started/switched HAART regimen
96% No antenatal care
81% Routine care only
92% Existing patient
19% Started/switched HAART regimen
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6.3.3.1 Base case estimates 
Annual patient costs were separated into staff costs (patient-facing and non 
patient-facing time) and diagnostic testing costs. The base case staff costs, 
weighted by centre were estimated for each branch of the model as follows, using 
Microsoft Excel® and STATA 12 (College Station, Texas): 
1) The estimated staff costs of each visit types in each centre was associated 
with the utilisation data from the micro-costing study i.e. generating a 
hypothetical staff cost for each centre, given the same resource utilisation 
as in CUH. 
2) The annual mean staff cost (and standard deviation) of each branch for each 
centre was then calculated using a generalised linear model (inverse 
Gaussian family, identity link). The choice of family and link used in the 
model were assessed using a modified Parks test [264]). 
3) A weighted mean annual staff cost for each branch was then calculated 
based on the proportions of patients attending each centre (as reported in a 
prevalence study carried out in 2009/2010 [85]). In order to account for 
uncertainty in the staff costs as well as in the proportions of patients 
attending each centre a probabilistic model (with 10,000 iterations) was 
used to generate a weighted mean and variance. Proportions of patients 
attending each centre were assumed to follow a Beta distribution while 
costs were assumed to follow a Gamma distribution [311]. 
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4) The average staff cost and variance for each branch generated by this 
probabilistic model was used as the base case estimate of annual staff costs 
per branch. 
The base case cost of diagnostic testing was based solely on the mean annual per 
patient cost of diagnostic testing estimated in the micro-costing study. 
6.3.3.2 Sensitivity analysis 
Both probabilistic sensitivity analysis (PSA) as well as deterministic one-way 
sensitivity analysis were used to examine uncertainty in the model. Sensitivity 
analyses were performed using Microsoft Excel®. 
PSA was used to assess uncertainty in the base case estimate of annual patient cost. 
The list of input parameters included in the PSA are shown in Table 6-2 along with 
the distributions used and 95% CIs/IQRs. The beta distribution was used for 
proportions of patients in each arm of the model and the gamma distribution was 
used for costs [311]. The number of iterations in the PSA was 10,000. 
One way sensitivity analysis was used to assess structural uncertainty in the model. 
Staff costs were varied by ±20% and diagnostic testing costs were varied by ±60% 
based on the same rationale as reported for the one way sensitivity analysis of the 
micro-costing study (Chapter 4). 
Proportions of patient in each arm of the model were varied based on 95% 
confidence intervals based on the results of the utilisation data collected as part of 
the micro-costing study. 
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An alternative estimates was also generated based on the use of the published 
national cost of an outpatient visit (€130 in 2011) [256]. 
Table 6-2. Model parameters for PSA 
Parameter % 95% CI 
Distribution 
in PSA 
Antenatal 4% 2%-7% Beta 
Non-Antenatal 96% 93%-98% Beta 
New patient (excl antenatal) 8% 5%-11% Beta 
Existing patient (excl antenatal) 92% 89%-95% Beta 
New patient, no antenatal, routine 20% 3%-37% Beta 
New patient, no antenatal, started/changed ART 80% 63%-97% Beta 
Existing patient, no antenatal, routine 81% 77%-86% Beta 
Existing patient, no antenatal, started/changed ART 19% 14%-23% Beta 
Mean annual costs    
Antenatal patients – staff €891 €849-€931* Gamma 
Antenatal patients – diagnostic testing €948 €744-€1,152 Gamma 
New patients, no antenatal care – staff €422 €393-€448* Gamma 
New patients, no antenatal care – diagnostic testing €695 €414-€879 Gamma 
New patient, no antenatal care, started/changed 
HAART - staff €594 €573-€616* Gamma 
New patient, no antenatal care, started/changed 
HAART – diagnostic testing €965 €648-€932 Gamma 
Existing patient, no antenatal care - staff €427 €421-€432* Gamma 
Existing patient, no antenatal care – diagnostic testing €568 €532-€591 Gamma 
Existing patient, no antenatal care, started/changed 
HAART - staff €618 €605-€632* Gamma 
Existing patient, no antenatal care, started/changed 
HAART – diagnostic testing €751 €650-€809 Gamma 
Wilson/Agresti-Coull 95% CIs for proportions. Means and 95% CIs for diagnostic test costs estimated 
from generalised linear model with Gamma family and identity link (family/link selection assessed 
using modified Parks test [264]) based on micro-costing data. * IQR, based on results of probabilistic 
estimate of mean staff costs. 
 
6.3.4 HAART data 
Early in the data collection process, it became apparent that most of the centres 
would not be able extract data from pharmacy information systems on the volume 
of HAART regimens dispensed. As an alternative, data on the volume and total 
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value of HAART drugs supplied from wholesale to hospital pharmacies was obtained 
from a commercial data company (IMS health). 
IMS health collects data on pharmaceutical sales in Ireland at the point of sale to 
pharmacies. They source around 16% of their data in Ireland from manufacturers 
and 84% from wholesalers and the data covers 99.9% of the retail and 97% of the 
hospital market (personal communication). Data on the total volume and sales of all 
HAART drugs, in Ireland from 1995 to 2014 were provided by IMS. The breakdown 
by drug class was available from 2007. The volume data was supplied in terms of 
“units” of drugs, “units” refer to the number of packs issued. As HAART drugs 
generally come in the form of monthly packs, units were assumed to be equivalent 
to a single month of an individual ARV. As a patient regimens are usually made up 
of a combination of two or more medications (unless on a single-tablet regimen), 
the number of units is not equivalent to the number of patient regimens. It should 
also be noted that the sales values provided by IMS health do not include any 
discounts negotiated between wholesalers and individual hospitals, so will over-
estimate the cost to the health service. Information on discount rates is 
commercially sensitive information but substantial discounts may be negotiated, 
particularly for off-patent products [312]. In Ireland, only one generic HAART drug, 
nevirapine, is currently available. Nevirapine, however is not a commonly used 
HAART drug, only 5% of the regimen-months dispensed in CUH in 2012 contained 
nevirapine. The IMS data would also include HAART used by patients not attending 
the public clinics (i.e. private patients), the proportion of patients attending 
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privately for HIV care is unknown. The classification of HAART drugs used by IMS is 
shown in Table 6-3. 
 
Table 6-3. Drug classification used by IMS health. 
Level 1 Level 2 Brand name Active ingredients 
J05C HIV 
antivirals 
J05C1 
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors (NRTIs) 
Truvada 
emtricitabine / tenofovir disoproxil 
fumarate 
Kivexa Abacavir / lamivudine 
Viread Tenofovir disoproxil fumarate 
Combivir Lamivudine / zidovudine 
Ziagen Abacavir 
Epivir Lamivudine 
Emtriva Emtricitabine 
Trizivir 
Abacavir (as sulfate) / lamivudine / 
zidovudine 
Retrovir Zidovudine 
Videx Didanosine 
Zerit Stavudine 
J05C2 Protease inhibitors 
(PIs) 
Prezista Darunavir 
Reyataz Atazanavir sulphate 
Norvir Ritonavir 
Kaletra Lopinavir / ritonavir 
Telzir Fosamprenavir calcium 
Invirase Saquinavir 
Aptivus Tipranavir 
Viracept Nelfinavir 
J05C3 Non-nucleoside 
reverse transcriptase 
inhibitors (NNRTIs) 
Intelence Etravirine 
Sustiva Efavirenz 
Viramune Nevirapine 
Edurant Rilpivirine hydrochloride 
Nevirapine 
Teva 
Nevirapine 
J05C4 HIV entry 
inhibitors 
Celsentri Maraviroc 
Fuzeon Enfuvirtide 
J05C5 HIV integrase 
inhibitors 
Isentress Raltegravir 
Tivicay Dolutegravir 
J05C9 Other HIV 
antivirals (multi-class 
combinations, MCCs) 
Atripla 
Efavirenz / emtricitabine / tenofovir 
disoproxil fumarate 
Eviplera 
Emtricitabine / rilpivirine 
hydrochloride /tenofovir disoproxil 
fumarate 
Stribild 
Elvitegravir / cobicistat / 
emtricitabine / tenofovir disoproxil 
fumarate 
Triumeq 
Abacavir sulfate / dolutegravir 
sodium / lamivudine 
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6.3.5 Cost projections 
The cost of providing ambulatory HIV care for the years 2013-2020, in 2012 prices, 
was calculated by multiplying the estimated number of patients in care each year 
(estimated in Chapter 2) by the total estimated annual cost of care per patient. The 
total estimated annual cost of care per patient was calculated by adding the annual 
non-drug cost per patient estimated in this chapter with the annual cost of HAART 
per patient in care. Two different sources of HAART cost data were used. The first 
was the average cost of HAART per patient in care in 2012, €9,601, as estimated in 
the micro-costing study in CUH (Chapter 4). The second was the average HAART 
sales per patient in care as estimated using IMS sales data for 2012. 
Sensitivity analysis 
One-way sensitivity analysis was carried out to investigate uncertainty in the 
estimates used. The annual non-drug cost of outpatient care per patient and the 
number of patients in care each year were both varied from their base cases to the 
minimum and maximum estimates generated by sensitivity analyses. 
6.4 Results 
6.4.1 Expert interviews 
The expert interviews took place between 24/02/2015 and 17/06/2015. The 
number and type of staff interviewed is shown in Table 6-4. 
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Table 6-4. The number and type of staff who participated in expert interviews 
Staff UCHG Beaumont 
Hospital 
UHL MMUH SJH 
Consultant 2 1 1 1 1 
Specialist nursing 1 1  1 1 
Pharmacy 1* 1 1* 1 1 
Other    Clerical manager Clerical manager, 
vaccine nurse, research 
nurse, data manager, 
social worker 
* email contact only 
 
6.4.1.1 Summary description of services 
The outpatient care provided by all six adult HIV centres in Ireland is generally quite 
similar and follows international best-practice guidelines [3,40,42]. On diagnosis 
patients generally receive a comprehensive health screen including a full STI screen, 
and a chest x-ray, as well as counselling regarding their diagnosis. All patients are 
monitored regularly, generally on a 4-6 monthly basis for stable patients, but more 
frequently on initiating or switching of HAART regimen (until fully suppressed), or if 
pregnant. There are additional vaccinations recommended for people living with 
HIV (both on diagnosis and on an on-going basis) [313] and HIV positive women are 
recommended to receive an annual cervical smear [314]. Some centres provide 
these services to patients as part of the outpatient HIV services however other 
centres generally refer patients to primary care for vaccinations and/or cervical 
smears. ID services also provide additional day-patient services (e.g. nebulised 
pentamidine) as well as in-patient care as required. 
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Beaumont Hospital, Dublin 
The HIV centre in Beaumont Hospital provides care for approximately 11% of HIV 
patients attending care in Ireland [85]. 
The patient population is made up of a relatively high proportion of non-Irish 
patients due to its proximity to the direct provision centre in Balseskin, but has a 
lower proportion of people who inject drugs than the other Dublin centres. 
Ambulatory HIV care is provided during two general ID clinics per week, 
approximately 80% of appointments at the clinics are HIV related. Patients are seen 
by either a consultant or a non-consultant hospital doctor (NCHD) with consultant 
review. All patients are also seen by a CNS/CNM/staff nurse as part of a routine 
outpatient visit. A pharmacist and social worker are available on-site at the clinic. 
There is a team focus on medication adherence. Patients co-infected with 
TB/hepatitis B/hepatitis C receive treatment for their co-infection(s) in the ID clinic. 
HIV positive patients requiring antenatal care attend obstetric care separately. 
Patients are routinely screened for STIs on diagnosis and annually (and as required) 
thereafter. A weekly nurse led-clinic also provides recommended vaccines (HAV, 
HBV, influenza and pneumococcal vaccines), annual cervical smear tests for female 
patients, monthly LFT monitoring of patients with latent TB and monthly nebulised 
pentamidine for HIV patients allergic to septrin. Patients also receive regular 
glucose and cholesterol screening. 
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University College Hospital Galway 
The HIV centre in UCHG provides care for approximately 5% of patients attending 
for HIV care in Ireland [85].  
One mixed clinic (general medicine, ID, OPAT and HIV) and one nurse-led clinic is 
held per week. All patients are seen by a consultant or a registrar/SHO with 
consultant review. Patients are also routinely seen by a clinical nurse specialist as 
part of their outpatient visit. There is currently no pharmacist support at the clinic 
itself, relevant medications are provided by pharmacy to the clinic beforehand and 
dispensed to patients by medical staff. 
Newly diagnosed patients referred to the service are seen initially by the CNS and 
return for medical review one to two weeks later, unless the patient is symptomatic 
in which case they would also be seen by a medic on the same day as the nurse 
visit.  
Patients requiring an STI screen (including all newly diagnosed patients) are 
referred to the STI clinic (a separate visit). Recommended vaccines are provided in 
the clinic, but female patients are referred to their GPs or the colposcopy clinic for 
annual smear tests. 
Pregnant patients attend obstetric services separately for their antenatal care. 
University Hospital, Limerick 
The ID service in UHL provides ambulatory HIV care for approximately 2% of HIV 
patients in care in Ireland [85]. 
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One clinic per week is held specifically for HIV positive patients in the STI clinic. All 
patients are seen by an ID consultant and either a clinical nurse manager or RGN. A 
pharmacist is also present at the clinic to dispense HIV medications. Patients 
receive STI screening routinely at each visit, recommended vaccines are 
administered in the clinic and female patients are offered cervical smear testing on 
an annual basis. 
In addition new patients are referred for counselling to external agency part-funded 
by HSE (GOSHH). 
Antenatal patients are scheduled to attend obstetric visits (located separately) on 
the same day as HIV visits.  
St James’ Hospital, Dublin 
The HIV centre located in the Department of GU Medicine and Infectious Diseases 
(GUIDE) of SJH is the largest in the country, providing care for over 50% of people 
with HIV who are attending for care in Ireland [85]. The centre provides care for a 
greater proportion of complex patients (e.g. older patients, patients with other 
comorbidities including co-infections, patients with multi drug resistant disease and 
people who inject drugs) compared to other HIV centres in Ireland. The volume of 
other resource intensive groups of patients, such as newly diagnosed patients and 
migrants, also makes the service demands unique at SJH. In addition SJH differs 
from other centres in that a large proportion (an estimated 50%) of patients do not 
have a GP, and so use the centre for both secondary and primary care, increasing 
the demands on clinic staff, in particular doctor and social worker time. Finally the 
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department operates a significant in-patient programme impacted upon by the out-
patient demographic mix and the number of late presenters to HIV care nationally 
(i.e. transfers from other sites). 
To provide appropriate care for the complex patient mix, SJH has a wide variety of 
staff types (social workers, vaccine nurse, research nurse, health advisors, 
phlebotomist, nutritionist, data manager) providing on-site support in addition to ID 
consultants, NCHDs, specialist nurses and pharmacists. 
The outpatient department at SJH has an electronic patient record system, enabling 
instant access to patient chart. While this system has many benefits its use has 
resulted in increased time spent scheduling and managing clinic appointments 
(clerical staff) and updating medical notes (medical staff). 
Services provided 
There are two HIV clinics, one viral hepatitis clinic, one TB/HIV co-infection clinic 
and one nurse led new diagnosis clinic per week. A vaccination programme is run in 
parallel, which provides patients with appropriate vaccines as recommended by the 
National Immunisation Guidelines.  
A day-ward service is available for patients that require any procedures as well as 
acting as an access point to medical care outside clinic hours when necessary. 
STI screening is provided as part of routine outpatient visits for men who have sex 
with men (MSMs) and as required for other patient groups. Cervical smears are 
offered on-site to female patients on an annual basis. SJH also provides facial fillers 
(New-fill®) for the treatment of lipodystrophy on-site. 
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There is also an active research programme at SJH, with a clinical studies unit and 
dedicated nursing staff. 
In addition clinics are provided on location at: 
• The Coombe Women and Infants University Hospital (fortnightly clinic 
providing combined antenatal and HIV care, staffed by GUIDE CNS and 
Consultant Physician) 
• Wheatfield and Clover Hill prisons (weekly clinic staffed by a GUIDE 
Consultant Physician) 
• National Centre for Hereditary Coagulation Disorders (Clinic for HIV positive 
haemophiliacs, located in NCHCD, bi-monthly clinic run by GUIDE Consultant 
Physician and CNS) 
• Drug treatment centre (Trinity Court) (GUIDE CNS visits DTC once monthly, 
overseen by GUIDE Consultant Physician)  
• Gay Men’s Health Service (HSE Sexual Health Clinic for MSMs, two evenings 
per week, staffed mostly by GUIDE Staff (some allocated, others as agency 
staff) and GUIDE Consultant Physician as Clinical Director)  
• Dublin AIDS Alliance (fortnightly STI screening run by GUIDE ANP)  
The Mater Misericordiae University Hospital, Dublin 
The HIV service provided by the ID Department of MMUH is the second largest in 
the country, providing care for approximately 17% of HIV patients in care in Ireland 
[85]. 
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The patient population attending MMUH is broadly similar to the other centres, 
although MMUH does provide care for a large cohort of patients who acquired HIV 
through intravenous drug use in the past and who are also co infected with HCV. 
More recently most newly diagnosed patients referred to the centre have been 
MSM, reflecting the increase in HIV diagnoses MSM nationally. 
There are three general HIV clinics held per week. Patients are seen by either an ID 
consultant or a registrar (with consultant input when required). Newly diagnosed 
patients, and a small proportion of routine patients, are also seen by a Clinical 
Nurse Specialist. Pharmacists and a social worker are also available on-site during 
clinic hours. Patients co-infected with hepatitis C virus (HCV) and/or tuberculosis 
(TB) are treated for their co-infections in the ID clinic. Antenatal patients attend an 
antenatal-HIV clinic held in the Rotunda Hospital on a monthly basis. General HIV 
patients are routinely scheduled for outpatient visits every 3-4 months. Patients on 
treatment for HCV or TB would be seen more frequently for the duration of the 
treatment. 
Patients undergo full STI screening on diagnosis and as required thereafter. Fasting 
cholesterol and glucose tests are performed annually for each patient, as are 
cervical smears for female patients. FibroScan® testing is also available on-site for 
patients co-infected with HCV. 
6.4.1.2 Clinic staffing 
A summary of the clinic characteristics and staffing levels can be seen in Table 6-5. 
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Table 6-5. Clinic characteristics and staffing 
  Beaumont Hospital CUH UCHG UHL MMUH SJH 
Clinic Type General 
ID 
Nurse 
led 
HIV Antenatal 
HIV 
General ID Nurse 
led 
General 
ID 
HIV HIV HCV co-
infectio
n 
New Dx 
(nurse 
led) 
TB (may be 
nurse led) 
Clinic 
frequency 
(number per 
week/mont
h) 
2/week 1/week 1/week 1/month 1/week 1/week 1/week 3/week 2/week 1/week 1/week 1/week 
Average 
number of 
patients 
attending 
per clinic 
60 5-10 28 4 20 7 16 40-45 60 45 4 1-2 
Proportion 
of patients 
attending 
which are 
NOT HIV 
positive 
20% 50% 5% 0% 40% 0% 0% 0% 0% 25% 0% n/a 
Please provide the usual number of the following staff working at each clinic 
RGN 1   0.5 0.5     2 2 3-4 2  * 
CNS/CNM 2 1 2 1-2 1 1 1 1 1 1 2 1 
Consultant 1-2   1   2*   1 3 1-2 1   * 
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  Beaumont Hospital CUH UCHG UHL MMUH SJH 
Clinic Type General 
ID 
Nurse 
led 
HIV Antenatal 
HIV 
General ID Nurse 
led 
General 
ID 
HIV HIV HCV co-
infectio
n 
New Dx 
(nurse 
led) 
TB (may be 
nurse led) 
Clinical tutor     1 1                 
Specialist 
registrar 
    1   1       4-5 3-4   * 
SHO 1-2   2                   
Registrar 1-2       1     2 (+ 1 
research ) 
      
Intern 1                       
Pharmacist 1   1-2 1-2       2 1 1     
Senior 
pharmacist 
            1   2 2     
Chief 
pharmacist 
                1 1     
Social 
worker 
1             1 1   2   
Clerical staff 1.5 0.5 0.5 0.5 2 1 2 3 2 2     
Nutritionist                 1 1 (part 
cover) 
    
Phlebotomy Done as 
part of 
CNS visit 
  Phlebot
omy 
service 
Mid-wife Phlebotomi
st + Nurse, 
on site also 
do 
vaccination
s 
    Phleboto
my Nurse 
(incl RGN 
above) 
1 1     
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  Beaumont Hospital CUH UCHG UHL MMUH SJH 
Clinic Type General 
ID 
Nurse 
led 
HIV Antenatal 
HIV 
General ID Nurse 
led 
General 
ID 
HIV HIV HCV co-
infectio
n 
New Dx 
(nurse 
led) 
TB (may be 
nurse led) 
Additional 
notes 
        One 
consultant 
available 
solely to 
advise 
NCHDs, 
pharmacy 
prepares 
meds prior 
to clinic 
    Psych 
consult 
may also 
be 
required 
vaccinati
on clinic 
runs in 
parallel 
(dedicat
ed 
nurse) 
   * clinic runs 
concurrently 
with ID clinic, 
patient may 
be seen by 
any provider 
in ID clinic, 
may be 
nurse led 
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6.4.2 Estimated variation in unit costs of HIV outpatient visits 
Centre specific flowcharts were generated based on information gathered during 
the expert interviews (Appendix 9) and these flowcharts were used to generate 
centre-specific estimates of the staff component of visit unit costs. 
The variation in estimated unit costs (staff costs only) of attended outpatient doctor 
visits is shown in Table 6-6. 
 
Table 6-6. Estimated unit costs of doctor visits by centre (in random order) 
 Baseline visit Routine visit Antenatal-HIV visit 
Patient on HAART? No Yes No Yes No Yes 
Centre A €199 €269 €118 €168 €144 €194 
Centre B €229 €249 €175 €195 €167 €187 
Centre C €146 €160 €100 €114 €100 €114 
Centre D €295 €339 €116 €163 €126 €167 
Centre E €306 €323 €116 €126 €116 €126 
Centre F €147 €178 €91 €111 €175 €195 
 
There did appear to be some evidence of economies of scale, as the larger centres 
generally tended to have lower staff visit costs, however this may have simply 
reflected limitations in the data collection process. 
In addition some centres provide nurse-led clinics. As nurse-led clinics were not 
routinely held in CUH in 2012 they were not included in the original micro-costing 
study in CUH. To attempt to estimate the additional annual per patient cost of 
these clinics, the cost of patient-facing and non patient-facing nurse and clerical 
time (assumed to be the same as a doctor led visit at the centre) was multiplied by 
the approximate number of visits per year (based on the estimated number of 
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patients seen per clinic and clinics per year) to generate an annual cost per patient. 
The estimated cost of nurse-led visits was between €11 and €86 per patient 
annually (although these estimates appear low, it should be noted that this is an 
average cost across all patients, but in general only a proportion of patients would 
attend nurse-led clinics). As nurse visits were not included in the original model 
(based on micro-costing in CUH) it was not possible to fully incorporate the costs of 
nurse-only visits into the cost analysis. 
6.4.3 National annual non-drug cost of outpatient care per patient 
6.4.3.1 Base case analysis and PSA 
The estimated annual cost per patient using PSA was €1,127 with a median of 
€1,111 and an IQR of €1,008-€1,230 (Figure 6-2). Based on this estimate, and 
assuming there were approximately 3,820 (Chapter 2) people in care in 2012 the 
approximate cost to the state would have been around €4.31 million. 
6.4.3.2 One way sensitivity analysis 
One way sensitivity was used to examine uncertainty associated with unit costs of 
visits (both staff costs and diagnostic testing costs), as well as uncertainty in the 
proportions of patients in each arm of the model.  
Variation of the proportions of patients in each arm of the model had little effect on 
the estimated average annual cost per patient (1%-2%) (Table 6-7). Variation in the 
staff costs had a stronger effect (±9%). However, as the costs of diagnostic testing is 
so uncertain, the diagnostic testing cost was varied by ±60%, and this resulted in a 
substantial effect on the estimated annual patient cost of about ±34% (Table 6-7). 
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Figure 6-2. Cost model with base case estimates 
Base case estimate (IQR)
4% Antenatal
€1,836 (€1,586-€2,045)
20% Routine
HIV population €1,114 (€910-€1,279)
8% New
80% Start/switch
€1,550 (€1,188-€1,823)
96% Not antenatal
81% Routine
€994 (€841-€1,117)
92% Existing
19% Start/switch
€1,365 (€1,150-€1,539)
€1,127 (€1,008-€1,230)
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Table 6-7. Results of one-way sensitivity analysis of national annual non-drug cost of HIV care per patient 
 Base case Low High Source of low/high estimate Annual cost per patient 
– low estimate 
Annual cost per patient 
– high estimate 
Annual cost of visits -staff €489 -20% +20% Microcosting €1,030 €1,225 
Annual cost of diagnostic 
testing 
€639 -60% +60% Microcosting €744 €1,511 
% antenatal 4% 2% 7% 95% CI from micro-costing €1,111 €1,148 
% new 8% 5% 11% 95% CI from micro-costing €1,114 €1,137 
New patient, no antenatal, 
start/switch HAART 
80% 63% 97% 95% CI from micro-costing €1,120 €1,131 
Existing patient, no antenatal, 
start/switch HAART 
19% 14% 23% 95% CI from micro-costing €1,109 €1,139 
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6.4.3.3 Alternative estimates 
The estimated annual per patient costs ranged between €1,063 and €1,358 per 
centre when centre specific estimated visit costs were used to parameterise the 
cost model (Table 6-8). The problems of using single-centre estimates is illustrated 
as using the estimates ranged from 6% below to 20% higher than the weighted 
average. In reality, the differences between centres could be even greater, as these 
estimates only attempt to incorporate variation in staff costs and do not take into 
account differences in utilisation rates, patient characteristics or diagnostic testing 
costs (unit costs or testing rates) across centres. 
Table 6-8. Estimated average annual non-drug patient cost per centre (in random order) 
 Average annual non-drug cost per patient 
Centre A €1,267 
Centre B €1,358 
Centre C €1,064 
Centre D €1,256 
Centre E €1,122 
Centre F €1,063 
 
The only routinely available estimate of the cost of an outpatient visit was €130 in 2011 
[256], use of this visit cost (inflated to €130.56 in 2012) as a standard cost for all scheduled 
visit types (staff costs + diagnostic testing costs) resulted in an estimated annual outpatient 
cost of €537 per patient. 
6.4.4 National cost of HAART 
The IMS HAART sales data showed that nearly €46 million was spent on HAART in 
Ireland in 2012. The total spend on HAART drugs has increased rapidly year on year 
since they became available in 1996 (Figure 6-3). This increase in the annual value 
of HAART sales reflects the increase in volume of HAART sold (Figure 6-4), rather 
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than any major changes in average cost per class (Figure 6-5, Figure 6-6). If 
anything, the average cost of protease inhibitors and multiclass combinations (the 
drug classes which have been more commonly prescribed in recent years) has fallen 
slightly (Table 6-9). The increase in volume of HAART being supplied in Ireland is 
probably due to the combination of increasing prevalence as well as ongoing 
changes in international recommendations of CD4 thresholds for treatment 
initiation e.g. the WHO recommended threshold for treatment initiation changed 
from ≤200 cells/µl to ≤350 cells/µl in 2010 [315], to ≤500 cells/µl in 2013 [40] and 
recently removed treatment threshold altogether [316]. 
 
 
Figure 6-3. Value of HAART sold, by class 1996-2014 
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Figure 6-4. Units HAART sold by class, 1996-2014 
 
 
Figure 6-5. Average cost per unit, by class, 1996-2014 
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Figure 6-6. Average cost (adjusted to 2014€) per unit 2008-2014 
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Table 6-9. Proportion of all units, average cost per unit and average cost per unit adjusted to 2014 prices*, by year and drug class 
    2008 2009 2010 2011 2012 2013 2014 
J05C1 NRTI proportion of all HAART units 46% 41% 38% 32% 31% 30% 30% 
Average cost per unit  €526 €560 €583 €596 €611 €614 €622 
Average cost per unit (2014 euros) €573 €589 €609 €603 €616 €613 €622 
J05C2 Protease inhibitors 
 
proportion of all HAART units 30% 31% 32% 42% 43% 43% 42% 
Average cost per unit €480 €493 €470 €322 €312 €310 €310 
Average cost per unit (2014 euros) €523 €519 €492 €325 €315 €309 €310 
J05C3 NNRTI proportion of all HAART units 15% 10% 8% 7% 5% 4% 3% 
Average cost per unit €297 €289 €289 €297 €310 €351 €360 
Average cost per unit (2014 euros) €323 €303 €302 €300 €312 €351 €360 
J05C9 Multiclass 
combinations 
proportion of all HAART units 10% 18% 21% 16% 17% 19% 19% 
Average cost per unit €1,028 €1,018 €1,006 €961 €957 €950 €954 
Average cost per unit (2014 euros) €1,120 €1,071 €1,052 €972 €964 €948 €954 
J05C5 Integrase 
inhibitors & J05C9 
Multiclass combinations 
proportion of all HAART units 0% 0% 0% 3% 3% 4% 6% 
Average cost per unit     €966 €873 €871 €870 €845 
Average cost per unit (2014 euros)     €1,010 €883 €878 €869 €845 
*Costs adjusted to 2014 prices using the Irish consumer price index for health[257] 
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6.4.4.1 Comparison to CUH data 
Some limited comparisons can be made between IMS data and data on HAART 
regimens collected in CUH in 2012 as part of the micro-costing study. In CUH, 45% 
of patients in care and on treatment at the end of 2012 (127/283) were being 
prescribed a multiclass combination drug. A small proportion of patients were 
prescribed an additional ARV in combination with a multiclass combination drug. In 
total 47% of all regimen-months contained a multiclass combination drug, and 24% 
of all ARV-months dispensed were multiclass combination ARVs. The comparison of 
the breakdown of number of months of ARVs dispensed in CUH compared to IMS is 
shown in Figure 6-7. 
 
 
Figure 6-7. Comparison of IMS and CUH ARV data, 2012 
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6.4.5 Projected costs 
The base case estimated cost, in 2012 prices, of providing ambulatory HIV care each 
year up to the year 2020, can be seen in Table 6-10. The average annual HAART cost 
per patient as estimated from IMS data was €12,023 in 2012, 25% higher than the 
estimate from the data collected as part of the micro-costing study in CUH (€9,601). 
This difference can be ascribed to differences in regimens prescribed in CUH 
compared to nationally, and also IMS data includes HAART supplied to private 
patients (and wastage) who are not included in the denominator used to calculate 
the average cost per year. The use of IMS-based HAART cost data resulted in a base 
case estimate 23% higher than CUH-based HAART cost data (Table 6-10). 
Sensitivity analysis of the estimates found that the estimates were more sensitive 
to variation of the estimated population than to variation in the annual non-drug 
costs per patient (Table 6-10). 
These projected costs need to be interpreted with caution because of the 
assumptions underlying the calculations: that the average HAART cost per patient in 
care; the proportion of patients on HAART; and the ratio of public to private 
patients will all remain stable over the projected period. 
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0
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Table 6-10. Sensitivity analysis of estimated projected costs of HIV care in Ireland 2012-2020 by source of estimated drug costs 
 2012 2013 2014 2015 2016 2017 2018 2019 2020 
CUH drug costs          
Base case €40,979,638 €42,224,046 €43,779,555 €44,873,776 €45,903,631 €46,847,664 €47,748,787 €48,564,089 €49,422,301 
Low visit costs  €39,516,578 €40,716,558 €42,216,532 €43,271,687 €44,264,774 €45,175,103 €46,044,054 €46,830,248 €47,657,820 
High visit costs  €42,446,518 €43,735,470 €45,346,659 €46,480,048 €47,546,767 €48,524,592 €49,457,971 €50,302,457 €51,191,389 
Low population  €37,868,618 €38,919,928 €40,335,979 €41,204,918 €42,009,493 €42,760,428 €43,446,998 €44,090,657 €44,712,861 
High population €44,348,121 €45,849,993 €47,684,421 €49,025,378 €50,301,969 €51,492,739 €52,672,780 €53,767,001 €54,807,584 
IMS drug costs          
Base case €50,233,458 €51,758,872 €53,665,640 €55,006,952 €56,269,363 €57,426,574 €58,531,184 €59,530,593 €60,582,603 
Low visit costs  €48,770,398 €50,251,384 €52,102,617 €53,404,863 €54,630,506 €55,754,013 €56,826,451 €57,796,752 €58,818,122 
High visit costs €51,700,338 €53,270,296 €55,232,744 €56,613,224 €57,912,499 €59,103,502 €60,240,368 €61,268,961 €62,351,691 
Low population  €46,419,923 €47,708,635 €49,444,451 €50,509,611 €51,495,870 €52,416,378 €53,257,986 €54,046,993 €54,809,700 
High population  €54,362,596 €56,203,613 €58,452,283 €60,096,048 €61,660,913 €63,120,576 €64,567,089 €65,908,401 €67,183,963 
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6.5 Discussion 
Cost-of-illness studies aim to identity all the costs associated with a particular disease, and 
although they have been criticised for being merely descriptive studies [317-320], they are a 
useful source of data for decision makers when planning services, particularly preventive 
services, as well as being useful for drawing the public’s attention to a particular health 
problem, encouraging policy debate, and as a source of input data for cost-effectiveness 
models [317,321-324]. 
Using a probabilistic cost model we estimated that the national average annual non-drug 
cost was €1,127 per patient in 2012. Based on this estimate, at a national level (assuming 
there were approximately 3,820 people in care in 2012) outpatient visits would have cost in 
the region of €4.31 million. The value of HAART sales for the same year was €45.93 million, 
making the total cost to the state of outpatient HIV care of around €50 million in 2012. 
While it is notoriously difficult to compare healthcare costs across countries, this estimate of 
the cost of outpatient care is broadly comparable to that reported in several other 
developed countries. In the UK the annual non-HAART cost of outpatient HIV care has been 
reported to be between £628-£1,295 (in 2008) depending on the CD4 strata/AIDS status 
[161,325], equivalent to €852-€1,756 in Ireland in 2012 (all conversions calculated using CPIs 
and PPPs available from the OECD). In Italy the annual outpatient cost was estimated to be 
€1,495 in 2011 (equivalent to €1,677 in Ireland in 2012) [128], while in the US outpatient 
care (including CD4 and viral load testing) was estimated to range from $915-$1,019 in 2006 
[123] (equivalent to €868-€966 in Ireland in 2012). In Canada, outpatient HIV care is 
estimated to cost around $2,400 annually (Canadian dollars, 2010, equivalent to €1,680 in 
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Ireland in 2012) [134], while the cost in Sweden was estimated to be €2,520 annually in 
2006 (equivalent to €2,388 in Ireland in 2012) [265].  
Differences in patient (e.g. patient demographics, epidemiology), clinician (e.g. experience, 
practice style), hospital/site (e.g. unit costs, resource use, capacity and scale) and health 
system (e.g. how care is organised nationally/locally, availability of resources to deliver 
healthcare) factors result in geographic variation in the cost of healthcare (both unit costs 
and total costs) [163]. The importance of accounting for variation in service delivery 
between centres was supported by the fact that a difference of up to 20% was found 
between the estimated base-case adjusted for staff-costs per centre (€1,127 per patient) 
and individual centres (between €1,063 and €1,358 per patient). The problems with use of 
cost estimates generated in single-centres has been described in the literature previously 
[163,310] with larger centre tending to have lower per patient costs due to economies of 
scale. The variation in annual patient costs between centres showed some evidence of 
economies of scale, and using a cost estimated in one of the smaller centres (CUH) without 
taking into account differences in service delivery would be likely to overestimate the cost 
nationally. However, the use of the published average national outpatient visit cost would 
have massively underestimated the cost nationally (€537 per patient). 
As would be expected the cost of HAART accounts for the overwhelming majority of the cost 
of care for people with HIV over 90% of the total cost of care (a very similar ratio to that 
reported in the micro-costing study [284]). Consequently, variations in prescribing patterns 
between centres are likely to result in considerable variation in the annual per patient cost 
of providing care between centres. Unfortunately we were not able to evaluate this source 
of variation in costs across centres as individual patient level HAART data was only available 
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for CUH, however we were able to make some limited comparisons between the HAART 
drugs prescribed in CUH in 2012 and those supplied into the market for the same year (data 
from IMS). A significantly higher proportion of multiclass combination drugs (i.e. Atripla® 
and Eviplera®) were used in CUH than were used nationally (24% vs 17% of units in 2012, χ2 
p < 0.001), and in CUH these multi-class combination drugs cost €273 less per month than 
the PI based regimens being dispensed (weighted averages €818/month multiclass 
combination drugs vs €1091 /month for PI based regimens). Without detailed data on 
HAART prescribing practices and/or local negotiated prices, it is impossible to determine the 
impact variation in prescribing between centres affects the cost of HIV care. 
The data provided by IMS also provides some useful insights into the changing trends in 
HAART use and cost at a national level. The value of the market in 2012 was nearly €46 
million and by 2014 this had increased by 24% to almost €57 million. In reality individual 
hospitals may negotiate discounts with wholesalers, making the cost to hospitals lower than 
this. These discount rates are commercially sensitive, making it difficult to establish the 
actual cost to the health service, a challenge noted previously when performing costing 
studies in Ireland [326]. However as IMS data is based on what is supplied into the market, it 
provides a global estimate that encompasses not only HAART supplied to public patients, 
but also HAART dispensed to private patients, as well as any wastage that may occur within 
hospitals. 
The cost of HAART is likely to continue to increase in the coming years, primarily because of 
the number new cases continuing to be diagnosed and the increased life expectancy of 
treated patients. The recent international recommendation to offer HAART to all patients 
regardless of CD4 count [316], may also result in an increasing in HAART use, although as 
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the vast majority of patients (between 80%-90% of patients [85,284]) are already on 
treatment the effect of the removal of the CD4 threshold on the proportion of patients on 
treatment is likely to be limited by a ceiling effect. 
Despite the evidence regarding the scale of variation in cost of providing outpatient HIV care 
between centres, in the absence of clinic level outcome data we cannot draw any 
conclusions about the efficiency (i.e. productive efficiency, defined as the maximisation of 
health outcomes for a given cost or minimisation of cost for a given outcome [327]) of any 
of the clinics in this study. The efficiency of any service will be influenced by a wide variety 
of factors both internal and external to the healthcare setting. A review of hospital 
efficiency in the UK conceptualised different levels of determinants of efficiency (see Figure 
6-8). Many of the higher level, external, determinants would be common to all the clinics 
(e.g. financial incentives) however, internal determinants are likely to vary across hospitals 
and clinics, for example, the use of technological advances such as electronic patient 
records, vary between hospitals. Various hospital processes can also be targeted for 
improved efficiency, such as: reducing unnecessary visits/tests/procedures; reviewing the 
skill mix of staff; redesigning patient pathways; reducing patient non-attendance at clinic; 
increasing use of generic medicines etc [328-330]. 
Efficiency in healthcare is usually measured by a form of benchmarking where the unit(s) 
with the highest ratio of outputs to inputs are taken as being on the efficiency frontier, and 
the observed inefficiencies of the remaining units are defined in relation to this (usually 
using techniques such as Data Envelopment Analysis or Stochastic Frontier Analysis) 
[330,331]. Although useful these types of analyses are often limited by the data (in 
particular patient outcome data) that are available. In future, as routine data systems 
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improve (e.g. hospital activity based costing systems) it may become possible to use that 
data to identify the most efficient clinics, which in turn could help identify the most efficient 
way of configuring services. 
 
 
Figure 6-8. Determinants of productive efficiency in hospitals (Source:[330] ) 
 
Some of the strengths of this study are that it is based on bottom-up micro-costing data, 
and that uncertainty was addressed using both probabilistic and deterministic methods. We 
also generated a base case estimate that reflected the effect of variation in service provision 
across centres on staff costs per visit. In addition the prevalence approach taken by this 
study is particularly useful for use in the planning of cost containment policies, as it provides 
a picture of the global burden as well as the major cost components, allowing areas where 
cost containment policies would have the greatest impact be identified [322]. 
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This study also has several important limitations which need to be recognised. 
The annual patient cost estimates were mainly based on data collected in one centre, and as 
previously mentioned these data may not be generalizable. We attempted to account for 
variation in service delivery through the generation of centre-specific staff costs per visit 
type, but were not able to account for any differences (either frequency or unit costs of 
tests) in diagnostic testing. As the unit costs of diagnostic testing are likely to be subject to 
economies of scale, the fact that this was not accounted for is likely to have reduced any 
evidence of economies of scale. In addition the proportions of patients in the various arms 
of the cost model and the outpatient visit utilisation rates per arm were based on the visit 
rates in CUH, which are slightly lower than the reported nationally visit rate [85,284], 
possibly due to differences in characteristics of the patient population attending CUH. 
We did attempt to account for differences in service delivery. However, information was 
collected through expert interviews and may have possibly been subject to reporting bias 
e.g. staff in busier centres may have underestimated, while staff in centres with fewer 
patients may have over-estimated the time they spent on HIV. Recall bias may also have 
been an issue as we collected data in 2014 on service organisation and delivery in 2012. In 
addition, some of the additional services provided by some centres were not included in the 
costing (e.g. nurse-led clinics, off-site clinics, contracted services etc). The cost model also 
only covers care provided in infectious disease outpatient departments, the costs of other 
services used (even if related to HIV) would not be included. Other costs not included were 
direct costs to the patient (time, money), intangible costs, and societal costs. 
 213 
 
While uncertainty in the cost estimates was addressed as far as possible using both 
probabilistic and deterministic sensitivity analyses, there may be other, unidentified, 
sources of uncertainty which remain which may have not been addressed [332]. 
As hospital-level data was not available on the volume of HAART dispensed by regimen, we 
had to rely on commercial drug market data. While these data provide an estimate of the 
total value of the market, as well as some information on the changing patterns of classes of 
HAART drugs being used, it was not possible to use the data provided to generate 
information on the regimens being used, which would be more clinically relevant 
information. Also the sales figures are likely to overestimate the cost to the state as 
discounts negotiated between individual hospitals and wholesalers are not taken into 
account. 
While data on the cost of providing a service is useful for planning purposes, cost is only one 
aspect of healthcare quality, and this study did not incorporate data on patient outcomes. 
Services which are more expensive may be providing better quality care in terms of 
virological outcomes and/or patient satisfaction. Differences in the characteristics of the 
patient populations attending each centre were also not addressed. 
6.6 Conclusion 
The annual cost of outpatient HIV care to the state was estimated to be €51 million in 2012. 
By 2014 the HAART costs alone had increased to €57 million. In the absence of either a 
reduction in incidence of new HIV infections or a reduction in annual per patient costs, the 
cost of caring for people with HIV will continue to increase for the foreseeable future. 
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7 Discussion 
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7.1 Introduction 
The last in-depth study examining the service use and cost of providing HIV care in Ireland 
was performed just as HAART became widely available and illustrated the associated 
decrease in use of in-patient services by HIV patients [143]. At that time, however, it was 
not clear what the long-term effects of HAART would be. Since then it has become apparent 
that, if diagnosed in time, patients can survive for decades on treatment [9]. The health 
consequences of living long term with HIV infection on treatment are only now being seen, 
with HIV patients at higher risk than the general population for many age related chronic 
diseases [236,275,276]. It is anticipated that the lifetime costs of HAART treatment, as well 
as the complex care needs of a population with high rates of multi-morbidity and poly-
pharmacy will place increasing demands on the services caring for these patients. 
This thesis aimed to study the current use and cost of services and their determinants, to 
serve as a baseline and to inform future cost-effectiveness analyses for new medications, 
health care technologies and models of care in the HAART era. This chapter outlines the 
findings, as well as the main strengths and limitations, of the research carried out. Potential 
implications of the results of this research for policy makers and service providers are then 
discussed and some prospective areas for future research proposed. 
7.2 Main Findings 
The cost of providing care for HIV patients at a national level is a function of the number of 
patients in care, the volume of resources they use (treatment regimens prescribed, type and 
frequency of healthcare services attended) and the unit costs of those resources. In this 
thesis we used a variety of methods to estimate all of these parameters, enabling us 
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generate national estimates of the current cost of HIV care in Ireland as well as explore the 
possible impact the changing epidemiology of HIV might have on health services. 
7.2.1 Number and age of patients in care 
Lack of data (e.g. CD4 count at diagnosis, treatment status and mortality) severely limits any 
modelling of the prevalence of HIV in Ireland. The only empiric data on the age structure of 
the HIV population in Ireland comes from a single prevalence survey of patients in care in 
2009/2010 [85], and while this study provided an accurate view of the age profile at that 
time, there are currently no estimates of how the age profile of patients is changing over 
time. 
We attempted to address this through use of simple deterministic models based on 
routinely available data as well as published estimates of mortality (Chapter 2). The 
estimated age profile of patients in care in Ireland generated by our model appears to be 
slightly younger than in other developed countries; for example, in the year 2010, about 
15% of patients in Ireland were estimated to be ≥50 years, compared to 21% (≥50 years) in 
the UK [200], 25% (>55 years) in Australia [141], 28% (>50 years) in the Netherlands [144], 
and 35% (≥50 years) in the US [202]. Some of these differences are due to variations in 
methodologies and definitions, but they may also be a result of differences in the historical 
(e.g. the high proportion of IDU cases in the early years of the Irish epidemic) and current 
epidemiology of HIV in Ireland (60% of notified cases in Ireland 2002-2013 were <35 years of 
age compared to 50% of all notifications in the UK in the same period and 44% of 
notification in the US [194,333]).  
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The rate of ageing of the population of patients in care as estimated by our model 
(approximately 0.5 years annually) appears to be very similar that reported by other 
countries (Figure 2-14). 
The overall model estimated that in 2012 18% of patients in care were aged ≥50 years of 
and that by 2020 this proportion would have increased to 30%. The rate of ageing of 
patients however is likely to vary across patient subgroups. Unvalidated exploratory 
modelling by risk category (for cases notified in 2003 and after) estimated that, 
unsurprisingly, patients notified before 2003 were the oldest group, with 34% aged ≥50 in 
2012, increasing to 65% by 2020. For patients notified after the start of 2003 MSMs had the 
highest proportion aged ≥50 in 2012 (17%) compared to those with a risk factor of 
other/unknown (15%), heterosexuals (11%) and IDUs (5%), however, by 2020 the estimated 
proportion of MSMs ≥50 years had only increased to 22%, while the age profile of the other 
risk groups were estimated to increase much more dramatically (other/unknown from 15% 
to 28%, heterosexual from 11% to 24% and IDUs from 5% to 22%). This reflects the relatively 
large number of young MSMs currently being diagnosed in Ireland each year [82].  
7.2.2 Current use and cost of HIV care in Ireland 
There is currently very little data available on outpatient costs in Ireland despite the fact 
that outpatient visits are the most frequent type of hospital contact [334] accounting for an 
estimated 18% of total current hospital healthcare expenditure in Ireland [335]. The 
national casemix programme does provide an estimate of the average cost of an outpatient 
visit (€130 in 2011), however this is an overall average and no data are available on the 
variation of outpatient costs by specialty [256]. Cost data from the UK show that unit costs 
of outpatient visits vary considerably by specialty and clinic type (min £25- max £1262, 
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average £103 in 2009/2010) [336]. Given the lack of existing data on outpatient costs in 
Ireland we examined two different sources of cost data from a single centre (CUH): routine 
cost data extracted from a newly implemented hospital activity based costing system as well 
as cost estimates from a bottom-up micro-costing study. We then extrapolated this single 
centre data, taking into account differences in outpatient service delivery to generate a 
national estimate of the annual cost of outpatient HIV care. 
The estimated cost of HIV outpatient care in CUH, using routine hospital finance data was 
nearly half (€63 ppm, 95% CI €59-€67 ppm) of the estimate generated by micro-costing 
(€117 ppm, 95% CI €111-€124 ppm). It would be expected that given the differences in the 
methodologies used to estimate the costs these two methods would produce differing 
estimates, however, it should also be noted that the activity based costing system in CUH 
had not been fully rolled out across all cost-categories at a patient level in 2012. Use of the 
national average cost of an outpatient visit resulted in an even lower estimated cost 
(€47ppm, 95% CI €44-€49ppm). 
While all centres provide care based on current international guidelines it was anticipated 
that there would be variations in how that care is provided, and that these variations would 
affect the cost of providing ambulatory care. When variation in clinical practice across the 
six clinical centres in Ireland was incorporated into the calculation of non-drug costs the 
estimated annual cost was €1,127 per patient. This ranged from €1,063 to €1,358 per 
patient across centres, with some evidence of economies of scale at the larger centres. 
The vast majority of the cost of HIV care is due to the provision of HAART and as choice of 
treatment regimen is influenced by many patient factors as well as clinician preferences 
[337], it is likely that the patterns of HAART use also differs across centres. As we only had 
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patient-level data on HAART regimens from CUH is was not possible to adjust for differences 
in regimens across centres, and instead used wholesaler sales data to estimate the total cost 
of ARVs at a national level. These data showed the cost of ARVs to be around €46 million in 
2012, an average of around €12,000 per patient in care in 2012 (based on the number of 
patients in care estimated in Chapter 2).  
Our final estimate of the cost of care for HIV in Ireland in 2012 was just under €50 million, 
90% of this being the cost of HAART (€46 million) with outpatient visits costing an estimated 
total of €4.3 million. 
In addition to HIV care, HIV patients also use a wide variety of other health care services. In 
our single centre study we found that outpatient ID care accounted for 35% of total non-
drug costs (bearing in mind this may be an underestimate) while in-patient care accounted 
for 47%, outpatient non-ID care 11%, day-case admissions 5% and ED care 2% of total non-
drug costs. While it is difficult to compare costs across studies and health systems, a recent 
systematic review of the economic impact of HIV in selected European countries reported a 
similar proportion (51%) of non-drug healthcare costs were due to hospitalisation in the UK, 
although this proportion varied from 20%-77% in the other four countries included (Italy, 
Spain, Germany and France) [125]. 
7.2.3 Determinants of the use and cost of HIV outpatient care 
The use of healthcare services is determined by a range of patient (sociodemographic 
and/or clinical) and healthcare related factors [210,211]. In the case of HIV care, as 
treatment costs account for the vast majority of the total cost of HIV outpatient care, the 
number of months of HAART combined with the monthly regimen costs are the primary 
determinants of annual patient costs. Analyses of HIV costs are complicated by this fact (as 
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analyses using total costs as an outcome are in reality analyses of the total cost of HAART). 
In order to examine the factors associated with the use and costs of services as opposed to 
the use and cost of HAART it is necessary to examine the determinants of HAART costs and 
outpatient care separately. 
Age 
Despite the widespread concern regarding the increasing costs of caring for an ageing 
population [24,144,167,172,338,339], there is relatively little data published in the literature 
which specifically examines the relationship between the use and/or cost of care for HIV 
patients by age group in developed countries. Studies have either focused on use and have 
not reported cost data [223,340], or if cost data is reported, it is difficult to interpret as 
detailed results are not presented by cost category [123,265,288]. Differences in the types 
of costs (e.g. total [123,265,288] vs HIV-related costs[134,341]) and patients included (e.g. 
only patients on treatment [341]) also make comparisons difficult. 
In terms of the relationship between age and total cost of care for HIV patients (i.e. 
including non-HIV care) we did not find any significant association between age and total 
non-drug cost of care (Table 5-10). The evidence in the literature regarding this association 
is mixed with some studies reporting a positive association with age [123,288] and others 
finding no difference [265,341]. Although it has been reported that older patients and those 
with greater levels of co-morbidity use more services and cost more to care for 
[135,136,223,288,340,341], we did not identify any published data reporting the breakdown 
of non-HIV (outpatient/ED/in-patient) care use or costs stratified by age group with which to 
compare our results in any detail. There could be a number of reasons neither use nor cost 
of non-HIV care did not increase with age in our population. Our study was limited to a 
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single centre and only included use of hospital resources, patients may have attended 
primary care or another hospital for their non-HIV care. The older patients in our study may 
also differ in mean age and/or risk category from other studies. Patients attending CUH may 
also be healthier than other centres, as less-healthy patients diagnosed and in care before 
the service was established in 1997 may have been less likely to transfer their care to CUH. 
In addition, there is currently no nationally co-ordinated approach to routine screening for 
age-related co-morbidities in HIV patients in Ireland, and it’s possible that less chronic 
disease screening is taking place in Ireland compared to other countries. In general, ongoing 
resource constraints in the Irish health service mean that chronic disease services have 
tended to prioritise treatment above screening and prevention. 
Our finding that there was no association between older age and total cost of HIV care (i.e. 
excluding non-HIV care) also contradicts previously published findings [134,341]. In order to 
identify the source of this difference, one needs to look at differences across cost-
categories. A recent analysis by Krentz and Gill (2015) found increased HAART costs 
appeared to be the primary driver of the increased cost of HIV care reported in the older 
patients [134]. This was attributed to more HAART use in the older group (better adherence 
and fewer interruptions) as well as the use of more expensive regimens. In our study older 
patients also had higher levels of HAART use (they were on HAART for 96% of patient 
months while younger patients on HAART for 88% of patient months) but in contrast to the 
Canadian study our patients were on less expensive regimens resulting in a lower mean 
HAART cost ppm (€833 vs €859). This difference may be due to a variety of factors including: 
different unit costs in HAART drugs between the countries; differences in prescribing 
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patterns (due to guidelines or physician preferences); differences in patient characteristics 
(including resistance rates); or a combination of all of these factors. 
Based on the results of our systematic review (Chapter 3), we expected age to be associated 
with increased use of outpatient services, however the opposite was found to be true in our 
micro-costing study. Patients ≥50 years had significantly fewer outpatient visits compared to 
younger patients (0.26 ppm vs 0.37ppm respectively, p<0.001), again we attribute this to 
the particular characteristics of the older patients attending CUH, as the anecdotal view of 
the clinicians in CUH was that the older patients, many of whom had been attending the 
centre long-term, were a very engaged group and therefore suitable for less frequent 
monitoring. Another explanation may be that as the “older” (≥50 years) population in CUH 
was still relatively young, as the patient population ages we may yet see increases in the use 
of outpatient services. While our finding that older patients did not have increased 
outpatient visits or non-drug costs was unexpected, in fact it has previously been reported 
by several studies that the cost of HIV outpatient care (excluding HAART costs) did not differ 
significantly by age group [128,134,288]. 
Other socio-demographic factors 
Female gender was the only other socio-demographic factor that was significantly 
associated with total HIV outpatient costs on multivariate analysis (Table 4-5), this was due 
to significantly increased HAART costs, as more women were prescribed PI based regimens 
(until recently PI based regimens were recommended in preference for women of child-
bearing potential [342]) which tended to be slightly more expensive than NNRTI based 
regimens. Although the monthly non-drug cost of HIV care for pregnant women was higher 
(€179, 95% CI €143-€215) than for non- pregnancy women (€111, 95% CI €101-€121) due to 
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their increased clinic visits and additional laboratory monitoring, because only a small 
proportion of women (10%) in our study used joint antenatal-HIV care in 2012, on average 
women did not have significantly increased costs compared to males (Table 4-4). Women 
also did not have increased non-drug outpatient HIV costs or increased use of non-ID 
outpatient, inpatient or ED services (Chapter 5). 
Clinical Factors 
Clinical severity is the most important determinant of the cost of care for HIV patients 
[121,123,128,135,343]. As would be expected, clinical severity (as indicated by CD4 
category) was also associated with increased use and cost of HIV outpatient care in our 
cohort (Table 4-5). Patients with lower CD4 counts were also more likely to use of non-ID 
outpatient services, be admitted as inpatients (both HIV-related/associated and HIV-
unrelated admissions) and attend the ED, and their total non-drug cost was significantly 
higher on multivariate analysis (Table 5-10). The resource-intensive nature of caring for 
people with very advanced HIV infection was illustrated by the fact that the 2% (n=7) of 
patients with CD4 counts <50 cells/µl accounted for 61% of all inpatients costs and 31% of 
the total costs of caring for HIV patients in CUH in 2012. Most of these patients were either 
recently diagnosed or had issues with treatment adherence/retention in care, highlighting 
the importance of timely diagnosis and engagement in care. 
The clinical benefits of being virally supressed was also reflected in the cost of care as 
patients on treatment who were not suppressed had significantly higher HIV outpatient 
costs on multivariate analysis (Table 4-5). While patients categorised as non-stable were five 
times more likely to have a HIV-related/associated admission and 60% more likely to use 
non-ID outpatient services (Table 5-5 and Table 5-7). 
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7.2.4 Strengths and limitations 
This section provides an overall summary of strengths and limitations of this thesis. The 
strengths and limitations of the individual studies included in this thesis have previously 
been discussed in the relevant chapters. 
Strengths 
This thesis addresses a timely topic in the field of HIV research as increasing HIV prevalence, 
the ageing of the patient population and movement towards universal treatment means 
there is increasing focus on identifying the most efficient care delivery models. We have 
documented the current level and patterns of resource use, enabling the identification of 
the main cost drivers, as well as patient and health care service characteristics associated 
with increased resource use. These data, in addition to estimates of the trends in the size 
and age breakdown of the patient population, are essential information for the planning of 
HIV care in Ireland. 
This research is also very timely in the context of the current changes in the financing of 
hospital services in Ireland, as hospital funding moves from a block-grant system to an 
activity based funding (ABF) programme [258]. Clinicians and providers will need access to 
data on resource use and costs in order to be able to effectively engage with the ABF 
programme during the development and implementation of ABF funding in Ireland [344]. 
This study provides up to date detailed information on the cost and resource use of 
outpatient HIV care.  
Another strength of this research is that a prevalence approach was used for the costing and 
utilisation studies. Taking this approach allows the ascertainment of the total economic 
burden of a disease given the particular mix of patients present, and is considered 
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particularly useful for planning cost containment policies, as information on the major cost 
components can help identify areas where cost containment policies could have most 
impact [322]. The alternative incidence based approach involves estimating the lifetime cost 
of new cases of a disease. Differences in the way future costs are treated by these 
approaches means that incidence-based cost estimates are generally lower than prevalence 
based estimates, particularly for chronic diseases, as all costs are present-valued and 
assigned to the year of disease onset, while a prevalence approach assigns costs to year 
they occur [322]. Information on lifetime costs of a disease are particularly useful for 
evaluating the full economic impact of preventative measures, but are less useful for 
decision makers who need to know what costs are likely to be incurred on an annual basis. 
Extensive efforts were made during data analysis to address known limitations in the study 
methodologies, through the use of generalised linear models, allowing for differences in 
length of follow-up time, and with selection of family and link functions based on 
recommended tests. Sensitivity analyses were also performed to explore the impact of 
uncertainty in the models developed. In addition the issue of generalisability, which is a 
recognised problem in single-centre costing studies, was addressed through collection of 
information from the other Irish centres on the most important differences in service 
delivery, which would be likely to affect the unit costs of visits (staff mix and time), and 
these variations were incorporated into the estimation of national cost. 
Limitations 
There were major limitations to the modelling of the numbers of patients in care. In 
addition to the uncertainty associated with the ages of diagnosis and HIV related mortality, 
many important factors (such as CD4 count at diagnosis, and proportion of patients on 
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HAART per year) could not be incorporated into the estimates due to a dearth of Irish data. 
In addition, as only one prevalence study has been carried out to date there was only one 
time point of observed data with which to compare the model results. It is possible that it 
was only co-incidence that the age breakdown of the modelled estimates were not 
significantly different from the observed values. We were also not able to validate the 
results of the stratified models as empiric data on the age breakdown by risk group of 
patients in care notified before 2003 was not available. As the estimated number of cases 
diagnosed between 2015-2020 was based on the average number of new diagnoses over 
the previous 5 years (2010-2014) any natural increase in number of cases due to an increase 
in the size of the general population was not taken into account. While it would have been 
preferable to base the future estimated number of HIV cases on incidence rates, sufficiently 
detailed projected population data were not available. The use of numbers as opposed to 
rates should result in a conservative estimate of the number of new infections. In addition, 
we assumed that the number of new cases 2015-2020 would be stable, but in reality recent 
surveillance data shows that the number new HIV cases notified is currently increasing 
[345]. 
Although we attempted to estimate the cost of ambulatory HIV care in Ireland using the 
most accurate methodology (micro-costing), the usefulness of performing costing studies is 
debated in the literature [317-319,346]. It has been argued that cost-of-illness studies do 
not provide policy makers with the type of information, needed to make important resource 
allocation decisions, and that research funding would be better spent on cost-
effectiveness/cost utility studies [317]. While we agree that cost data should not be used in 
isolation for priority setting, information on the economic burden associated with a disease 
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is useful in a variety of ways, including for the justification of intervention programmes and 
setting disease research priorities, as well as providing an economic framework for 
programme evaluation [321]. 
The perspective and epidemiological approach chosen for the costing study has inherent 
limitations. As we chose to estimate the cost of ambulatory HIV care from the health service 
provider perspective, only ID clinic outpatient visits were included in the micro-costing and 
hospital costs in the utilisation study. No other direct costs (either to the health service or to 
the patient themselves) or indirect (e.g. societal) costs were included. Data collection was 
limited to that recorded electronically in the hospital information systems; no data was 
sought directly from patients. This meant that no data could be collected on patients’ co-
morbidities or use of health services outside the hospital. There is a paucity of evidence 
regarding the health service costs of HIV care other than inpatient, outpatient and 
emergency care [125,131]. A recent study in Germany estimated these costs (including 
rehabilitation, home care and domestic help) to be around 2% of total direct health care 
cost of HIV [121]. 
Although we attempted to account for some of the variation in service delivery, as unit costs 
depend on the interplay of a wide variety of patient, hospital, health system and societal 
factors [163] it is likely that there are other unmeasured differences which could result in 
further variation in unit costs across centres. In addition we did not have access to centre-
level data on HAART regimens and had to rely on national data on the volume and value of 
the ARV market in Ireland. While this data source is comprehensive, the format of the data 
(based on “units” equivalent to a single pack of a single medication) did not allow analysis of 
trends in the use of particular regimens over time or of patient or centre level differences. 
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The proportion of patients on PI-based vs NNRTI based regimens has fluctuated over time as 
new medications have been introduced into the market [337,347,348]. In the last 10 years 
the use of fixed dose combinations of drugs has increased [349] and a substantial 
proportion of patients (25%-27% in the US and Australia [350,351]) are now on single tablet 
regimens. When data on the proportion of months of single tablet regimens dispensed in 
CUH was compared to IMS data, CUH appeared to have higher use of single drug regimens 
(Figure 6-7). Variation in regimen choice by clinic has been reported previously in a study in 
the UK, where clinic and calendar year were found to be more important in determining the 
choice of particular regimen than patient factors [337]. 
Although data on patient outcome (i.e. suppression status) were collected in CUH, no data 
on patient outcomes were collected at a national level, meaning that differences in 
efficiency of the variation in models of care could not be evaluated. In any case, the small 
number of centres providing adult HIV care in Ireland would limit any attempt to evaluate 
differences between centres in a quantitative manner.  
It should also be noted that costing studies reflect current practice, which may differ from 
best-practice. Centres providing services with fewer resources may appear less expensive on 
paper, but without information on patient outcomes we cannot say that those services are 
more efficient, as quality of care is an integral part of the definition of efficiency. 
Another limitation, which has been mentioned in the relevant chapters, but which is 
sufficiently important to warrant a further mention is the issue of generalisability of our 
results as the centre in CUH where the micro-costing and utilisation studies were performed 
is relatively small, and has a lower proportion of IDUs than some of the larger Dublin 
centres. In addition, variation in the patient population means that centres vary in the scope 
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of care they provide (e.g. SJH provides primary care to approximately 50% of their patients 
as they either do not have a regular GP or they do not attend their GPs for primary care). 
The small number of older patients and newly diagnosed patients with advanced disease did 
not allow in-depth examination of these groups of interest.  
7.3 Public health and policy implications 
Planning for the care of chronic diseases, as HIV now is, requires information on the 
underlying trends in patient numbers and demographics as well as information on their 
resource use and costs. Previous disease specific strategies in Ireland have highlighted the 
limited information on resource use and costs in Ireland and the importance of such data for 
the on-going assessment of service delivery models, as well as workforce planning 
[352,353]. This thesis provides estimates of potential changes in the size of the HIV patient 
population requiring care, and the aging of that population in Ireland in the near future.  
As HIV services worldwide struggle to meet the increasing demands placed on them, various 
service delivery changes have been proposed in the literature which have the potential to 
improve efficiency, including several strategies now recommended by the WHO such as 
task-shifting, decentralisation and integration of care [40]. Despite the fact that evidence 
regarding their cost-effectiveness is limited these strategies are often promoted for reasons 
other than cost, such as increasing access to treatment in resource limited settings. Their 
applicability in other contexts is not currently clear. Other suggested methods of reducing 
costs, such as reducing the frequency of clinical and/or laboratory monitoring [119], may be 
more useful in the Irish context, but again the cost-effectiveness of such strategies would 
need to be rigorously evaluated in terms of both clinical outcome and costs before 
implementation should be considered. 
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As HAART is the main driver of the cost of HIV care it offers the greatest scope for cost-
savings. Use of generic medications [127,159,160], simplification of regimens [161,268,354], 
local treatment guidelines and/or centralised procurement [162,355] have all been 
suggested as means of reducing HIV treatment costs. The results of these strategies are 
promising in terms of cost savings but further data on the possible clinical impact of such 
interventions is still needed. The availability of proven strategies to control drug costs will 
become even more essential as the patient population ages and becomes more treatment 
experienced, as it appears that the increased cost of HIV care associated with older age may 
be a result of increased treatment costs [134]. The data in this thesis will be available for use 
in any HTA of new intervention or service delivery model, as well as for modelling studies. 
This research has wider implications in terms of the restructuring of hospital financing in 
Ireland. It is planned that initially prices will be set based on national average costs, which 
have the advantage of being relatively straightforward to calculate. Use of average costs 
should incentivise hospitals with above average costs to drive down their costs to the 
average costs [258]. However, due to economies of scale the use of average costs tends to 
underestimate the cost of providing services in smaller centres and overestimate costs in 
larger centres. Our results show that centre specific costs varied from the estimated average 
by up to 20%, a difference of that magnitude between the funding of a service and what it 
actually costs to provide the service could have a detrimental effect on smaller centres 
under new funding mechanisms, while larger centres might not have any incentive to 
reduce their costs. 
The benefits of clear clinical leadership on patient outcomes have been shown for other 
chronic diseases, such as stroke and cancer, when care was reorganised based on best 
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available evidence [352,353]. In the case of cancer, services have been centralised [356], 
while for stroke care designated stroke units have been established in many acute hospitals, 
with access to additional speciality services via stroke networks [352,357]. 
While HIV care is already centralised a nationally coordinated approach, to HIV care through 
the establishment of a National Clinical Program, would help ensure the quality of care 
being delivered is standardised and maintained e.g. through the use of agreed key 
performance indicators; the development of recommendations for the 
screening/prevention of chronic-diseases in HIV patients; and the introduction of HIV 
prevention initiatives (e.g. pre-exposure prophylaxis, PrEP). As part of this approach, it is 
vital that a National Disease Registry be established, to facilitate data collection on key 
performance indicators, as well as to track of patients’ use of services and outcomes 
(including outcomes of prevention interventions, such as PrEP). Data from such as database 
would be invaluable for the ongoing monitoring of the quality of HIV care, the planning of 
HIV services and the evaluation of HIV prevention programmes (e.g. PrEP). 
A Nationally Coordinated approach to HIV care in Ireland would also have the potential to 
reduce drug costs, for example through the development of nationally agreed first line 
treatment options, centralised procurement and introduction of medicines management 
schemes that would include the use of generics [162]. In addition, as it is proposed that 
best-practice based pricing will be introduced in Ireland [258], it will be particularly 
important to have strong stakeholder involvement (supported by data) in that process. For 
example, a best-practice tariff introduced in the UK for fragility hip fracture involves a base 
tariff with an additional payment only if six clinical characteristics of best practice are met. 
This approach involves not only extensive stakeholder involvement in agreeing the 
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indicators of “best practice”, but also requires the availability of data on the clinical 
characteristics of care of interest [358]. 
7.4 Future research 
Historically there have been many gaps in the reporting of the basic epidemiology of HIV in 
Ireland, with little information available on age at diagnosis during the early years of the 
epidemic, CD4 count at diagnosis, proportion of patients on treatment, and mortality, all of 
which have limited the ability to model of the epidemic here. While recognising the 
difficulty and limitations in carrying out retrospective studies, we feel further research is 
warranted into these areas, to enable more sophisticated modelling of the HIV epidemic in 
Ireland, in terms of both number of patients as well as their likely future resource needs 
(e.g. comorbidities and HAART requirements).  
To date, the definition of “older” HIV patients has been 50 years of age. However, as the 
patient population continues to age and understanding of the metabolic, neurologic and 
neuropsychiatric changes associated with ageing with HIV improves more nuanced analysis 
of older patients use and costs of healthcare should be carried out (e.g. breakdown by 50-64 
years, 65-74 years, 75+ years). 
Further research is also needed to investigate possible methods of improving service 
efficiency. Qualitative research involving both service users and service providers, would be 
beneficial in the development of novel service innovations, as well as to assess the 
acceptability of potential changes prior to their implementation. Development of 
interventions in conjunction with clinicians, ensuring the clinical independence of the 
treating clinician and also involving the patients themselves has been highlighted as key in 
previous studies [162]. There is a lack of data internationally on perceived need (see 
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Chapter 3), which may be an important factor in patient acceptability of potential service 
delivery changes e.g. if trying to reduce number of visits. Full economic evaluations of viable 
innovations should be carried out prior to implementation, to allow the cost-effectiveness 
of such innovations be assessed in an Irish context. 
7.5 Conclusion 
The number and age profile of HIV patients in care in Ireland is increasing in line with global 
trends. Demands on health services will also increase in coming years and health services 
are under pressure to find innovative ways of improving the efficiency of their services. The 
cost of providing HIV care is influenced by individual patient factors, but also clinic, hospital 
and health system factors. The drive to improve efficiency should not negatively impact the 
quality of care being provided; to ensure this a nationally co-ordinated approach, developed 
in consultation with care providers and patients, is needed. 
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Appendix 2. Search strategy used in “Determinants of HIV outpatient 
utilisation: a systematic review” 
 
Example of search strategy and results returned (date of search 01/03/2013) 
# Terms entered Search carried out PubMed 
1 health service health services[MeSH Terms] OR ("health"[All Fields] 
AND "services"[All Fields]) OR "health services"[All 
Fields] OR ("health"[All Fields] AND "service"[All Fields]) 
OR "health service"[All Fields] 
1681245 
2 healthcare OR health 
care 
("delivery of health care"[MeSH Terms] OR 
("delivery"[All Fields] AND "health"[All Fields] AND 
"care"[All Fields]) OR "delivery of health care"[All 
Fields] OR "healthcare"[All Fields]) OR ("delivery of 
health care"[MeSH Terms] OR ("delivery"[All Fields] 
AND "health"[All Fields] AND "care"[All Fields]) OR 
"delivery of health care"[All Fields] OR ("health"[All 
Fields] AND "care"[All Fields]) OR "health care"[All 
Fields]) 
1231106 
3 ambulatory care ambulatory care[MeSH Terms] OR ("ambulatory"[All 
Fields] AND "care"[All Fields]) OR "ambulatory care"[All 
Fields] 
70443 
4 hospital hospitals[MeSH Terms] OR "hospitals"[All Fields] OR 
"hospital"[All Fields] 
2649336 
5 outpatient OR out-
patient 
("outpatients"[MeSH Terms] OR "outpatients"[All 
Fields] OR "outpatient"[All Fields]) OR 
("outpatients"[MeSH Terms] OR "outpatients"[All 
Fields] OR ("out"[All Fields] AND "patient"[All Fields]) 
OR "out patient"[All Fields]) 
219819 
6 1 OR 2 OR 3 OR 4 OR 5  4431632 
7 utilisation OR utilization utilisation[All Fields] OR ("utilization"[Subheading] OR 
"utilization"[All Fields]) 
247645 
8 Cost economics[Subheading] OR "economics"[All Fields] OR 
"cost"[All Fields] OR "costs and cost analysis"[MeSH 
Terms] OR ("costs"[All Fields] AND "cost"[All Fields] 
AND "analysis"[All Fields]) OR "costs and cost 
analysis"[All Fields] 
540569 
9 Expenditure health expenditures[MeSH Terms] OR ("health"[All 
Fields] AND "expenditures"[All Fields]) OR "health 
expenditures"[All Fields] OR "expenditure"[All Fields] 
42637 
10 7 OR 8 OR 9  765770 
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11 Human 
immunodeficiency virus 
OR HIV OR AIDS 
(("hiv"[MeSH Terms] OR "hiv"[All Fields] OR 
("human"[All Fields] AND "immunodeficiency"[All 
Fields] AND "virus"[All Fields]) OR "human 
immunodeficiency virus"[All Fields]) OR ("hiv"[MeSH 
Terms] OR "hiv"[All Fields])) OR ("acquired 
immunodeficiency syndrome"[MeSH Terms] OR 
("acquired"[All Fields] AND "immunodeficiency"[All 
Fields] AND "syndrome"[All Fields]) OR "acquired 
immunodeficiency syndrome"[All Fields] OR "aids"[All 
Fields]) 
342385 
    
12 Patient characteristics ("patients"[MeSH Terms] OR "patients"[All Fields] OR 
"patient"[All Fields]) AND characteristics[All Fields] 
215275 
13 Determinants determinants[All Fields] 98474 
14 Predictors predictors[All Fields] 112007 
15 12 OR 13 OR 14  408350 
16 6 AND 10 AND 11 AND 
15 
 1299 
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Appendix 3. Local clinical guidelines, CUH 2012 
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Appendix 4. Distribution of number of routine tests per patient 2012 
(patients in care for 12 months, n=287) 
 
 
Figure A. Number of CD4 counts performed per patient in 2012, by patient type (n=287) 
 
 
Figure B. Number of viral load tests performed per patient in 2012, by patient type (n=287) 
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Figure C. Number of FBCs performed per patient in 2012, by patient type (n=287) 
 
 
Figure D. Number of biochemistry profiles* performed per patient in 2012, by patient type (n=287) 
* Includes “patient”, “ward”, “bone”, “renal/bone”, “patient & lipid”, “patient & lipoprotein”, “urea, 
electrolytes & creatinine” and “liver function tests” 
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Appendix 5. International guidelines for laboratory monitoring of (stable) patients on HAART 
 
Test WHO [40,302] EACS [41] BHIVA [75] US (DHHS) [3] 
CD4 6 months-can 
consider stopping 
CD4 monitoring 
CD4 >350 12 months 3-6 months < 2 years ART 3-6 months; >2 years suppressed 
CD4 300-500 12 months; > 2 years suppressed 
CD4>500 optional 
VL 12 months 3-6 months 3-6 months 3-4 months, > 2 years suppressed 6 months 
FBC   3-12 months 12 months 3-6 months (CBC with differential) 
Bone profile iv)   6-12 months 3-6 months   
Renal         
Creatinine at follow up if on 
tenofovir 
  3-6 months 3-6 months 
Urine protein/creatinine ratio     12 months   
eGFR   3-12 monthsi 3-6 months 3-6 months 
Urinalysis/urine dipstick analysis at follow-up 12 monthsii 12 months; if on 
tenofovir 3-6 months 
12 months; if on tenofovir 6 monthsiii 
LFTs   3-12 months 3-6 months 3-6 months 
Fasting glucosev   12 months 3-6 months if previous test abnormal 3-6 months; if previous 
test normal 12 months 
Lipid profilevi   12 months 6-12 months if previous test abnormal 6 months; if previous 
test normal 12 months 
  
 
3
0
7
 
Test WHO [40,302] EACS [41] BHIVA [75] US (DHHS) [3] 
Syphilis  serology   12 months MSM 3-6 months; 
Others 12 months 
  
Sexual health screen   12 months 12 months   
Cervical cytology   1-3 years 12 months   
Basic chemistry (Serum sodium, potassium, 
HCO3, CI, BUN, creatinine, glucose) 
      3-6 months 
Other recommended tests   hepatitis B & C 
depending on 
serology 12 months; 
Mammography 1-3 
years; Rectal exam 
and anoscopy (MSM) 
1-3 years; ultrasound 
and alphafetoprotein 
6 months; 
hepatitis B & C if 
indicated annually; 
hepatitis B & C if indicated 
i) More frequent monitoring if eGFR < 90mL/min, CKD risk factors present and/or prior to starting and on treatment with nephrotoxic drugs 
ii) Every 6 months if eGFR < 60 mL/min, if proteinuria ≥ 1+ and/or eGFR < 60 mL/min perform UP/C or UA/C 
iii) More frequent monitoring may be indicated for patients with evidence of kidney disease (e.g., proteinuria, decreased glomerular dysfunction) or increased risk of 
renal insufficiency (e.g., patients with diabetes, hypertension). 
iv) Assessment of fracture risk (FRAX score) recommended also in pre-HAART and HAART patients. BHIVA recommend screening of all patients ≥ 50 years of age every 
3 years, while EASC recommend screening of patients >40 years of age every 2 years 
v) BHIVA guidelines do not specify glucose test to be fasting glucose. DHHS specifies either fasting glucose or HbA1C 
vi) vi) DHHS specify fasting lipids 
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Appendix 6. Ethical approval letters 
 
 
 
 309 
 
 
 310 
 
 
 
 311 
 
 
 312 
 
 
 
 313 
 
 
 
 314 
 
 
 
 315 
 
 
  
 316 
 
Appendix 7. Survey 
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Appendix 8. Flow-charts, Cork University Hospital 
 
Estimate
Timed
Routine ID clinic visit
On ART at time of visit?
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
CNS?
Pharmacy visit
(15.41 mins) 
Clerical officer: schedule
next appt
Patient Leaves
No (38%)
Yes (62%)
Yes (92%)
No (8%)
CNS visit
(14.30 mins) 
Clinical tutor
(13.48 mins)
Specialist Registrar
(23.50 mins )
32%
SHO (x2)
(24.48 mins )
Consultant
(15.49 mins)
23%22%24%
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Baseline ID clinic visit
Estimate
Timed
On ART at time of visit?
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical
assessment
(3 mins)
Patient arrives
Pharmacy visit
(15.41 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (46%)
No (54%)
CNS visit
(20 mins) 
Clinical tutor
(25 mins)
Specialist Registrar
(25 mins )
Consultant
(25 mins)
10%45%45%
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Estimate
Timed
Antenatal ID clinic visit
On ART at time of visit?
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
Pharmacy visit
(15.41 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (95%)
No (5%)
CNS visit
(14.30 mins) 
Consultant
(15 mins)
Clinical tutor
(15 mins)
80%20%
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Appendix 9. Visit flow charts by centre 
Beaumont Hospital 
 
Routine ID clinic visit (including antenatal patients)
On ART at time of visit?
Clerical officer: check in
(5 mins)
Patient arrives
Pharmacy visit
( 7 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (92%)
No (8%)
CNM I
(20 mins) 
Registrar
(25 mins)
SHO
(25 mins)
Intern
(25 mins)
Consultant 
(15  mins)
Medical student (x2)
(25 mins )
25%
Consultant 
(5 mins)
15% 15% 15% 30%
CNS
(20 mins) 
Staff nurse
(20 mins) 
33% 33% 33%
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Baseline ID clinic visit
On ART at time of visit?
Clerical officer: check in
(5 mins)
Patient arrives
Pharmacy visit
(7 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (46%)
No (54%)
Consultant
(20 mins) 
Medical student (x2)
(60 mins)
SHO
(60 mins )
Intern
(60 mins)
20%40%20%
CNM I
(20 mins) 
CNS
(20 mins) 
Staff nurse
(20 mins) 
33% 33% 33%
Registrar
(60 mins)
20%
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University College Hospital Galway 
 
Routine ID clinic visit
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
CNS?
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
No 80%
Specialist Registrar
On HAART: 30 mins (92% of visits)
Not on HAART: 25 (8% of visits) 
Registrar
On HAART: 30 mins (92% of visits)
Not on HAART: 25 mins (8% of visits)
20%
SHO
On HAART: 30 mins (92% of visits)
Not on HAART: 25 mins (8% of visits)
Consultant
On HAART: 20 mins (92% visits)
Not on HAART: 15 mins (8% visits)
20%20%30%
CNS
(30 mins)
Consultant
(5 mins)
Yes 20%
10%
CNS
(15 mins)
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Antenatal visit
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
Specialist Registrar
On HAART: 30 mins (95% of visits)
Not on HAART: 25 (5% of visits) 
Registrar
On HAART: 30 mins (95% of visits)
Not on HAART: 25 mins (5% of visits)
22%
SHO
On HAART: 30 mins (95% of visits)
Not on HAART: 25 mins (5% of visits)
Consultant
On HAART: 20 mins (95% visits)
Not on HAART: 15mins (5% visits)
22%22%33%
CNS
(15 mins)
Consultant
(5 mins)
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Nurse-only visit
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical
assessment
(3 mins)
Patient arrives
Clerical officer: schedule next appt
(1 min)
Patient Leaves
CNS
( 30 mins/90 mins if 1st visit) 
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Baseline doctor clinic visit
Phlebotomy
(8 mins)
Clerical officer: check in
(0.5 mins)
Staff nurse: physical
assessment
(3 mins)
Patient arrives
Clerical officer: schedule next appt
(1 min)
Patient Leaves
CNS visit
(10 mins) 
Registrar 
On HAART: 45 mins (33% of visits)
Not on HAART: 40 mins (67% of visits)
Consultant
On HAART:  45 mins (33% of visits)
Not on HAART : 40 mins (67% of visits)
10%45%45%
Specialist Registrar
On HAART: 45mins (33% of visits)
Not on HAART: 40 mins (67% of visits)
Consultant (5 mins)
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University Hospital Limerick 
 
NOTES:
Antenatal visit includes additional 10 mins consultant non patient-facing time
Routine/Antenatal ID clinic visit
On ART at time of visit?
Clerical officer: check in
(0.5 mins)
Staff nurse:
(30 mins)
Patient arrives
Pharmacy visit
(10-12mins) 
Clerical officer: schedule
next appt
Patient Leaves
Yes (92%)
No (8%)
Consultant
(15.49 mins)
CNM
(30 mins)
40% 60%
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New diagnoses/complex transfers
Baseline ID clinic visit
On ART at time of visit?
Clerical officer: check in
(0.5 mins)
Patient arrives
Pharmacy visit
( 20-45 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (25%)
No (75%)
CNM visit
(30 mins) 
Consultant
(45 mins)
Staff nurse visit
(30 mins) 
95% 5%
External counselling (GOSHH)
 330 
 
The Mater Misericordiae University Hospital 
 
Routine ID clinic visit
On ART at time of visit?
Phlebotomy Nurse
(8 mins)
Clerical officer: check in
(0.5 mins)
RGN
(3 mins)
Patient arrives
CNS?
Pharmacy visit
(15 mins) 
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
No (95%)
Yes (5%)
Yes (91%)
No (9%)
CNS visit
(25 mins) 
Registrar
(30 mins )
Consultant
(30 mins)
Yes (30%)
No (70%)
25%
Physical 
assessment?
75%
Social worker?
Social worker visit
(30 mins) 
Yes (5%)
No (95%)
Addiction psychiatry?
Consultant Psychiatrist
(NA)
Yes (1%)
No (99%)
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Baseline ID clinic visit
On ART at time of visit?
Phlebotomy Nurse
(15 mins)
Clerical officer: check in
(8 mins)
Patient arrives
Pharmacy visit
(30 mins) 
Clerical officer: schedule next appt
(1 min)
Patient Leaves
Yes (20%)
No (80%)
CNS visit
(45 mins) 
RGN
(3 mins)
Registrar
(45 mins )
Consultant
(45 mins)
Yes (30%)
No (70%)
25%
Physical 
assessment?
75%
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St James’s Hospital 
 
Routine ID clinic visit
On ART at time of visit?
Phlebotomy
(8 mins)
Clerical officer: check in
(10 mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
No (80%)
Yes (20%)
Yes (92%)
No (8%)
CNS visit
(20 mins) 
Specialist Registrar
(20 mins )
Consultant
(20 mins)
40%40%
Registrar
(20 mins )
Social worker?
Dietician?
Clinical nurse specialist?
No (90%)
Yes (10%) Social worker visit
(20-25 mins) 
No (88%)
Yes (12%)
Dietician visit
(15-30 mins) 
20%
Pharmacy visit (5-10 mins) 
Chief pharmacist
Senior Pharmacist (x2) 
Pharmacist 
27%
53%
20%
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Baseline nurse-led visit Baseline doctor visit
On ART at time of visit?
Phlebotomy
(8 mins)
Clerical officer: check in
(? mins)
Staff nurse: physical assessment
(3 mins)
Patient arrives
Pharmacy visit
(5-10 mins) 
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
No (80%)
Yes (20%)
Yes (?%)
No (?%)
CNS visit
(20 mins) 
Consultant
(20 mins)
Social worker?
Dietician?
Clinical nurse specialist?
No (20%)
Yes (80%) Social worker visit
(60 mins) 
No (88%)
Yes (12%)
Dietician visit
(30-45 mins) 
Phlebotomy
(8 mins)
Clerical officer: check in
(? mins)
Patient arrives
CNS
(60-90 mins)
On ART at time of visit?
Pharmacy visit
(5-10 mins) 
Yes (?%)
Clerical officer: schedule
next appt
(1 min)
Patient Leaves
No (?%)
